

Graphical Analysis of Reversible Radioligand Binding from
Applied to [*N*-¹¹C-Methyl]- α -Cocaine

Journal of Cerebral Blood Flow and Metabolism

10, 740-747

DOI: 10.1038/jcbfm.1990.127

Citation Report

#	ARTICLE	IF	CITATIONS
1	Functional brain imaging of acute pain in healthy humans. , 0, , 329-422.		0
2	Age-related decreases in muscarinic cholinergic receptor binding in the human brain measured with positron emission tomography (PET). Journal of Neuroscience Research, 1990, 27, 569-575.	1.3	93
3	Tropane alkaloids. Natural Product Reports, 1991, 8, 603.	5.2	17
4	Effects of endogenous dopamine on measures of [18F]N-methylspiperidol binding in the basal ganglia: Comparison of simulations and experimental results from PET studies in baboons. Synapse, 1991, 9, 195-207.	0.6	106
5	In vivo binding of [11C]tetrabenazine to vesicular monoamine transporters in mouse brain. Life Sciences, 1992, 51, 593-600.	2.0	45
6	GABAergic inhibition of endogenous dopamine release measured in vivo with 11C-raclopride and positron emission tomography. Journal of Neuroscience, 1992, 12, 3773-3780.	1.7	199
7	Comparative PET studies of the kinetics and distribution of cocaine and cocaethylene in baboon brain. Synapse, 1992, 12, 220-227.	0.6	34
8	Alcohol intoxication does not change [11C]cocaine pharmacokinetics in human brain and heart. Synapse, 1992, 12, 228-235.	0.6	28
9	Synthesis of halogenated analogs of 5-(4-chlorophenyl)-2,3-dihydro-5-hydroxy-5H-imidazo[2,1-a]-isoindole or mazindol for exploration of the dopamine transporter. European Journal of Medicinal Chemistry, 1993, 28, 927-933.	2.6	5
10	Striatal binding of the PET ligand 11C-raclopride is altered by drugs that modify synaptic dopamine levels. Synapse, 1993, 13, 350-356.	0.6	275
11	Comparison of Bolus and Infusion Methods for Receptor Quantitation: Application to [¹⁸ F]Cyclofoxy and Positron Emission Tomography. Journal of Cerebral Blood Flow and Metabolism, 1993, 13, 24-42.	2.4	343
12	Histamine H1 receptors in complex partial seizures. Lancet, The, 1993, 341, 238.	6.3	81
13	Subintimal angioplasty for femoropopliteal artery occlusion. Lancet, The, 1993, 341, 238.	6.3	14
14	Positron-emitting radioligands for studies in vivo-probes for human psychopharmacology. Journal of Psychopharmacology, 1993, 7, 139-158.	2.0	81
15	Effects of central cholinergic blockade on striatal dopamine release measured with positron emission tomography in normal human subjects.. Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 11816-11820.	3.3	121
16	Statistical methods in neuroimaging with particular application to emission tomography. Statistical Methods in Medical Research, 1994, 3, 63-86.	0.7	22
17	Multicompartmental study of fluorine-18 altanserin binding to brain 5HT2 receptors in humans using positron emission tomography. European Journal of Nuclear Medicine and Molecular Imaging, 1994, 21, 937-46.	2.2	75
18	Imaging endogenous dopamine competition with [11C]raclopride in the human brain. Synapse, 1994, 16, 255-262.	0.6	362

#	ARTICLE	IF	CITATIONS
19	Pharmacokinetics and in vivo specificity of [LLC]dl-threo-methylphenidate for the presynaptic dopaminergic neuron. <i>Synapse</i> , 1994, 18, 152-160.	0.6	65
20	Decreased dopamine transporters with age in healthy human subjects. <i>Annals of Neurology</i> , 1994, 36, 237-239.	2.8	155
21	Effects of Blood Flow on [¹¹ C]Raclopride Binding in the Brain: Model Simulations and Kinetic Analysis of PET Data. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1994, 14, 995-1010.	2.4	150
22	PET studies of patients with partial epilepsy: visual interpretation vs. semi-quantification/quantification. <i>Acta Neurologica Scandinavica</i> , 1994, 89, 175-178.	1.0	59
23	In vivo quantification of dopamine D2 receptor parameters in nonhuman primates with [123I]iodobenzofuran and single photon emission computerized tomography. <i>European Journal of Pharmacology</i> , 1994, 263, 39-51.	1.7	33
25	Estimation of brain 5HT2 receptor binding potential with a single-dose PET paradigm. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1995, 22, 585-586.	2.2	0
26	Long-lasting inhibition of in vivo cocaine binding to dopamine transporters by 3?-(4-Iodophenyl)Tropane-2-Carboxylic acid Methyl Ester: RTI-55 or ?CIT. <i>Synapse</i> , 1995, 19, 206-211.	0.6	16
27	Sensitivity of striatal [11C]cocaine binding to decreases in synaptic dopamine. <i>Synapse</i> , 1995, 20, 137-144.	0.6	30
28	Systemic and Cerebral Kinetics of 16Î±[¹⁸ F]Fluoro-17Î²-Estradiol: A Ligand for the in vivo Assessment of Estrogen Receptor Binding Parameters. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1995, 15, 301-311.	2.4	22
29	Serotonergic modulation of striatal dopamine measured with positron emission tomography (PET) and in vivo microdialysis. <i>Journal of Neuroscience</i> , 1995, 15, 821-829.	1.7	219
30	A comparative study of three fast algorithms to estimate cerebral blood flow and distribution volume using N-isopropyl-p-(123I)iodoamphetamine and two SPECT scans. <i>Physics in Medicine and Biology</i> , 1995, 40, 1499-1515.	1.6	5
31	Histamine H ₁ receptor occupancy in human brains after single oral doses of histamine H ₁ antagonists measured by positron emission tomography. <i>British Journal of Pharmacology</i> , 1995, 116, 1649-1655.	2.7	104
32	Comparison of two PET radioligands for imaging extrastriatal dopamine transporters in human brain. <i>Life Sciences</i> , 1995, 57, PL187-PL191.	2.0	42
33	Binding of d-threo-[11C]methylphenidate to the dopamine transporter in vivo: insensitivity to synaptic dopamine. <i>European Journal of Pharmacology</i> , 1995, 281, 141-149.	1.7	30
34	Is Methylphenidate Like Cocaine?. <i>Archives of General Psychiatry</i> , 1995, 52, 456.	13.8	539
35	Evaluation of age-related changes in serotonin 5-HT2 and dopamine D2 receptor availability in healthy human subjects. <i>Life Sciences</i> , 1995, 56, PL249-PL253.	2.0	66
36	Serotonin 5-HT2 receptor availability in chronic cocaine abusers. <i>Life Sciences</i> , 1995, 56, PL299-PL303.	2.0	5
37	Serotonin 5HT2 Receptor Imaging in the Human Brain Using Positron Emission Tomography and a New Radioligand, [18F]Altanserin: Results in Young Normal Controls. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1995, 15, 787-797.	2.4	83

#	ARTICLE	IF	CITATIONS
38	Measuring age-related changes in dopamine D2 receptors with 11C-raclopride and 18F-N-methylspiroperidol. <i>Psychiatry Research - Neuroimaging</i> , 1996, 67, 11-16.	0.9	126
39	Opioid receptor imaging and displacement studies with [6-O-[11C]methyl]buprenorphine in baboon brain. <i>Nuclear Medicine and Biology</i> , 1996, 23, 325-331.	0.3	35
40	Age associated decrements in dopamine D2 receptors in thalamus and in temporal insula of human subjects. <i>Life Sciences</i> , 1996, 59, PL31-PL35.	2.0	28
41	Visualisation of loss of 5-HT2A receptors with age in healthy volunteers using [18F]altanserin and positron emission tomographic imaging. <i>Psychiatry Research - Neuroimaging</i> , 1996, 68, 11-22.	0.9	65
42	Dopamine transporters are markedly reduced in Lesch-Nyhan disease in vivo.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1996, 93, 5539-5543.	3.3	227
43	Relationship between psychostimulant-induced "high" and dopamine transporter occupancy.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1996, 93, 10388-10392.	3.3	135
44	Cocaine Uptake Is Decreased in the Brain of Detoxified Cocaine Abusers. <i>Neuropsychopharmacology</i> , 1996, 14, 159-168.	2.8	110
45	Temporal relationships between the pharmacokinetics of methylphenidate in the human brain and its behavioral and cardiovascular effects. <i>Psychopharmacology</i> , 1996, 123, 26-33.	1.5	54
46	Decreases in Dopamine Receptors but not in Dopamine Transporters in Alcoholics. <i>Alcoholism: Clinical and Experimental Research</i> , 1996, 20, 1594-1598.	1.4	530
47	[11C]?-CIT-FE, a radioligand for quantitation of the dopamine transporter in the living brain using positron emission tomography. , 1996, 22, 386-390.		76
48	Quantification of dopamine transporter density in monkeys by dynamic PET imaging of multiple injections of 11C-CFT. , 1996, 24, 262-272.		33
49	Cocaine doses equivalent to those abused by humans occupy most of the dopamine transporters. , 1996, 24, 399-402.		30
50	Mapping nicotinic acetylcholine receptors with PET. , 1996, 24, 403-407.		70
51	Para-[18F]fluorobenzylguanidine kinetics in a canine coronary artery occlusion model1. <i>Journal of Nuclear Cardiology</i> , 1996, 3, 119-129.	1.4	12
52	Comparison of Methods for Analysis of Clinical [11C]Raclopride Studies. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1996, 16, 42-52.	2.4	441
53	From Graphical Analysis to Multilinear Regression Analysis of Reversible Radioligand Binding. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1996, 16, 750-751.	2.4	15
55	Distribution Volume Ratios without Blood Sampling from Graphical Analysis of PET Data. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1996, 16, 834-840.	2.4	1,351
56	The Role of Positron Emission Tomography in Pharmacokinetic Analysis. <i>Drug Metabolism Reviews</i> , 1997, 29, 923-956.	1.5	67

#	ARTICLE	IF	CITATIONS
57	Effects of methylphenidate on regional brain glucose metabolism in humans: relationship to dopamine D2 receptors. <i>American Journal of Psychiatry</i> , 1997, 154, 50-55.	4.0	164
58	Serotonergic modulation of dopamine measured with [¹¹ C]raclopride and PET in normal human subjects. <i>American Journal of Psychiatry</i> , 1997, 154, 490-496.	4.0	83
59	Quantitative comparison of 3D and 2D PET with brain studies. , 0, , .		0
60	Preclinical evaluation of [¹²³ I]R93274 as a SPECT radiotracer for imaging 5-HT _{2A} receptors. <i>European Journal of Pharmacology</i> , 1997, 321, 285-293.	1.7	30
61	Model for estimating dopamine transporter occupancy and subsequent increases in synaptic dopamine using positron emission tomography and carbon-11-labeled cocaine. <i>Biochemical Pharmacology</i> , 1997, 53, 43-52.	2.0	34
62	Carbon-11 labelled ketamineâ€™Synthesis, distribution in mice and PET studies in baboons. <i>Nuclear Medicine and Biology</i> , 1997, 24, 145-150.	0.3	35
63	Cocaine abusers do not show loss of dopamine transporters with age. <i>Life Sciences</i> , 1997, 61, 1059-1065.	2.0	39
64	Quantification of Amphetamine-Induced Changes in [¹¹ C]Raclopride Binding with Continuous Infusion. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1997, 17, 437-447.	2.4	237
65	Equilibrium versus Compartmental Analysis for Assessment of the Vesicular Monoamine Transporter Using (+)-[¹¹ C]Dihydrotrabenzazine (DTBZ) and Positron Emission Tomography. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1997, 17, 919-931.	2.4	88
66	Relationship between subjective effects of cocaine and dopamine transporter occupancy. <i>Nature</i> , 1997, 386, 827-830.	13.7	663
67	Decreased striatal dopaminergic responsiveness in detoxified cocaine-dependent subjects. <i>Nature</i> , 1997, 386, 830-833.	13.7	794
68	Dopamine D2 Receptor Availability in Opiate-Dependent Subjects before and after Naloxone-Precipitated Withdrawal. <i>Neuropsychopharmacology</i> , 1997, 16, 174-182.	2.8	240
69	Time Course of 5-HT _{2A} Receptor Occupancy in the Human Brain after a Single Oral Dose of the Putative Antipsychotic Drug MDL 100,907 Measured by Positron Emission Tomography. <i>Neuropsychopharmacology</i> , 1997, 17, 175-185.	2.8	56
70	Chiral drugs: comparison of the pharmacokinetics of [¹¹ C] d-threo and l-threo -methylphenidate in the human and baboon brain. <i>Psychopharmacology</i> , 1997, 131, 71-78.	1.5	142
71	Concentration and occupancy of dopamine transporters in cocaine abusers with [¹¹ C]cocaine and PET. <i>Synapse</i> , 1997, 27, 347-356.	0.6	50
72	Muscarinic Cholinergic Receptor Measurements with [¹⁸ F]FP-TZTP: Control and Competition Studies. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1998, 18, 1130-1142.	2.4	98
73	Assessment of Dynamic Neurotransmitter Changes with Bolus or Infusion Delivery of Neuroreceptor Ligands. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1998, 18, 1196-1210.	2.4	72
74	Reduced binding of [¹⁸ F]altanserin to serotonin type 2A receptors in aging: persistence of effect after partial volume correction. <i>Brain Research</i> , 1998, 813, 167-171.	1.1	121

#	ARTICLE	IF	CITATIONS
75	Glutamate Modulation of Dopamine Measured in Vivo with Positron Emission Tomography (PET) and 11C-Raclopride in Normal Human Subjects. <i>Neuropsychopharmacology</i> , 1998, 18, 18-25.	2.8	174
76	Parallel loss of presynaptic and postsynaptic dopamine markers in normal aging. <i>Annals of Neurology</i> , 1998, 44, 143-147.	2.8	160
77	Long-term stability of neurotransmitter activity investigated with 11C-raclopride PET. , 1998, 28, 66-70.		24
78	Measuring dopamine transporter occupancy by cocaine in vivo: Radiotracer considerations. , 1998, 28, 111-116.		61
79	Evaluation of the importance of rebinding to receptors in slowing the approach to equilibrium of high-affinity PET and SPECT radiotracers. , 1998, 28, 167-175.		27
80	Rapid detection of Parkinson's disease by SPECT with altoprane: A selective ligand for dopamine transporters. , 1998, 29, 128-141.		104
81	PET studies of peripheral catechol-O-methyltransferase in non-human primates using [18 F]Ro41-0960. <i>Journal of Neural Transmission</i> , 1998, 105, 1199-1211.	1.4	5
82	How to obtain high-accuracy image registration: application to movement correction of dynamic positron emission tomography data. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1998, 25, 575-586.	3.3	37
83	Comparison of FORE, OSEM and SAGE algorithms to 3DRP in 3D PET using phantom and human subject data. , 0, , .		6
84	Dopamine Transporter Occupancies in the Human Brain Induced by Therapeutic Doses of Oral Methylphenidate. <i>American Journal of Psychiatry</i> , 1998, 155, 1325-1331.	4.0	826
85	Pharmacology of Cocaine. , 1998, , 161-185.		2
86	Positron emission tomographic analysis of central dopamine D1 receptor binding in normal subjects treated with the atypical neuroleptic, SDZ MAR 327.. <i>International Journal of Molecular Medicine</i> , 1998, 1, 243-7.	1.8	5
87	Spatially-coordinated regression for image-wise model fitting to dynamic PET data for generating parametric images. <i>IEEE Transactions on Nuclear Science</i> , 1998, 45, 1194-1199.	1.2	19
89	Measuring Neurotransmitter Release with PET: Methodological Issues 1 1Transcripts of the BRAINPET97 discussion of this chapter can be found in Section VIII.. , 1998, , 449-454.		24
90	Brain Mapping of the Effects of Aging on Histamine H 1 Receptors in Humans: A PET Study with [11 C]Doxepin. , 1998, , 207-214.		3
91	Association of Methylphenidate-Induced Craving With Changes in Right Striato-orbitofrontal Metabolism in Cocaine Abusers: Implications in Addiction. <i>American Journal of Psychiatry</i> , 1999, 156, 19-26.	4.0	384
92	Loss of D2 Receptor Binding with Age in Rhesus Monkeys: Importance of Correction for Differences in Striatal Size. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1999, 19, 218-229.	2.4	65
93	Quantification of [11C]FLB 457 Binding to Extrastriatal Dopamine Receptors in the Human Brain. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1999, 19, 1164-1173.	2.4	164

#	ARTICLE	IF	CITATIONS
94	Assessment of Extrastriatal Vesicular Monoamine Transporter Binding Site Density Using Stereoisomers of [11C]Dihydrotrabenazine. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1999, 19, 1376-1384.	2.4	77
95	Iodine-123 labelled PE2I for dopamine transporter imaging: influence of age in healthy subjects. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1999, 26, 1486-1488.	3.3	11
96	Dopamine transporter and D ₂ -receptor density in late-onset alcoholism. <i>Psychopharmacology</i> , 1999, 147, 314-318.	1.5	89
97	Transplant of Cultured Neuron-Like Differentiated Chromaffin Cells in a Parkinson's Disease Patient. A Preliminary Report. <i>Archives of Medical Research</i> , 1999, 30, 33-39.	1.5	25
98	PET Imaging of Dopamine D ₂ Receptors with [18F]Fluorocleobopride in Monkeys Effects of Isoflurane- and Ketamine-Induced Anesthesia. <i>Neuropsychopharmacology</i> , 1999, 21, 589-596.	2.8	28
99	PET Measures of Amphetamine-Induced Dopamine Release in Ventral versus Dorsal Striatum. <i>Neuropsychopharmacology</i> , 1999, 21, 694-709.	2.8	110
100	Presynaptic and postsynaptic dopaminergic binding densities in the nigrostriatal and mesocortical systems in early Parkinson's disease: A double-tracer positron emission tomography study. <i>Annals of Neurology</i> , 1999, 46, 723-731.	2.8	56
101	Comparable changes in synaptic dopamine induced by methylphenidate and by cocaine in the baboon brain. , 1999, 31, 59-66.		65
102	A pharmacologic strategy for the treatment of nicotine addiction. <i>Synapse</i> , 1999, 31, 76-86.	0.6	165
103	Distribution of tracer levels of cocaine in the human brain as assessed with averaged [11C]cocaine images. , 1999, 31, 290-296.		30
104	Concentration of dopamine transporters: To B _{max} or not to B _{max} ?. <i>Synapse</i> , 1999, 32, 136-140.	0.6	11
105	PET studies of binding competition between endogenous dopamine and the D ₁ radiotracer [11C]NNC 756. , 1999, 32, 93-109.		103
106	Comparison of FORE, OSEM and SAGE algorithms to 3DRP in 3D PET using phantom and human subject data. <i>IEEE Transactions on Nuclear Science</i> , 1999, 46, 1114-1120.	1.2	12
107	Effects of dopamine on the in vivo binding of dopamine d ₂ receptor radioligands in rat striatum. <i>Nuclear Medicine and Biology</i> , 1999, 26, 91-98.	0.3	10
108	Comparative studies of epibatidine derivatives [18F]NFEP and [18F]N-Methyl-NFEP: kinetics, nicotine effect, and toxicity. <i>Nuclear Medicine and Biology</i> , 1999, 26, 139-148.	0.3	53
109	Dopamine imaging markers and predictive mathematical models for progressive degeneration in Parkinson's disease. <i>Biomedicine and Pharmacotherapy</i> , 1999, 53, 131-140.	2.5	18
110	PET Studies of the Effect of the Antidepressant Drugs Nefazodone or Paroxetine on [11C]Raclopride Binding in Human Brain. <i>Molecular Imaging and Biology</i> , 1999, 2, 205-209.	0.3	4
111	Toxic effect of MDMA on brain serotonin neurons. <i>Lancet, The</i> , 1999, 353, 1269.	6.3	9

#	ARTICLE	IF	CITATIONS
112	Uptake and distribution of a new SSRI, NS2381, studied by PET in living porcine brain. <i>European Neuropsychopharmacology</i> , 1999, 9, 351-359.	0.3	21
113	Methylphenidate and cocaine have a similar in vivo potency to block dopamine transporters in the human brain. <i>Life Sciences</i> , 1999, 65, PL7-PL12.	2.0	166
114	Occupancy of brain nicotinic acetylcholine receptors by nicotine doses equivalent to those obtained when smoking a cigarette. , 2000, 35, 234-237.		24
115	Dopamine D2 receptor quantification in extrastriatal brain regions using [123I]epidepride with bolus/infusion. <i>Synapse</i> , 2000, 36, 322-329.	0.6	18
116	Fluorine-18-labeled tropane analogs for PET imaging studies of the dopamine transporter. <i>Synapse</i> , 2000, 37, 109-117.	0.6	23
117	Quantitation of striatal and extrastriatal D-2 dopamine receptors using PET imaging of [18F]fallypride in nonhuman primates. <i>Synapse</i> , 2000, 38, 71-79.	0.6	72
118	Measurement of Striatal and Extrastriatal Dopamine D1 Receptor Binding Potential With [11C]NNC 112 in Humans: Validation and Reproducibility. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2000, 20, 225-243.	2.4	137
119	Evaluation of Serotonergic Transporters using PET and [11C](+)McN-5652: Assessment of Methods. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2000, 20, 253-262.	2.4	69
120	Imaging Synaptic Neurotransmission with in Vivo Binding Competition Techniques: A Critical Review. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2000, 20, 423-451.	2.4	919
121	Modeling Dynamic PET-SPECT Studies in the Wavelet Domain. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2000, 20, 879-893.	2.4	54
122	Kinetic Analysis of the 5-HT _{2A} Ligand [11C]MDL 100,907. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2000, 20, 899-909.	2.4	78
123	Validation and Reproducibility of Measurement of 5-HT _{1A} Receptor Parameters with [carbonyl-11C]WAY-100635 in Humans: Comparison of Arterial and Reference Tissue Input Functions. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2000, 20, 1111-1133.	2.4	211
124	Functional neuroimaging of cognition impaired by a classical antihistamine, d -chlorpheniramine. <i>British Journal of Pharmacology</i> , 2000, 129, 115-123.	2.7	112
125	Measurement of extrastriatal D2-like receptor binding with [11C]FLB 457 – a test-retest analysis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2000, 27, 1666-1673.	3.3	50
126	Simplified quantification of dopamine transporters in humans using [99mTc]TRODAT-1 and single-photon emission tomography. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2000, 27, 1714-1718.	3.3	31
127	Association Between Age-Related Decline in Brain Dopamine Activity and Impairment in Frontal and Cingulate Metabolism. <i>American Journal of Psychiatry</i> , 2000, 157, 75-80.	4.0	261
128	Histamine H1 receptors in patients with Alzheimer’s disease assessed by positron emission tomography. <i>Neuroscience</i> , 2000, 99, 721-729.	1.1	127
129	A pet study of adenosine A1 receptor in anesthetized monkey brain. <i>Nuclear Medicine and Biology</i> , 2000, 27, 401-406.	0.3	16

#	ARTICLE	IF	CITATIONS
130	Synthesis and evaluation of 6-[18F]fluoro-3-(2(S)-azetidylmethoxy)pyridine as a PET tracer for nicotinic acetylcholine receptors. <i>Nuclear Medicine and Biology</i> , 2000, 27, 381-389.	0.3	53
131	Quantitative imaging of 5-HT1A receptor binding in healthy volunteers with [18f]p-MPPF. <i>Nuclear Medicine and Biology</i> , 2000, 27, 473-476.	0.3	35
132	PET evaluation of [18F]FCWAY, an analog of the 5-HT1A receptor antagonist, WAY-100635. <i>Nuclear Medicine and Biology</i> , 2000, 27, 493-497.	0.3	71
133	Graphical analysis of PET data applied to reversible and irreversible tracers. <i>Nuclear Medicine and Biology</i> , 2000, 27, 661-670.	0.3	361
134	Pet physiological measurements using constant infusion. <i>Nuclear Medicine and Biology</i> , 2000, 27, 657-660.	0.3	83
135	The role of model-based methods in the development of single scan techniques. <i>Nuclear Medicine and Biology</i> , 2000, 27, 637-642.	0.3	20
136	18F-labeled FECNT: a selective radioligand for PET imaging of brain dopamine transporters. <i>Nuclear Medicine and Biology</i> , 2000, 27, 1-12.	0.3	115
137	Stereoselective inhibition of dopaminergic activity by gamma vinyl-GABA following a nicotine or cocaine challenge: A pet/microdialysis study. <i>Life Sciences</i> , 2000, 66, PL169-PL173.	2.0	42
138	Effects of route of administration on cocaine induced dopamine transporter blockade in the human brain. <i>Life Sciences</i> , 2000, 67, 1507-1515.	2.0	156
139	Amphetamine-induced dopamine release in human ventral striatum correlates with euphoria. <i>Biological Psychiatry</i> , 2001, 49, 81-96.	0.7	650
141	Effects of ageing on serotonin transporters in healthy females. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2001, 28, 911-913.	2.2	30
142	Morphine-induced spinal cholinergic activation: in vivo imaging with positron emission tomography. <i>Pain</i> , 2001, 91, 139-145.	2.0	18
143	Synthesis and evaluation of racemic [11C]NS2456 and its enantiomers as selective serotonin reuptake radiotracers for PET. <i>Nuclear Medicine and Biology</i> , 2001, 28, 265-270.	0.3	10
144	In vivo imaging of nicotinic receptor upregulation following chronic (-)-nicotine treatment in baboon using SPECT. <i>Nuclear Medicine and Biology</i> , 2001, 28, 165-175.	0.3	59
145	[11]Cocaine: PET studies of cocaine pharmacokinetics, dopamine transporter availability and dopamine transporter occupancy. <i>Nuclear Medicine and Biology</i> , 2001, 28, 561-572.	0.3	71
146	Receptor binding radiotracers: personal history of the past 20 years. <i>Nuclear Medicine and Biology</i> , 2001, 28, 573-583.	0.3	4
147	Models and methods for derivation of in vivo neuroreceptor parameters with PET and SPECT reversible radiotracers. <i>Nuclear Medicine and Biology</i> , 2001, 28, 595-608.	0.3	191
148	Therapeutic Doses of Oral Methylphenidate Significantly Increase Extracellular Dopamine in the Human Brain. <i>Journal of Neuroscience</i> , 2001, 21, RC121-RC121.	1.7	605

#	ARTICLE	IF	CITATIONS
150	Loss of Dopamine Transporters in Methamphetamine Abusers Recovers with Protracted Abstinence. <i>Journal of Neuroscience</i> , 2001, 21, 9414-9418.	1.7	675
151	Physiological Modelling of Positron Emission Tomography Images. , 2001, , 179-211.		2
152	Altered Serotonin 2A Receptor Activity in Women Who Have Recovered From Bulimia Nervosa. <i>American Journal of Psychiatry</i> , 2001, 158, 1152-1155.	4.0	135
153	SPET imaging of central muscarinic acetylcholine receptors with iodine-123 labelled E-IQNP and Z-IQNP. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2001, 28, 13-24.	2.2	12
154	Neuroimaging of histamine H1-receptor occupancy in human brain by positron emission tomography (PET): A comparative study of ebastine, a second-generation antihistamine, and (+)-chlorpheniramine, a classical antihistamine. <i>British Journal of Clinical Pharmacology</i> , 2001, 52, 501-509.	1.1	90
155	Synthesis and Characterization of Binding of 5-[76Br] Bromo-3-[[2(S)-Azetidiny]methoxy]pyridine, a Novel Nicotinic Acetylcholine Receptor Ligand, in Rat Brain. <i>Journal of Neurochemistry</i> , 2001, 73, 1264-1272.	2.1	22
156	Analyses of [18F]altanserin bolus injection PET data. II: Consideration of radiolabeled metabolites in humans. <i>Synapse</i> , 2001, 41, 11-21.	0.6	54
157	Cholinergic activity of aged rhesus monkeys revealed by positron emission tomography. <i>Synapse</i> , 2001, 39, 95-100.	0.6	30
158	Modeling of Receptor Ligand Data in PET and SPECT Imaging: A Review of Major Approaches. <i>Journal of Neuroimaging</i> , 2001, 11, 30-39.	1.0	29
159	A Strategy for Removing the Bias in the Graphical Analysis Method. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2001, 21, 307-320.	2.4	152
160	A Reversible Tracer Analysis Approach to the Study of Effective Dopamine Turnover. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2001, 21, 469-476.	2.4	67
161	Positron Emission Tomography Compartmental Models. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2001, 21, 635-652.	2.4	470
162	Cerebral Glucose Transport Implies Individualized Glial Cell Function. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2001, 21, 1160-1170.	2.4	11
163	Positron Emission Tomography Quantification of [11C]-DASB Binding to the Human Serotonin Transporter: Modeling Strategies. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2001, 21, 1342-1353.	2.4	262
164	Gender-specific aging effects on the serotonin 1A receptor. <i>Brain Research</i> , 2001, 895, 9-17.	1.1	99
165	Evaluation of Dopamine D-2 Receptor Occupancy by Clozapine, Risperidone, and Haloperidol In Vivo in the Rodent and Nonhuman Primate Brain Using 18F-Fallypride. <i>Neuropsychopharmacology</i> , 2001, 25, 476-488.	2.8	71
166	Low Level of Brain Dopamine D2Receptors in Methamphetamine Abusers: Association With Metabolism in the Orbitofrontal Cortex. <i>American Journal of Psychiatry</i> , 2001, 158, 2015-2021.	4.0	840
167	Association of Dopamine Transporter Reduction With Psychomotor Impairment in Methamphetamine Abusers. <i>American Journal of Psychiatry</i> , 2001, 158, 377-382.	4.0	894

#	ARTICLE	IF	CITATIONS
168	Parametric imaging and statistical mapping of brain tumor in Ga-68 EDTA dynamic PET studies. , 0, , .		1
169	Rezeptordarstellung mit der Positronen-Emissions-Tomographie - Anwendung in Klinik und Forschung - . Aktuelle Neurologie, 2002, 29, 1-11.	0.1	0
170	Dopaminergic Function and Dopamine Transporter Binding Assessed With Positron Emission Tomography in Parkinson Disease. Archives of Neurology, 2002, 59, 580.	4.9	125
171	Human [¹²³ I]5-I-A-85380 dynamic SPECT studies in normals: kinetic analysis and parametric imaging. , 0, , .		0
172	Impact of scatter correction in the kinetic analysis of a D2 receptor ligand SPECT study. , 0, , .		1
173	Reduced 5-HT _{2A} receptor binding after recovery from anorexia nervosa. Biological Psychiatry, 2002, 52, 896-906.	0.7	197
174	[¹¹ C]Mirtazapine for PET neuroimaging: radiosynthesis and initial evaluation in the living porcine brain. European Neuropsychopharmacology, 2002, 12, 427-432.	0.3	16
175	Pharmacokinetic Imaging. Clinical Pharmacokinetics, 2002, 41, 581-602.	1.6	86
176	Study of brain uptake and biodistribution of [¹¹ C]toluene in non-human primates and mice. Life Sciences, 2002, 70, 2811-2828.	2.0	42
177	Effect of Simple Motor Performance on Regional Dopamine Release in the Striatum in Parkinson Disease Patients and Healthy Subjects: A Positron Emission Tomography Study. Journal of Cerebral Blood Flow and Metabolism, 2002, 22, 746-752.	2.4	55
178	Improved Parametric Image Generation Using Spatial-Temporal Analysis of Dynamic PET Studies. NeuroImage, 2002, 15, 697-707.	2.1	53
180	Measuring drug-related receptor occupancy with positron emission tomography. Methods, 2002, 27, 278-286.	1.9	63
181	Positron emission tomography: imaging and quantification of neurotransmitter availability. Methods, 2002, 27, 287-299.	1.9	95
182	PET studies of ¹⁸ F-memantine in healthy volunteers. Nuclear Medicine and Biology, 2002, 29, 227-231.	0.3	46
183	Effect of vehicle on brain uptake of [¹¹ C]toluene. Nuclear Medicine and Biology, 2002, 29, 607-612.	0.3	12
184	MR atlas of the baboon brain for functional neuroimaging. Brain Research Bulletin, 2002, 58, 429-438.	1.4	36
185	Localization of Neurofibrillary Tangles and Beta-Amyloid Plaques in the Brains of Living Patients With Alzheimer Disease. American Journal of Geriatric Psychiatry, 2002, 10, 24-35.	0.6	650
187	Imaging Brain Function with Positron Emission Tomography. , 2002, , 485-511.		21

#	ARTICLE	IF	CITATIONS
188	Evidence of increased serotonin-1A receptor binding in type 2 diabetes: a positron emission tomography study. <i>Brain Research</i> , 2002, 927, 97-103.	1.1	27
189	Effects of alcohol detoxification on dopamine D2 receptors in alcoholics: a preliminary study. <i>Psychiatry Research - Neuroimaging</i> , 2002, 116, 163-172.	0.9	156
190	Ketamine does not decrease striatal dopamine D 2 receptor binding in man. <i>Psychopharmacology</i> , 2002, 164, 401-406.	1.5	65
191	Quantification of [123I]PE2I binding to dopamine transporters with SPET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2002, 29, 623-631.	3.3	13
192	Quantification of dopamine transporters in the mouse brain using ultra-high resolution single-photon emission tomography. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2002, 29, 691-698.	3.3	90
193	Dopamine Receptor-Mediated Regulation of Striatal Cholinergic Activity. <i>Journal of Neurochemistry</i> , 2002, 74, 1514-1521.	2.1	40
194	Relationship between blockade of dopamine transporters by oral methylphenidate and the increases in extracellular dopamine: Therapeutic implications. <i>Synapse</i> , 2002, 43, 181-187.	0.6	273
195	Measurement of dopamine transporter occupancy for multiple injections of cocaine using a single injection of [F-18]FECNT. <i>Synapse</i> , 2002, 44, 203-210.	0.6	41
196	PET imaging of brain acetylcholinesterase using [11C]CP-126,998, a brain selective enzyme inhibitor. <i>Synapse</i> , 2002, 45, 1-9.	0.6	33
197	?Nonhedonic? food motivation in humans involves dopamine in the dorsal striatum and methylphenidate amplifies this effect. <i>Synapse</i> , 2002, 44, 175-180.	0.6	400
198	Î¼4-Receptor agonism with alfentanil increases striatal dopamine D2 receptor binding in man. <i>Synapse</i> , 2002, 45, 25-30.	0.6	56
199	Brain DA D2 receptors predict reinforcing effects of stimulants in humans: Replication study. <i>Synapse</i> , 2002, 46, 79-82.	0.6	242
200	Modified Regression Model for the Logan Plot. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2002, 22, 240-244.	2.4	92
201	Quantitative Analysis for Estimating Binding Potential of the Brain Serotonin Transporter with [11C]McN5652. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2002, 22, 490-501.	2.4	36
202	Modeling [18F]MPPF Positron Emission Tomography Kinetics for the Determination of 5-Hydroxytryptamine(1A) Receptor Concentration with Multiinjection. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2002, 22, 753-765.	2.4	58
203	Strategies to Improve Neuroreceptor Parameter Estimation by Linear Regression Analysis. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2002, 22, 1271-1281.	2.4	286
204	Positron Emission Tomography Compartmental Models: A Basis Pursuit Strategy for Kinetic Modeling. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2002, 22, 1425-1439.	2.4	181
205	Social dominance in monkeys: dopamine D2 receptors and cocaine self-administration. <i>Nature Neuroscience</i> , 2002, 5, 169-174.	7.1	645

#	ARTICLE	IF	CITATIONS
206	PET imaging of human cardiac opioid receptors. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2002, 29, 1385-1388.	3.3	42
207	Use of positron emission tomography in anticancer drug development. <i>Investigational New Drugs</i> , 2003, 21, 169-181.	1.2	33
208	Quantifying tumour hypoxia with fluorine-18 fluoroerythronitroimidazole ([¹⁸ F]FETNIM) and PET using the tumour to plasma ratio. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2003, 30, 101-108.	3.3	76
209	Potential of an adenosine A2A receptor antagonist [¹¹ C]TMSX for myocardial imaging by positron emission tomography: a first human study. <i>Annals of Nuclear Medicine</i> , 2003, 17, 457-462.	1.2	27
210	Imaging of adenosine A1 receptors in the human brain by positron emission tomography with [¹¹ C]MPDX. <i>Annals of Nuclear Medicine</i> , 2003, 17, 511-515.	1.2	34
211	Cardiovascular effects of methylphenidate in humans are associated with increases of dopamine in brain and of epinephrine in plasma. <i>Psychopharmacology</i> , 2003, 166, 264-270.	1.5	89
212	Positron emission tomography and its use to image the occupancy of drug binding sites. <i>Drug Development Research</i> , 2003, 59, 194-207.	1.4	13
213	Brain dopamine is associated with eating behaviors in humans. <i>International Journal of Eating Disorders</i> , 2003, 33, 136-142.	2.1	197
214	Synthesis of the serotonin transporter ligand (Å±)-10-methyl 3-[6-nitro-(2-quinoliny)]-3,10-diazabicyclo-[4.3.1]-decane ([¹¹ C-methyl]NS 2495) and first in vivo results. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2003, 46, 873-882.	0.5	4
215	Deep brain stimulation of the subthalamic nucleus does not increase the striatal dopamine concentration in parkinsonian humans. <i>Movement Disorders</i> , 2003, 18, 41-48.	2.2	146
216	Positron emission tomography (PET) advances in neurological applications. <i>Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment</i> , 2003, 510, 107-115.	0.7	3
217	Graphical analysis of 2-[¹⁸ F]FA binding to nicotinic acetylcholine receptors in rhesus monkey brain. <i>Synapse</i> , 2003, 48, 25-34.	0.6	81
218	[¹¹ C]-NS 4194 versus [¹¹ C]-DASB for PET imaging of serotonin transporters in living porcine brain. <i>Synapse</i> , 2003, 49, 170-177.	0.6	16
219	Evaluation of a new norepinephrine transporter PET ligand in baboons, both in brain and peripheral organs. <i>Synapse</i> , 2003, 50, 345-352.	0.6	88
220	Estimation of kinetic parameters in graphical analysis of PET imaging data. <i>Statistics in Medicine</i> , 2003, 22, 3557-3568.	0.8	82
221	On the Undecidability among Kinetic Models: From Model Selection to Model Averaging. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2003, 23, 490-498.	2.4	115
222	Improved Statistical Power of the Multilinear Reference Tissue Approach to the Quantification of Neuroreceptor Ligand Binding by Regularization*. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2003, 23, 612-620.	2.4	11
223	Linearized Reference Tissue Parametric Imaging Methods: Application to [¹¹ C]DASB Positron Emission Tomography Studies of the Serotonin Transporter in Human Brain. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2003, 23, 1096-1112.	2.4	574

#	ARTICLE	IF	CITATIONS
224	Determination of Volume of Distribution using Likelihood Estimation in Graphical Analysis: Elimination of Estimation Bias. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2003, 23, 1471-1478.	2.4	40
225	Principles of tracer kinetic analysis. <i>Neuroimaging Clinics of North America</i> , 2003, 13, 689-704.	0.5	14
226	Widespread increases of cortical serotonin type 2A receptor availability after hormone therapy in euthymic postmenopausal women. <i>Fertility and Sterility</i> , 2003, 80, 554-559.	0.5	75
227	Linear regression with spatial constraint to generate parametric images of ligand-receptor dynamic PET studies with a simplified reference tissue model. <i>NeuroImage</i> , 2003, 18, 975-989.	2.1	117
228	Effects of acute nicotine on hemodynamics and binding of [¹¹ C]raclopride to dopamine D _{2,3} receptors in pig brain. <i>NeuroImage</i> , 2003, 19, 1127-1136.	2.1	64
229	Presymptomatic diagnosis of experimental Parkinsonism with ¹²³ I-PE2I SPECT. <i>NeuroImage</i> , 2003, 19, 810-816.	2.1	37
230	In vivo imaging of adenosine A ₁ receptors in the human brain with [¹⁸ F]CPFPX and positron emission tomography. <i>NeuroImage</i> , 2003, 19, 1760-1769.	2.1	84
231	Quantitative assessment of P-glycoprotein function in the rat blood-brain barrier by distribution volume of [¹¹ C]verapamil measured with PET. <i>NeuroImage</i> , 2003, 20, 1775-1782.	2.1	80
232	Influence of synaptic serotonin level on [¹⁸ F]altanserin binding to 5HT ₂ receptors in man. <i>Behavioural Brain Research</i> , 2003, 139, 21-29.	1.2	26
233	Radiotracers for positron emission tomography imaging. <i>Seminars in Nuclear Medicine</i> , 2003, 33, 14-27.	2.5	41
234	Quantification of brain μ -opioid receptors with [¹¹ C]carfentanil: reference-tissue methods. <i>Nuclear Medicine and Biology</i> , 2003, 30, 177-186.	0.3	62
235	Kinetics of the uptake and distribution of the dopamine D _{2,3} agonist (R)-N-[¹¹ C]n-propylnorapomorphine in brain of healthy and MPTP-treated Göttingen miniature pigs. <i>Nuclear Medicine and Biology</i> , 2003, 30, 547-553.	0.3	31
236	Kinetic modelling of [¹²³ I]CNS 1261 as a potential SPET tracer for the NMDA receptor. <i>Nuclear Medicine and Biology</i> , 2003, 30, 441-454.	0.3	46
237	Synthesis and in vivo evaluation of [¹¹ C]zolpidem, an imidazopyridine with agonist properties at central benzodiazepine receptors. <i>Nuclear Medicine and Biology</i> , 2003, 30, 435-439.	0.3	18
238	A review of graphical methods for tracer studies and strategies to reduce bias. <i>Nuclear Medicine and Biology</i> , 2003, 30, 833-844.	0.3	80
239	A linear wavelet filter for parametric imaging with dynamic pet. <i>IEEE Transactions on Medical Imaging</i> , 2003, 22, 289-301.	5.4	65
240	Mapping the Cerebral Monoamine Oxidase Type A: Positron Emission Tomography Characterization of the Reversible Selective Inhibitor [¹¹ C]Befloxatone. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2003, 305, 467-473.	1.3	32
241	Positron Emission Tomography Studies of Potential Mechanisms Underlying Phencyclidine-Induced Alterations in Striatal Dopamine. <i>Neuropsychopharmacology</i> , 2003, 28, 2192-2198.	2.8	21

#	ARTICLE	IF	CITATIONS
242	Direct reconstruction of kinetic parameter images from dynamic PET data. , 0, , .		3
243	Rank-shaping regularization of exponential spectral analysis for application to functional parametric mapping. <i>Physics in Medicine and Biology</i> , 2003, 48, 3819-3841.	1.6	36
244	Wavelet variance components in image space for spatio-temporal neuroimaging data. , 2003, , .		0
245	The role of dopamine in cognition. <i>Current Opinion in Neurology</i> , 2003, 16, S37-S41.	1.8	29
246	Strategies for reducing noise level of parametric images in emission tomography. <i>IFAC Postprint Volumes IPPV / International Federation of Automatic Control</i> , 2003, 36, 5-10.	0.4	0
247	Low Level of Brain Dopamine D ₂ Receptors in Methamphetamine Abusers: Association With Metabolism in the Orbitofrontal Cortex. <i>Focus (American Psychiatric Publishing)</i> , 2003, 1, 150-157.	0.4	6
248	Kinetic Modeling in Positron Emission Tomography. , 2004, , 499-540.		91
249	Altered 5-HT _{2A} Receptor Binding after Recovery from Bulimia-Type Anorexia Nervosa: Relationships to Harm Avoidance and Drive for Thinness. <i>Neuropsychopharmacology</i> , 2004, 29, 1143-1155.	2.8	158
250	Evidence That Methylphenidate Enhances the Saliency of a Mathematical Task by Increasing Dopamine in the Human Brain. <i>American Journal of Psychiatry</i> , 2004, 161, 1173-1180.	4.0	241
251	Acetylcholinesterase Imaging: Its Use in Therapy Evaluation and Drug Design. <i>Current Pharmaceutical Design</i> , 2004, 10, 1505-1517.	0.9	43
252	The influence of measurement uncertainties on the evaluation of the distribution volume ratio in rat studies on a microPET R4: a phantom study. , 0, , .		0
253	Quantification of Cerebral A1 Adenosine Receptors in Humans using [18F]CPFPX and PET. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2004, 24, 323-333.	2.4	33
254	Decreased histamine H1 receptor binding in the brain of depressed patients. <i>European Journal of Neuroscience</i> , 2004, 20, 803-810.	1.2	79
255	Reduced brain serotonin transporter binding in patients with panic disorder. <i>Psychiatry Research - Neuroimaging</i> , 2004, 132, 173-181.	0.9	65
256	Positron emission tomography in molecular imaging. <i>IEEE Engineering in Medicine and Biology Magazine</i> , 2004, 23, 28-37.	1.1	12
257	SPECT imaging of serotonin transporter binding in patients with generalized anxiety disorder. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2004, 254, 392-396.	1.8	44
258	Characterization of dopamine D1 and D2 receptor function in socially housed cynomolgus monkeys self-administering cocaine. <i>Psychopharmacology</i> , 2004, 174, 381-8.	1.5	76
259	[N-methyl-11C]Mirtazapine for positron emission tomography neuroimaging of antidepressant actions in humans. <i>Psychopharmacology</i> , 2004, 174, 260-5.	1.5	13

#	ARTICLE	IF	CITATIONS
260	Non-invasive assessment of distribution volume ratios and binding potential: tissue heterogeneity and interindividually averaged time-activity curves. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2004, 31, 564-577.	3.3	8
261	6-[18F]Fluoro-A-85380, a new PET tracer for the nicotinic acetylcholine receptor: Studies in the human brain and in vivo demonstration of specific binding in white matter. <i>Synapse</i> , 2004, 53, 184-189.	0.6	89
262	MDMA-evoked changes in [11C]raclopride and [11C]NMSP binding in living pig brain. <i>Synapse</i> , 2004, 53, 222-233.	0.6	36
263	Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. <i>Annals of Neurology</i> , 2004, 55, 306-319.	2.8	3,777
264	Tracer kinetic parametric imaging in PET. , 0, , .		4
265	Central Effects of Fexofenadine and Cetirizine: Measurement of Psychomotor Performance, Subjective Sleepiness, and Brain Histamine H1-Receptor Occupancy Using 11C-Doxepin Positron Emission Tomography. <i>Journal of Clinical Pharmacology</i> , 2004, 44, 890-900.	1.0	119
266	Quantification in PET. <i>Radiologic Clinics of North America</i> , 2004, 42, 1055-1062.	0.9	48
267	Gradients of dopamine D1- and D2/3-binding sites in the basal ganglia of pig and monkey measured by PET. <i>NeuroImage</i> , 2004, 22, 1076-1076.	2.1	0
268	Decreased hippocampal 5-HT2A receptor binding in major depressive disorder: in vivo measurement with [18F]altanserin positron emission tomography. <i>Biological Psychiatry</i> , 2004, 55, 217-224.	0.7	148
269	[123I]AM281 single-photon emission computed tomography imaging of central cannabinoid CB1 receptors before and after δ^9 -tetrahydrocannabinol therapy and whole-body scanning for assessment of radiation dose in tourette patients. <i>Biological Psychiatry</i> , 2004, 55, 904-915.	0.7	51
270	A new positron emission tomography imaging agent for the serotonin transporter: synthesis, pharmacological characterization, and kinetic analysis of [11C]2-[2-(dimethylaminomethyl)phenylthio]-5-fluoromethylphenylamine ([11C]AFM). <i>Nuclear Medicine and Biology</i> , 2004, 31, 543-556.	0.3	38
271	PET evaluation of the uptake of N-[11C]methyl CP-643,051, an NK1 receptor antagonist, in the living porcine brain. <i>Nuclear Medicine and Biology</i> , 2004, 31, 699-704.	0.3	7
272	Potential of [11C]TMSX for the evaluation of adenosine A2A receptors in the skeletal muscle by positron emission tomography. <i>Nuclear Medicine and Biology</i> , 2004, 31, 949-956.	0.3	14
273	Quantitative analysis of adenosine A1 receptors in human brain using positron emission tomography and [1-methyl-11C]8-dicyclopropylmethyl-1-methyl-3-propylxanthine. <i>Nuclear Medicine and Biology</i> , 2004, 31, 975-981.	0.3	35
274	Kinetic analysis of neuroreceptor binding using PET. <i>International Congress Series</i> , 2004, 1265, 12-24.	0.2	7
275	Formation of parametric images with statistical clustering. <i>International Congress Series</i> , 2004, 1265, 25-30.	0.2	1
276	Cluster analysis in kinetic modelling of the brain: a noninvasive alternative to arterial sampling. <i>NeuroImage</i> , 2004, 21, 483-493.	2.1	123
277	Bootstrapped DEPICT for error estimation in PET functional imaging. <i>NeuroImage</i> , 2004, 21, 1096-1104.	2.1	14

#	ARTICLE	IF	CITATIONS
278	A database of [18F]-altanserin binding to 5-HT _{2A} receptors in normal volunteers: normative data and relationship to physiological and demographic variables. <i>NeuroImage</i> , 2004, 21, 1105-1113.	2.1	111
279	Gradients of dopamine D ₁ - and D _{2/3} -binding sites in the basal ganglia of pig and monkey measured by PET. <i>NeuroImage</i> , 2004, 22, 1076-1083.	2.1	27
280	NeuroReceptor Mapping 2004 Oral Presentation. <i>NeuroImage</i> , 2004, 22, T13-T59.	2.1	5
281	Limitations of bi-linear regression analysis for the determination of receptor occupancy with positron emission tomography. <i>Nuclear Medicine Communications</i> , 2004, 25, 451-459.	0.5	5
282	Effects of Metabolite Correction for Arterial Input Function on Quantitative Receptor Images With ¹¹ C-Flumazenil in Clinical Positron Emission Tomography Studies. <i>Journal of Computer Assisted Tomography</i> , 2004, 28, 428-435.	0.5	16
283	Quantitative Functional Imaging with Positron Emission Tomography: Principles and Instrumentation. , 2005, , 57-116.		1
284	Activation of Orbital and Medial Prefrontal Cortex by Methylphenidate in Cocaine-Addicted Subjects But Not in Controls: Relevance to Addiction. <i>Journal of Neuroscience</i> , 2005, 25, 3932-3939.	1.7	285
285	Comparative evaluation of positron emission tomography radiotracers for imaging the norepinephrine transporter: (S,S) and (R,R) enantiomers of reboxetine analogs ([¹¹ C]methylreboxetine,) Tj ETQq1 1 0.784314 rgBT /Ov 2.1 65 2005. 94. 337-351.	2.1	65
286	New positron emission tomography tracer [¹¹ C]carvedilol reveals P-glycoprotein modulation kinetics. <i>British Journal of Pharmacology</i> , 2005, 145, 1045-1051.	2.7	46
287	Regional Heterogeneity of 5-HT _{1A} Receptors in Human Cerebellum as Assessed by Positron Emission Tomography. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2005, 25, 785-793.	2.4	114
288	Kinetic Modeling of Amyloid Binding in Humans using PET Imaging and Pittsburgh Compound-B. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2005, 25, 1528-1547.	2.4	622
289	A REVIEW OF SMALL ANIMAL IMAGING PLANAR AND PINHOLE SPECT gamma CAMERA IMAGING. <i>Veterinary Radiology and Ultrasound</i> , 2005, 46, 162-170.	0.4	63
290	Measuring SSRI occupancy of SERT using the novel tracer [¹²³ I]ADAM: a SPECT validation study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2005, 32, 1329-1336.	3.3	51
291	Non-uniform blockade of intrastriatal D ₂ /D ₃ receptors by risperidone and amisulpride. <i>Psychopharmacology</i> , 2005, 180, 664-669.	1.5	21
292	Principles of quantitative positron emission tomography. <i>Amino Acids</i> , 2005, 29, 341-353.	1.2	32
293	Use of reference tissue models for quantification of histamine H ₁ receptors in human brain by using positron emission tomography and [¹¹ C]doxepin. <i>Annals of Nuclear Medicine</i> , 2005, 19, 425-433.	1.2	18
294	An Internet-Based Kinetic Imaging System (KIS) for MicroPET. <i>Molecular Imaging and Biology</i> , 2005, 7, 330-341.	1.3	44
295	A Computational Positron Emission Tomography Simulation Model for Imaging β -Amyloid in Mice. <i>Molecular Imaging and Biology</i> , 2005, 7, 69-77.	1.3	11

#	ARTICLE	IF	CITATIONS
296	Simplified quantification of cerebral A1 adenosine receptors using [18F]CPFPX and PET: Analyses based on venous blood sampling. <i>Synapse</i> , 2005, 55, 212-223.	0.6	12
297	Behaviour of [11C]R(?) - and [11C]S(+)-rolipram in vitro and in vivo, and their use as PET radiotracers for the quantitative assay of PDE4. <i>Synapse</i> , 2005, 55, 270-279.	0.6	30
298	PET imaging of striatal dopamine D2 receptors in nonhuman primates: Increases in availability produced by chronic raclopride treatment. <i>Synapse</i> , 2005, 58, 215-219.	0.6	19
299	Using Bootstrap Identifiability as a Metric for Model Selection for Dynamic [¹¹ C]DASB PET Data. , 0, , .		1
300	Tracer Kinetic Modeling in PET. , 2005, , 127-159.		91
301	Model-based receptor quantization analysis for PET parametric imaging. , 2005, 2005, 5908-11.		4
302	The influence of measurement uncertainties on the evaluation of the distribution volume ratio and binding potential in rat studies on a microPET [®] R4: a phantom study. <i>Physics in Medicine and Biology</i> , 2005, 50, 2859-2869.	1.6	12
303	Histamine H1 receptors in schizophrenic patients measured by positron emission tomography. <i>European Neuropsychopharmacology</i> , 2005, 15, 185-191.	0.3	60
304	Quantification of cerebral A1 adenosine receptors in humans using [18F]CPFPX and PET: an equilibrium approach. <i>NeuroImage</i> , 2005, 24, 1192-1204.	2.1	25
305	Wavelet variance components in image space for spatiotemporal neuroimaging data. <i>NeuroImage</i> , 2005, 25, 159-168.	2.1	18
306	Omission of serial arterial blood sampling in neuroreceptor imaging with independent component analysis. <i>NeuroImage</i> , 2005, 26, 885-890.	2.1	29
308	Synthesis and evaluation of inhaled [11C]butane and intravenously injected [11C]acetone as potential radiotracers for studying inhalant abuse. <i>Nuclear Medicine and Biology</i> , 2005, 32, 201-208.	0.3	28
309	Modeling and analysis of PET studies with norepinephrine transporter ligands: the search for a reference region. <i>Nuclear Medicine and Biology</i> , 2005, 32, 531-542.	0.3	32
310	Simplified quantification of nicotinic receptors with 2[18F]F-A-85380 PET. <i>Nuclear Medicine and Biology</i> , 2005, 32, 585-591.	0.3	41
311	New-generation radiotracers for nAChR and NET. <i>Nuclear Medicine and Biology</i> , 2005, 32, 707-718.	0.3	35
312	Greater adenosine A2A receptor densities in cardiac and skeletal muscle in endurance-trained men: a [11C]TMSX PET study. <i>Nuclear Medicine and Biology</i> , 2005, 32, 831-836.	0.3	35
313	A factor-image framework to quantification of brain receptor dynamic PET studies. <i>IEEE Transactions on Signal Processing</i> , 2005, 53, 3473-3487.	3.2	3
314	The slow and long-lasting blockade of dopamine transporters in human brain induced by the new antidepressant drug radafaxine predict poor reinforcing effects. <i>Biological Psychiatry</i> , 2005, 57, 640-646.	0.7	48

#	ARTICLE	IF	CITATIONS
315	Neuroreceptor Imaging in Psychiatry: Theory and Applications. <i>International Review of Neurobiology</i> , 2005, 67, 385-440.	0.9	15
316	Direct reconstruction of kinetic parameter images from dynamic PET data. <i>IEEE Transactions on Medical Imaging</i> , 2005, 24, 636-650.	5.4	215
318	Cocaine Cues and Dopamine in Dorsal Striatum: Mechanism of Craving in Cocaine Addiction. <i>Journal of Neuroscience</i> , 2006, 26, 6583-6588.	1.7	1,021
319	A comparison of recent parametric neuroreceptor mapping approaches based on measurements with the high affinity PET radioligands [11C]FLB 457 and [11C]WAY 100635. <i>NeuroImage</i> , 2006, 32, 1690-1708.	2.1	71
320	Multi-resolution Bayesian regression in PET dynamic studies using wavelets. <i>NeuroImage</i> , 2006, 32, 111-121.	2.1	38
322	A1 adenosine receptor PET using [18F]CPFPX: Displacement studies in humans. <i>NeuroImage</i> , 2006, 32, 1100-1105.	2.1	20
323	An extended simplified reference tissue model for the quantification of dynamic PET with amphetamine challenge. <i>NeuroImage</i> , 2006, 33, 550-563.	2.1	42
324	PET neuroimaging of [11C]mirtazapine enantiomers in pigs. <i>European Neuropsychopharmacology</i> , 2006, 16, 350-357.	0.3	10
325	PET Imaging of the AT1 receptor with [11C]KR31173. <i>Nuclear Medicine and Biology</i> , 2006, 33, 5-13.	0.3	29
326	Parkinson's disease and dopamine transporter neuroimaging: a critical review. <i>Sao Paulo Medical Journal</i> , 2006, 124, 168-175.	0.4	51
327	A STUDY OF PARTIAL VOLUME EFFECTS ON CLUSTERING-AIDED PARAMETRIC IMAGES. <i>IFAC Postprint Volumes IPPV / International Federation of Automatic Control</i> , 2006, 39, 261-266.	0.4	0
328	Kinetics of (R)-[11C] rolipram and (S)-[11C] rolipram In the Dog Heart: Investigation of Four Compartment Models. , 2006, , .		0
329	METHODS FOR IMPROVING RELIABILITY OF GLLS FOR PARAMETRIC IMAGE GENERATION. <i>IFAC Postprint Volumes IPPV / International Federation of Automatic Control</i> , 2006, 39, 237-241.	0.4	2
330	Behavioral Depression and Positron Emission Tomography—Determined Serotonin 1A Receptor Binding Potential in Cynomolgus Monkeys. <i>Archives of General Psychiatry</i> , 2006, 63, 396.	13.8	101
331	Fuzzy C-mean clustering on kinetic parameter estimation with generalized linear least square algorithm in SPECT. , 2006, 6144, 1268.		2
332	Therapeutic doses of amphetamine or methylphenidate differentially increase synaptic and extracellular dopamine. <i>Synapse</i> , 2006, 59, 243-251.	0.6	109
333	Inhibition of [11C]mirtazapine binding by $\hat{1}\pm 2$ -adrenoceptor antagonists studied by positron emission tomography in living porcine brain. <i>Synapse</i> , 2006, 59, 463-471.	0.6	21
334	Imaging triiodothyronine binding kinetics in rat brain: A model for studies in human subjects. <i>Synapse</i> , 2006, 60, 212-222.	0.6	10

#	ARTICLE	IF	CITATIONS
335	Quantification of serotonin 5-HT1A receptors in monkey brain with [11C](R)-(α^*)-RWAY. <i>Synapse</i> , 2006, 60, 510-520.	0.6	39
336	PET imaging of dopamine D2 receptors during chronic cocaine self-administration in monkeys. <i>Nature Neuroscience</i> , 2006, 9, 1050-1056.	7.1	412
337	Positron Emission Tomography Quantification of [11C]-Harmine Binding to Monoamine Oxidase-A in the Human Brain. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2006, 26, 330-344.	2.4	100
338	Dopamine Storage Capacity in Caudate and Putamen of Patients with Early Parkinson's Disease: Correlation with Asymmetry of Motor Symptoms. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2006, 26, 358-370.	2.4	44
339	A positron emission tomography microdosing study with a potential anti-amyloid drug in healthy volunteers and patients with Alzheimer's disease. <i>Clinical Pharmacology and Therapeutics</i> , 2006, 80, 216-227.	2.3	53
340	Synthesis, radiosynthesis and in vivo preliminary evaluation of [11C]LBT-999, a selective radioligand for the visualisation of the dopamine transporter with PET. <i>Bioorganic and Medicinal Chemistry</i> , 2006, 14, 1115-1125.	1.4	39
341	Common Human ϵ^2 Dopamine Transporter (SLC6A3) Haplotypes Yield Varying Expression Levels In Vivo. <i>Cellular and Molecular Neurobiology</i> , 2006, 26, 873-887.	1.7	45
342	Quantitative analyses of regional [11C]PE2I binding to the dopamine transporter in the human brain: a PET study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2006, 33, 657-668.	3.3	65
343	Peripheral benzodiazepine receptors in the brain of cirrhosis patients with manifest hepatic encephalopathy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2006, 33, 810-816.	3.3	31
344	Simplified quantification of small animal [18F]FDG PET studies using a standard arterial input function. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2006, 33, 948-954.	3.3	51
345	Amyloid imaging of Alzheimer's disease using Pittsburgh compound B. <i>Current Neurology and Neuroscience Reports</i> , 2006, 6, 496-503.	2.0	21
346	PET kinetic analysis's compartmental model. <i>Annals of Nuclear Medicine</i> , 2006, 20, 583-588.	1.2	164
347	A feasibility study of [11C]SA4503-PET for evaluating sigma1 receptor occupancy by neuroleptics: The binding of haloperidol to sigma1 and dopamine D2-like receptors. <i>Annals of Nuclear Medicine</i> , 2006, 20, 569-573.	1.2	33
348	Feasibility of central cannabinoid CB1 receptor imaging with [124I]AM281 PET demonstrated in a schizophrenic patient. <i>Psychiatry Research - Neuroimaging</i> , 2006, 147, 249-256.	0.9	18
349	Enhanced parameter estimation with GLLS and the Bootstrap Monte Carlo method for dynamic SPECT. , 2006, 2006, 468-71.		4
350	Visualizing Pathology Deposits in the Living Brain of Patients with Alzheimer's Disease. <i>Methods in Enzymology</i> , 2006, 412, 144-160.	0.4	44
351	High Levels of Dopamine D2 Receptors in Unaffected Members of Alcoholic Families. <i>Archives of General Psychiatry</i> , 2006, 63, 999.	13.8	312
352	Neuroimaging of the Serotonin Transporter: Possibilities and Pitfalls. <i>Current Psychiatry Reviews</i> , 2006, 2, 111-149.	0.9	25

#	ARTICLE	IF	CITATIONS
353	Increased Occupancy of Dopamine Receptors in Human Striatum during Cue-Elicited Cocaine Craving. <i>Neuropsychopharmacology</i> , 2006, 31, 2716-2727.	2.8	280
354	Concepts of Registration and Correction of Head Motion in Positron Emission Tomography. <i>Zeitschrift Fur Medizinische Physik</i> , 2006, 16, 67-74.	0.6	15
355	[11C]PIB in a nondemented population: Potential antecedent marker of Alzheimer disease. <i>Neurology</i> , 2006, 67, 446-452.	1.5	1,000
356	Human 5-HT Transporter Availability Predicts Amygdala Reactivity <i>In Vivo</i> . <i>Journal of Neuroscience</i> , 2007, 27, 9233-9237.	1.7	86
357	Amyloid imaging in distinguishing atypical prion disease from Alzheimer disease. <i>Neurology</i> , 2007, 69, 283-290.	1.5	58
358	Cerebral Acetylcholinesterase Imaging: Development of the Radioprobes. <i>Current Topics in Medicinal Chemistry</i> , 2007, 7, 1790-1799.	1.0	23
359	Validation of an Extracerebral Reference Region Approach for the Quantification of Brain Nicotinic Acetylcholine Receptors in Squirrel Monkeys with PET and 2-18F-Fluoro-A-85380. <i>Journal of Nuclear Medicine</i> , 2007, 48, 1492-1500.	2.8	9
360	5-HTT Binding in Recovered Depressed Patients and Healthy Volunteers: A Positron Emission Tomography Study With [¹¹ C]DASB. <i>American Journal of Psychiatry</i> , 2007, 164, 1858-1865.	4.0	66
361	Enhanced formation of parametric images using fast regressive GLSL for noisy functional imaging. Annual International Conference of the IEEE Engineering in Medicine and Biology Society, 2007, 2007, 4177-80.	0.5	1
362	PET Studies of d-Methamphetamine Pharmacokinetics in Primates: Comparison with l-Methamphetamine and (-)-Cocaine. <i>Journal of Nuclear Medicine</i> , 2007, 48, 1724-1732.	2.8	47
363	Investigating the Dopaminergic Synapse <i>In Vivo</i> . I. Molecular Imaging Studies in Humans. <i>Reviews in the Neurosciences</i> , 2007, 18, 439-72.	1.4	46
364	Depressed Dopamine Activity in Caudate and Preliminary Evidence of Limbic Involvement in Adults With Attention-Deficit/Hyperactivity Disorder. <i>Archives of General Psychiatry</i> , 2007, 64, 932.	13.8	282
365	Evaluation of the Metabotropic Glutamate Receptor Subtype 5 Using PET and 11C-ABP688: Assessment of Methods. <i>Journal of Nuclear Medicine</i> , 2007, 48, 1207-1215.	2.8	68
366	Profound Decreases in Dopamine Release in Striatum in Detoxified Alcoholics: Possible Orbitofrontal Involvement. <i>Journal of Neuroscience</i> , 2007, 27, 12700-12706.	1.7	425
367	Effect of aging on cerebral A1 adenosine receptors: A [18F]CPFPX PET study in humans. <i>Neurobiology of Aging</i> , 2007, 28, 1914-1924.	1.5	63
368	Imaging the norepinephrine transporter in humans with (S,S)-[11C]O-methyl reboxetine and PET: problems and progress. <i>Nuclear Medicine and Biology</i> , 2007, 34, 667-679.	0.3	65
369	Synthesis and positron emission tomography studies of C-11-labeled isotopomers and metabolites of GTS-21, a partial \pm 7 nicotinic cholinergic agonist drug. <i>Nuclear Medicine and Biology</i> , 2007, 34, 541-551.	0.3	16
370	Brain dopamine transporter levels in treatment and drug naïve adults with ADHD. <i>NeuroImage</i> , 2007, 34, 1182-1190.	2.1	226

#	ARTICLE	IF	CITATIONS
371	Mapping of human cerebral sigma1 receptors using positron emission tomography and [11C]SA4503. <i>NeuroImage</i> , 2007, 35, 1-8.	2.1	56
372	SPM analysis of parametric (R)-[11C]PK11195 binding images: Plasma input versus reference tissue parametric methods. <i>NeuroImage</i> , 2007, 35, 1473-1479.	2.1	26
373	Using a reference tissue model with spatial constraint to quantify [11C]Pittsburgh compound B PET for early diagnosis of Alzheimer's disease. <i>NeuroImage</i> , 2007, 36, 298-312.	2.1	96
374	Balancing bias, reliability, noise properties and the need for parametric maps in quantitative ligand PET: [11C]diprenorphine test-retest data. <i>NeuroImage</i> , 2007, 38, 82-94.	2.1	46
376	P.1.e.012 Assessment of serotonin release capacity in the human brain using dexfenfluramine challenge and [18F]altanserin-PET. <i>European Neuropsychopharmacology</i> , 2007, 17, S287.	0.3	0
377	Fast and Reliable Estimation of Multiple Parametric Images Using an Integrated Method for Dynamic SPECT. <i>IEEE Transactions on Medical Imaging</i> , 2007, 26, 179-189.	5.4	10
378	18F-FDOPA Kinetics in Brain Tumors. <i>Journal of Nuclear Medicine</i> , 2007, 48, 1651-1661.	2.8	117
379	Cutting-Edge Brain Imaging with Positron Emission Tomography. <i>Neuroimaging Clinics of North America</i> , 2007, 17, 427-440.	0.5	7
380	Cutting-Edge Brain Imaging with Positron Emission Tomography. <i>PET Clinics</i> , 2007, 2, 91-104.	1.5	3
381	Quantification of nicotinic acetylcholine receptors in Parkinson's disease with 123I-5IA SPECT. <i>Journal of the Neurological Sciences</i> , 2007, 256, 52-60.	0.3	43
382	Exaggerated 5-HT1A but Normal 5-HT2A Receptor Activity in Individuals Ill with Anorexia Nervosa. <i>Biological Psychiatry</i> , 2007, 61, 1090-1099.	0.7	142
383	5HT2A Receptor Binding is Increased in Borderline Personality Disorder. <i>Biological Psychiatry</i> , 2007, 62, 580-587.	0.7	105
384	Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. <i>Annals of Neurology</i> , 2007, 62, 229-234.	2.8	465
385	PET imaging of neurokinin-1 receptors with [18F]SPA-RQ in human subjects: Assessment of reference tissue models and their test-retest reproducibility. <i>Synapse</i> , 2007, 61, 242-251.	0.6	17
386	[18F]FPhEP and [18F]F2PhEP, two new epibatidine-based radioligands: Evaluation for imaging nicotinic acetylcholine receptors in baboon brain. <i>Synapse</i> , 2007, 61, 764-770.	0.6	11
387	Quantitative Analysis for Estimating Binding Potential of the Peripheral Benzodiazepine Receptor with [11C]DAA1106. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2007, 27, 173-184.	2.4	71
388	In vivo Quantification of Serotonin Transporters Using [11C]DASB and Positron Emission Tomography in Humans: Modeling Considerations. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2007, 27, 205-217.	2.4	125
389	Evaluation of Tracer Kinetic Models for Quantification of P-Glycoprotein Function using (R)-[11C]Verapamil and PET. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2007, 27, 424-433.	2.4	87

#	ARTICLE	IF	CITATIONS
390	Positron Emission Tomography Displacement Sensitivity: Predicting Binding Potential Change for Positron Emission Tomography Tracers Based on Their Kinetic Characteristics. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2007, 27, 606-617.	2.4	46
391	Positron Emission Tomography Quantification of [¹¹ C]-(+)-PHNO Binding in the Human Brain. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2007, 27, 857-871.	2.4	88
392	Quantification of Dopamine Transporter Binding Using [¹⁸ F]FP- β -CIT and Positron Emission Tomography. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2007, 27, 1397-1406.	2.4	34
393	Evaluation of Methods for Generating Parametric (R)-[¹¹ C]PK11195 Binding Images. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2007, 27, 1603-1615.	2.4	32
394	Evaluation of Four Pyridine Analogs to Characterize 6-OHDA-Induced Modulation of mGluR5 Function in Rat Brain Using microPET Studies. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2007, 27, 1623-1631.	2.4	17
396	Pharmacoresistance in Epilepsy: A Pilot PET Study with the P-Glycoprotein Substrate R-[¹¹ C]verapamil. <i>Epilepsia</i> , 2007, 48, 1774-1784.	2.6	119
397	NIDA522131, a new radioligand for imaging extrathalamic nicotinic acetylcholine receptors: in vitro and in vivo evaluation. <i>Journal of Neurochemistry</i> , 2007, 104, 071106220615006-???	2.1	7
398	The physiological and pathophysiological roles of neuronal histamine: An insight from human positron emission tomography studies. , 2007, 113, 1-15.		169
399	PET kinetic analysis – Pitfalls and a solution for the Logan plot. <i>Annals of Nuclear Medicine</i> , 2007, 21, 1-8.	1.2	39
400	Issues in quantification of cardiac PET studies. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2007, 34, 316-319.	3.3	4
401	Quantification of adenosine A2A receptors in the human brain using [¹¹ C]TMSX and positron emission tomography. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2007, 34, 679-687.	3.3	30
402	The Application of Positron-Emitting Molecular Imaging Tracers in Alzheimer’s Disease. <i>Molecular Imaging and Biology</i> , 2007, 9, 204-216.	1.3	27
403	Voxel-based NK1 Receptor Occupancy Measurements with [¹⁸ F]SPA-RQ and Positron Emission Tomography: A Procedure for Assessing Errors from Image Reconstruction and Physiological Modeling. <i>Molecular Imaging and Biology</i> , 2007, 9, 284-294.	1.3	5
404	Distribution volume as an alternative to the binding potential for sigma1 receptor imaging. <i>Annals of Nuclear Medicine</i> , 2007, 21, 533-535.	1.2	17
405	Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer’s disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2008, 35, 2169-2181.	3.3	250
406	PET kinetic analysis: error consideration of quantitative analysis in dynamic studies. <i>Annals of Nuclear Medicine</i> , 2008, 22, 1-11.	1.2	28
407	Shortened protocol in practical [¹¹ C]SA4503-PET studies for sigma1 receptor quantification. <i>Annals of Nuclear Medicine</i> , 2008, 22, 143-146.	1.2	13
408	Studies with Differentially Labeled [¹¹ C]Cocaine, [¹¹ C]Norcocaine, [¹¹ C]Benzoylcegonine, and [¹¹ C]and [¹⁸ F]Fluorococaine to Probe the Extent to Which [¹¹ C]Cocaine Metabolites Contribute to PET Images of the Baboon Brain. <i>Journal of Neurochemistry</i> , 1994, 62, 1154-1162.	2.1	29

#	ARTICLE	IF	CITATIONS
409	Incorporating the effects of transcytolemmal water exchange in a reference region model for DCEâ€MRI analysis: Theory, simulations, and experimental results. <i>Magnetic Resonance in Medicine</i> , 2008, 59, 326-335.	1.9	37
410	Effects of Citalopram Infusion on the Serotonin Transporter Binding of [¹¹ C]DASB in Healthy Controls. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2008, 28, 1478-1490.	2.4	89
411	Comparison of Noninvasive Quantification Methods of <i>in Vivo</i> Vesicular Acetylcholine Transporter Using [¹²³ I]-IBVM SPECT Imaging. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2008, 28, 1624-1634.	2.4	16
412	Multiple Linear Analysis Methods for the Quantification of Irreversibly Binding Radiotracers. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2008, 28, 1965-1977.	2.4	10
413	Myocardial blood flow and adenosine A _{2A} receptor density in endurance athletes and untrained men. <i>Journal of Physiology</i> , 2008, 586, 5193-5202.	1.3	32
414	Quantification of Cerebral Nicotinic Acetylcholine Receptors by PET Using 2-[¹⁸ F]Fluoro-A-85380 and the Multiinjection Approach. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2008, 28, 172-189.	2.4	23
415	VMAT2 and dopamine neuron loss in a primate model of Parkinsonâ€™s disease. <i>Journal of Neurochemistry</i> , 2008, 105, 78-90.	2.1	111
416	Dynamic Positron Emission Tomography Data-Driven Analysis Using Sparse Bayesian Learning. <i>IEEE Transactions on Medical Imaging</i> , 2008, 27, 1356-1369.	5.4	24
417	Enhanced parameter estimation methods for noisy SPECT data. <i>Computer Methods and Programs in Biomedicine</i> , 2008, 89, 102-111.	2.6	1
418	Decreased [¹⁸ F]MPPF Binding Potential in the Dorsal Raphe Nucleus After a Single Oral Dose of Fluoxetine: A Positron-Emission Tomography Study in Healthy Volunteers. <i>Biological Psychiatry</i> , 2008, 63, 1135-1140.	0.7	41
419	Validation of the reference tissue model for estimation of dopaminergic D2-like receptor binding with [¹⁸ F](N-methyl)benperidol in humans. <i>Nuclear Medicine and Biology</i> , 2008, 35, 335-341.	0.3	11
420	Serotonin transporter binding and acquired obesity â€™ An imaging study of monozygotic twin pairs. <i>Physiology and Behavior</i> , 2008, 93, 724-732.	1.0	35
421	Measurement of Striatal and Extrastriatal Dopamine Transporter Binding with High-Resolution PET and [¹¹ C]PE2I: Quantitative Modeling and Testâ€™Retest Reproducibility. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2008, 28, 1059-1069.	2.4	63
422	Quantification of nicotinic acetylcholine receptors in the human brain with PET: Bolus plus infusion administration of 2-[¹⁸ F]F-A85380. <i>NeuroImage</i> , 2008, 39, 717-727.	2.1	45
423	Estimating neurotransmitter kinetics with ntPET: A simulation study of temporal precision and effects of biased data. <i>NeuroImage</i> , 2008, 39, 1162-1179.	2.1	24
424	Dopamine increases in striatum do not elicit craving in cocaine abusers unless they are coupled with cocaine cues. <i>NeuroImage</i> , 2008, 39, 1266-1273.	2.1	208
425	Robust estimation of the arterial input function for Logan plots using an intersectional searching algorithm and clustering in positron emission tomography for neuroreceptor imaging. <i>NeuroImage</i> , 2008, 40, 26-34.	2.1	19
426	Measurement of GABAA receptor binding in vivo with [¹¹ C]Flumazenil: A testâ€™retest study in healthy subjects. <i>NeuroImage</i> , 2008, 41, 260-269.	2.1	38

#	ARTICLE	IF	CITATIONS
427	Imaging dopamine release with Positron Emission Tomography (PET) and ¹¹ C-raclopride in freely moving animals. <i>NeuroImage</i> , 2008, 41, 1051-1066.	2.1	55
428	Quantification of ¹¹ C-PIB kinetics in mouse brain using metabolite-corrected arterial input function. <i>NeuroImage</i> , 2008, 41, T32.	2.1	1
430	Altered serotonin 1A binding potential in major depression using [¹¹ C]WAY 100635: A second patient cohort. <i>NeuroImage</i> , 2008, 41, T44.	2.1	3
431	Low dopamine striatal D2 receptors are associated with prefrontal metabolism in obese subjects: Possible contributing factors. <i>NeuroImage</i> , 2008, 42, 1537-1543.	2.1	488
432	Fast uptake and long-lasting binding of methamphetamine in the human brain: Comparison with cocaine. <i>NeuroImage</i> , 2008, 43, 756-763.	2.1	83
433	Automated ¹¹ C-PiB Standardized Uptake Value Ratio. <i>Academic Radiology</i> , 2008, 15, 1376-1389.	1.3	24
434	Wavelet denoising in voxel-based parametric estimation of small animal PET images: a systematic evaluation of spatial constraints and noise reduction algorithms. <i>Physics in Medicine and Biology</i> , 2008, 53, 5899-5915.	1.6	9
435	Tariquidar-Induced P-Glycoprotein Inhibition at the Rat Blood-Brain Barrier Studied with [¹¹ C]-Verapamil and PET. <i>Journal of Nuclear Medicine</i> , 2008, 49, 1328-1335.	2.8	104
436	Imaging of opioid receptors in the central nervous system. <i>Brain</i> , 2008, 131, 1171-1196.	3.7	179
437	Mechanisms of Dopaminergic and Serotonergic Neurotransmission in Tourette Syndrome: Clues from an In Vivo Neurochemistry Study with PET. <i>Neuropsychopharmacology</i> , 2008, 33, 1239-1251.	2.8	227
438	Compartmental Modeling of [¹¹ C]-HOMADAM Binding to the Serotonin Transporter in the Healthy Human Brain. <i>Journal of Nuclear Medicine</i> , 2008, 49, 2018-2025.	2.8	25
439	Modeling Considerations for ¹¹ C-CUMI-101, an Agonist Radiotracer for Imaging Serotonin 1A Receptor In Vivo with PET. <i>Journal of Nuclear Medicine</i> , 2008, 49, 587-596.	2.8	49
440	The Potential of a Radiosensitive Intracerebral Probe to Monitor [¹⁸ F]-MPPF Binding in Mouse Hippocampus In Vivo. <i>Journal of Nuclear Medicine</i> , 2008, 49, 1155-1161.	2.8	5
441	A method to estimate dispersion in sampling catheters and to calculate dispersion-free blood time-activity curves. <i>Medical Physics</i> , 2008, 35, 3471-3481.	1.6	28
442	Impact of wavelet based denoising of [¹¹ C]-PK11195 time activity curves on accuracy and precision of kinetic analysis. <i>Medical Physics</i> , 2008, 35, 5069-5078.	1.6	1
443	Increased Vesicular Monoamine Transporter Binding during Early Abstinence In Human Methamphetamine Users: Is VMAT2 a Stable Dopamine Neuron Biomarker?. <i>Journal of Neuroscience</i> , 2008, 28, 9850-9856.	1.7	86
444	Alzheimer Disease and Cognitive Reserve. <i>Archives of Neurology</i> , 2008, 65, 1467.	4.9	189
445	Imaging Alzheimer Pathology in Late-Life Depression With PET and Pittsburgh Compound-B. <i>Alzheimer Disease and Associated Disorders</i> , 2008, 22, 261-268.	0.6	119

#	ARTICLE	IF	CITATIONS
446	[¹¹ C]CHIBA-1001 as a Novel PET Ligand for $\alpha 7$ Nicotinic Receptors in the Brain: A PET Study in Conscious Monkeys. PLoS ONE, 2008, 3, e3231.	1.1	56
448	Direct 4D parametric image reconstruction with plasma input and reference tissue models in reversible binding imaging. , 2009, , .		6
449	The Role of Imaging in Proof of Concept for CNS Drug Discovery and Development. Neuropsychopharmacology, 2009, 34, 187-203.	2.8	161
450	Quantitative assessment of hypoxia kinetic models by a cross-study of dynamic ¹⁸ F-FAZA and ¹⁵ O-H ₂ O in head and neck tumors. , 2009, , .		0
451	Cortical Hubs Revealed by Intrinsic Functional Connectivity: Mapping, Assessment of Stability, and Relation to Alzheimer's Disease. Journal of Neuroscience, 2009, 29, 1860-1873.	1.7	2,576
452	Cognitive Decline and Brain Volume Loss as Signatures of Cerebral Amyloid- $\beta 2$ Peptide Deposition Identified With Pittsburgh Compound B. Archives of Neurology, 2009, 66, 1476-81.	4.9	281
453	Cerebral Histamine H ₁ Receptor Binding Potential Measured with PET Under a Test Dose of Olopatadine, an Antihistamine, Is Reduced After Repeated Administration of Olopatadine. Journal of Nuclear Medicine, 2009, 50, 887-892.	2.8	12
454	Initial Evaluation of ¹¹ C-DPA-713, a Novel TSPO PET Ligand, in Humans. Journal of Nuclear Medicine, 2009, 50, 1276-1282.	2.8	117
455	Medial Prefrontal Cortex 5-HT _{2A} Density Is Correlated with Amygdala Reactivity, Response Habituation, and Functional Coupling. Cerebral Cortex, 2009, 19, 2499-2507.	1.6	110
456	Imaging of Cyclosporine Inhibition of P-Glycoprotein Activity Using ¹¹ C-Verapamil in the Brain: Studies of Healthy Humans. Journal of Nuclear Medicine, 2009, 50, 1267-1275.	2.8	127
457	A Multitracer Dopaminergic PET Study of Young-Onset Parkinsonian Patients With and Without Parkin Gene Mutations. Journal of Nuclear Medicine, 2009, 50, 1244-1250.	2.8	37
458	Effects of Modafinil on Dopamine and Dopamine Transporters in the Male Human Brain. JAMA - Journal of the American Medical Association, 2009, 301, 1148.	3.8	466
459	Biomarkers and imaging: physics and chemistry for noninvasive analyses. Bioanalysis, 2009, 1, 321-356.	0.6	8
460	Brain serotonin transporter binding in former users of MDMA (â€ˆecstasyâ€™). British Journal of Psychiatry, 2009, 194, 355-359.	1.7	45
461	Quantitative Analysis of Peripheral Benzodiazepine Receptor in the Human Brain Using PET with ¹¹ C-AC-5216. Journal of Nuclear Medicine, 2009, 50, 1095-1101.	2.8	26
462	Effect of Menstrual Cycle Phase on Dopamine D ₂ Receptor Availability in Female Cynomolgus Monkeys. Neuropsychopharmacology, 2009, 34, 548-554.	2.8	91
463	Phase 1 Study of the Pittsburgh Compound B Derivative ¹⁸ F-Flutemetamol in Healthy Volunteers and Patients with Probable Alzheimer Disease. Journal of Nuclear Medicine, 2009, 50, 1251-1259.	2.8	273
464	Evaluating Dopamine Reward Pathway in ADHD. JAMA - Journal of the American Medical Association, 2009, 302, 1084.	3.8	518

#	ARTICLE	IF	CITATIONS
465	18F-ZW-104: A New Radioligand for Imaging Neuronal Nicotinic Acetylcholine Receptorsâ€”In Vitro Binding Properties and PET Studies in Baboons. <i>Journal of Nuclear Medicine</i> , 2009, 50, 1349-1355.	2.8	18
466	A Pilot Study to Assess the Efficacy of Tariquidar to Inhibit P-glycoprotein at the Human Bloodâ€”Brain Barrier with (<i>R</i>)- ¹¹ C-Verapamil and PET. <i>Journal of Nuclear Medicine</i> , 2009, 50, 1954-1961.	2.8	99
467	An Activity-Subspace Approach for Estimating the Integrated Input Function and Relative Distribution Volume in PET Parametric Imaging. <i>IEEE Transactions on Information Technology in Biomedicine</i> , 2009, 13, 25-36.	3.6	4
468	Dopamine D1 receptor binding in the striatum of patients with obsessiveâ€”compulsive disorder. <i>Journal of Affective Disorders</i> , 2009, 114, 321-326.	2.0	68
469	Dose dependency of brain histamine H1 receptor occupancy following oral administration of cetirizine hydrochloride measured using PET with [¹¹ C]doxepin. <i>Human Psychopharmacology</i> , 2009, 24, 540-548.	0.7	42
470	FDGâ€”PET parametric imaging by total variation minimization. <i>Computerized Medical Imaging and Graphics</i> , 2009, 33, 295-303.	3.5	17
471	Improvement of likelihood estimation in Logan graphical analysis using maximum a posteriori for neuroreceptor PET imaging. <i>Annals of Nuclear Medicine</i> , 2009, 23, 163-171.	1.2	8
472	Kinetic modelling of [¹¹ C]flumazenil using data-driven methods. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009, 36, 659-670.	3.3	18
473	Robust fitting for neuroreceptor mapping. <i>Statistics in Medicine</i> , 2009, 28, 1004-1016.	0.8	2
474	Evaluation of the Novel 5-HT ₄ Receptor PET Ligand [¹¹ C]SB207145 in the CÃ¶ttingen Minipig. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2009, 29, 186-196.	2.4	52
475	The dopaminergic basis of human behaviors: A review of molecular imaging studies. <i>Neuroscience and Biobehavioral Reviews</i> , 2009, 33, 1109-1132.	2.9	150
476	In vivo imaging of synaptic function in the central nervous system. <i>Behavioural Brain Research</i> , 2009, 204, 1-31.	1.2	118
477	Evaluation of 6-([¹⁸ F]fluoroacetamido)-1-hexanoicanilide for PET imaging of histone deacetylase in the baboon brain. <i>Nuclear Medicine and Biology</i> , 2009, 36, 247-258.	0.3	48
478	Pharmacokinetics and Modeling. , 2009, , 205-214.		2
479	Disruption of Functional Connectivity in Clinically Normal Older Adults Harboring Amyloid Burden. <i>Journal of Neuroscience</i> , 2009, 29, 12686-12694.	1.7	530
480	Synthesis and Preclinical Evaluation of Novel PET Probes for P-Glycoprotein Function and Expression. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 4524-4532.	2.9	52
481	Reducing the noise effects in Logan graphic analysis for PET receptor measurements. , 2009, , .		1
482	Molecular tools for assessing human depression by positron emission tomography. <i>European Neuropsychopharmacology</i> , 2009, 19, 611-628.	0.3	32

#	ARTICLE	IF	CITATIONS
483	A consistent and efficient graphical analysis method to improve the quantification of reversible tracer binding in radioligand receptor dynamic PET studies. <i>NeuroImage</i> , 2009, 44, 661-670.	2.1	51
484	[¹⁸ F]Flumazenil binding to central benzodiazepine receptor studies by PET. <i>NeuroImage</i> , 2009, 45, 891-902.	2.1	74
485	Quantitative analysis of donepezil binding to acetylcholinesterase using positron emission tomography and [⁵ - ¹¹ C-methoxy]donepezil. <i>NeuroImage</i> , 2009, 46, 616-623.	2.1	28
486	Strategies for the generation of parametric images of [¹¹ C]PIB with plasma input functions considering discriminations and reproducibility. <i>NeuroImage</i> , 2009, 48, 329-338.	2.1	23
487	Impact of early life stress on the reinforcing and behavioral-stimulant effects of psychostimulants in rhesus monkeys. <i>Behavioural Pharmacology</i> , 2010, 21, 69-76.	0.8	11
488	In Vivo Evaluation of $\alpha 7$ Nicotinic Acetylcholine Receptor Agonists [¹¹ C]A-582941 and [¹¹ C]A-844606 in Mice and Conscious Monkeys. <i>PLoS ONE</i> , 2010, 5, e8961.	1.1	31
489	Reduced parahippocampal and lateral temporal GABA _A -[¹¹ C]flumazenil binding in major depression: preliminary results. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 565-574.	3.3	79
490	Quantitative analysis of dopamine transporters in human brain using [¹¹ C]PE2I and positron emission tomography: evaluation of reference tissue models. <i>Annals of Nuclear Medicine</i> , 2010, 24, 249-260.	1.2	24
491	Dopamine transporter binding in females with panic disorder may vary with clinical status. <i>Journal of Psychiatric Research</i> , 2010, 44, 56-59.	1.5	17
492	Gender, personality, and serotonin-2A receptor binding in healthy subjects. <i>Psychiatry Research - Neuroimaging</i> , 2010, 181, 77-84.	0.9	43
493	Dopamine D1 receptor binding in the anterior cingulate cortex of patients with obsessive-compulsive disorder. <i>Psychiatry Research - Neuroimaging</i> , 2010, 183, 85-88.	0.9	31
494	Cerebral $\beta 2$ -amyloid detected by Pittsburgh compound B positron emission topography predisposes to recombinant tissue plasminogen activator-related hemorrhage. <i>Annals of Neurology</i> , 2010, 68, 959-962.	2.8	30
495	Striatal dopamine D2 receptor availability predicts the thalamic and medial prefrontal responses to reward in cocaine abusers three years later. <i>Synapse</i> , 2010, 64, 397-402.	0.6	51
496	Measuring Drug Occupancy in the Absence of a Reference Region: The Lassen Plot Re-Visited. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2010, 30, 46-50.	2.4	231
497	Kinetic Modeling of the Serotonin 5-HT _{1B} Receptor Radioligand [¹¹ C]P943 in Humans. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2010, 30, 196-210.	2.4	83
498	Robust Fitting of [¹¹ C]-WAY-100635 PET Data. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2010, 30, 1366-1372.	2.4	0
499	<i>In vivo</i> and <i>in vitro</i> Validation of Reference Tissue Models for the mGluR ₅ Ligand [¹¹ C]ABP688. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2010, 30, 1538-1549.	2.4	60
500	Fetal Dopamine Receptor Characteristics Assessed in Utero. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2010, 30, 1437-1440.	2.4	3

#	ARTICLE	IF	CITATIONS
502	Positron Emission Tomography in Schizophrenia: A New Perspective. <i>Journal of Nuclear Medicine</i> , 2010, 51, 511-520.	2.8	55
503	Quantitative Assessment of Hypoxia Kinetic Models by a Cross-Study of Dynamic ¹⁸ F-FAZA and ¹⁵ O-H ₂ O in Patients with Head and Neck Tumors. <i>Journal of Nuclear Medicine</i> , 2010, 51, 1386-1394.	2.8	32
504	<i>In Vivo</i> Quantification of Human Serotonin 1A Receptor Using ¹¹ C-CUMI-101, an Agonist PET Radiotracer. <i>Journal of Nuclear Medicine</i> , 2010, 51, 1892-1900.	2.8	80
505	Chronic stress and antidepressant treatment have opposite effects on P-glycoprotein at the blood-brain barrier: an experimental PET study in rats. <i>Journal of Psychopharmacology</i> , 2010, 24, 1237-1242.	2.0	28
506	Elevated Brain Monoamine Oxidase A Binding in the Early Postpartum Period. <i>Archives of General Psychiatry</i> , 2010, 67, 468.	13.8	177
507	GABAergic Dysfunction in Essential Tremor: An ¹¹ C-Flumazenil PET Study. <i>Journal of Nuclear Medicine</i> , 2010, 51, 1030-1035.	2.8	122
508	Using PET Studies of P-gp Function to Elucidate Mechanisms Underlying the Disposition of Drugs. <i>Current Topics in Medicinal Chemistry</i> , 2010, 10, 1799-1809.	1.0	28
509	Decreased cerebral cortical serotonin transporter binding in ecstasy users: a positron emission tomography/[¹¹ C]DASB and structural brain imaging study. <i>Brain</i> , 2010, 133, 1779-1797.	3.7	134
510	Quantification of cerebral cannabinoid receptors subtype 1 (CB1) in healthy subjects and schizophrenia by the novel PET radioligand [¹¹ C]OMAR. <i>NeuroImage</i> , 2010, 52, 1505-1513.	2.1	186
511	Reducing modeling error of graphical methods for estimating volume of distribution measurements in PiB- ¹⁸ F PET study. <i>Mathematical Biosciences</i> , 2010, 226, 134-146.	0.9	4
512	Empirical Bayesian estimation in graphical analysis: a voxel-based approach for the determination of the volume of distribution in PET studies. <i>Nuclear Medicine and Biology</i> , 2010, 37, 443-451.	0.3	14
513	A new graphic plot analysis for determination of neuroreceptor binding in positron emission tomography studies. <i>NeuroImage</i> , 2010, 49, 578-586.	2.1	8
514	Multi-graphical analysis of dynamic PET. <i>NeuroImage</i> , 2010, 49, 2947-2957.	2.1	47
515	Simplified quantification of 5-HT _{2A} receptors in the human brain with [¹¹ C]MDL 100,907 PET and non-invasive kinetic analyses. <i>NeuroImage</i> , 2010, 50, 984-993.	2.1	21
516	Simplified parametric methods for [¹⁸ F]FDDNP studies. <i>NeuroImage</i> , 2010, 49, 433-441.	2.1	7
517	Technical aspects of amyloid imaging for Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2011, 3, 25.	3.0	8
519	Advances in biomathematical modeling for PET neuroreceptor imaging. <i>Drug Discovery Today: Technologies</i> , 2011, 8, e45-e51.	4.0	7
520	Inter-rater reliability of manual and automated region-of-interest delineation for PiB PET. <i>NeuroImage</i> , 2011, 55, 933-941.	2.1	47

#	ARTICLE	IF	CITATIONS
521	Evaluation of [¹¹ C]MRB for assessment of occupancy of norepinephrine transporters: Studies with atomoxetine in non-human primates. <i>NeuroImage</i> , 2011, 56, 268-279.	2.1	50
522	A Combined Accelerator Mass Spectrometry-Positron Emission Tomography Human Microdose Study with ¹⁴ C- and ¹¹ C-Labelled Verapamil. <i>Clinical Pharmacokinetics</i> , 2011, 50, 111-120.	1.6	31
523	Basic Sciences of Nuclear Medicine. , 2011, , .		23
525	Neurokinetics. , 2011, , .		10
526	In vivo evaluation of carbon-11-labelled non-sarcosine-based glycine transporter 1 inhibitors in mice and conscious monkeys. <i>Nuclear Medicine and Biology</i> , 2011, 38, 517-527.	0.3	12
527	Optimal scanning time window for ¹⁸ F-FP-(+)-DTBZ (¹⁸ F-AV-133) summed uptake measurements. <i>Nuclear Medicine and Biology</i> , 2011, 38, 1149-1155.	0.3	25
528	Positron Emission Tomography Imaging of Mu ϵ and Delta ϵ Opioid Receptor Binding in Alcohol ϵ Dependent and Healthy Control Subjects. <i>Alcoholism: Clinical and Experimental Research</i> , 2011, 35, 2162-2173.	1.4	88
529	Enhanced Striatal Dopamine Release During Food Stimulation in Binge Eating Disorder. <i>Obesity</i> , 2011, 19, 1601-1608.	1.5	260
530	The Use of Alternative Forms of Graphical Analysis to Balance Bias and Precision in PET Images. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2011, 31, 535-546.	2.4	18
531	Parametric Mapping of [¹⁸ F]Fluoromisonidazole Positron Emission Tomography using Basis Functions. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2011, 31, 648-657.	2.4	19
532	Quantitative Analysis of [¹¹ C]AZ10419369 Binding to 5-HT _{1B} Receptors in Human Brain. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2011, 31, 113-123.	2.4	72
533	Motivation deficit in ADHD is associated with dysfunction of the dopamine reward pathway. <i>Molecular Psychiatry</i> , 2011, 16, 1147-1154.	4.1	308
534	PET kinetics of radiolabeled antidepressant, [N-methyl- ¹¹ C]mirtazapine, in the human brain. <i>EJNMMI Research</i> , 2011, 1, 36.	1.1	2
535	In vivo positron emission tomography imaging with [¹¹ C]ABP688: binding variability and specificity for the metabotropic glutamate receptor subtype 5 in baboons. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 1083-1094.	3.3	57
536	Assessment of α 7 nicotinic acetylcholine receptor availability in juvenile pig brain with [¹⁸ F]NS10743. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 1541-1549.	3.3	34
537	Quantification of receptor-ligand binding with [¹⁸ F]fluciclatide in metastatic breast cancer patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 2186-2197.	3.3	40
538	Diminished brain 5-HT transporter binding in major depression: a positron emission tomography study with [¹¹ C]DASB. <i>Psychopharmacology</i> , 2011, 213, 555-562.	1.5	65
539	Dose-dependent binding of AZD3783 to brain 5-HT _{1B} receptors in non-human primates and human subjects: a positron emission tomography study with [¹¹ C]AZ10419369. <i>Psychopharmacology</i> , 2011, 213, 533-545.	1.5	29

#	ARTICLE	IF	CITATIONS
540	Translocator Protein PET Imaging for Glial Activation in Multiple Sclerosis. <i>Journal of NeuroImmune Pharmacology</i> , 2011, 6, 354-361.	2.1	98
541	(R)-[¹¹ C]Verapamil PET studies to assess changes in P-glycoprotein expression and functionality in rat blood-brain barrier after exposure to kainate-induced status epilepticus. <i>BMC Medical Imaging</i> , 2011, 11, 1.	1.4	43
542	Medial prefrontal cortex serotonin 1A and 2A receptor binding interacts to predict threat-related amygdala reactivity. <i>Biology of Mood & Anxiety Disorders</i> , 2011, 1, 2.	4.7	45
543	Validation of reference tissue model of PET ligand [¹¹ C](+)-3-MPB for the muscarinic cholinergic receptor in the living brain of conscious monkey. <i>Synapse</i> , 2011, 65, 548-551.	0.6	5
544	Sensitivity of kinetic macro parameters to changes in dopamine synthesis, storage, and metabolism: A simulation study for [¹⁸ F]FDOPA PET by a model with detailed dopamine pathway. <i>Synapse</i> , 2011, 65, 751-762.	0.6	10
545	A nonlocal averaging technique for kinetic parameter estimation from dynamic PET data. , 2011, , .		1
546	Brain and Whole-Body Imaging in Rhesus Monkeys of ¹¹ C-NOP-1A, a Promising PET Radioligand for Nociceptin/Orphanin FQ Peptide Receptors. <i>Journal of Nuclear Medicine</i> , 2011, 52, 1638-1645.	2.8	50
547	¹¹ C-NS14492 as a Novel PET Radioligand for Imaging Cerebral ± 7 Nicotinic Acetylcholine Receptors: In Vivo Evaluation and Drug Occupancy Measurements. <i>Journal of Nuclear Medicine</i> , 2011, 52, 1449-1456.	2.8	56
548	Kinetic Analysis and Quantification of the Dopamine Transporter in the Nonhuman Primate Brain with ¹¹ C-PE2I and ¹⁸ F-FE-PE2I. <i>Journal of Nuclear Medicine</i> , 2011, 52, 132-139.	2.8	51
549	Imaging of the Striatal and Extrastriatal Dopamine Transporter with ¹⁸ F-LBT-999: Quantification, Biodistribution, and Radiation Dosimetry in Nonhuman Primates. <i>Journal of Nuclear Medicine</i> , 2011, 52, 1313-1321.	2.8	19
550	Relationship of monoamine oxidase A binding to adaptive and maladaptive personality traits. <i>Psychological Medicine</i> , 2011, 41, 1051-1060.	2.7	43
551	<i>in vivo</i> Variation in Metabotropic Glutamate Receptor Subtype 5 Binding Using Positron Emission Tomography and [¹¹ C]ABP688. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2011, 31, 2169-2180.	2.4	70
552	Correlation of Individual Differences in Schizotypal Personality Traits With Amphetamine-Induced Dopamine Release in Striatal and Extrastriatal Brain Regions. <i>American Journal of Psychiatry</i> , 2011, 168, 418-426.	4.0	73
553	Presynaptic 5-HT1A is Related to 5-HTT Receptor Density in the Human Brain. <i>Neuropsychopharmacology</i> , 2011, 36, 2258-2265.	2.8	35
554	Muscarinic Receptor Occupancy and Cognitive Impairment: A PET Study with [¹¹ C](+)-3-MPB and Scopolamine in Conscious Monkeys. <i>Neuropsychopharmacology</i> , 2011, 36, 1455-1465.	2.8	24
555	Mixed-Affinity Binding in Humans with 18-kDa Translocator Protein Ligands. <i>Journal of Nuclear Medicine</i> , 2011, 52, 24-32.	2.8	330
557	Failure to Modulate Attentional Control in Advanced Aging Linked to White Matter Pathology. <i>Cerebral Cortex</i> , 2012, 22, 1038-1051.	1.6	68
558	PET Imaging of Nicotinic Acetylcholine Receptors in Baboons with ¹⁸ F-AZAN, a Radioligand with Improved Brain Kinetics. <i>Journal of Nuclear Medicine</i> , 2012, 53, 121-129.	2.8	32

#	ARTICLE	IF	CITATIONS
559	PET Imaging of $\hat{1}\pm 4\hat{1}^{22*}$ Nicotinic Acetylcholine Receptors: Quantitative Analysis of 18F-Nifene Kinetics in the Nonhuman Primate. <i>Journal of Nuclear Medicine</i> , 2012, 53, 1471-1480.	2.8	26
560	Brain and Whole-Body Imaging of Nociceptin/Orphanin FQ Peptide Receptor in Humans Using the PET Ligand $\langle \sup \rangle 11 \langle /sup \rangle$ C-NOP-1A. <i>Journal of Nuclear Medicine</i> , 2012, 53, 385-392.	2.8	65
561	Methylphenidate-Elicited Dopamine Increases in Ventral Striatum Are Associated with Long-Term Symptom Improvement in Adults with Attention Deficit Hyperactivity Disorder. <i>Journal of Neuroscience</i> , 2012, 32, 841-849.	1.7	181
562	Direct 4D parametric imaging for linearized models of reversibly binding PET tracers using generalized AB-EM reconstruction. <i>Physics in Medicine and Biology</i> , 2012, 57, 733-755.	1.6	35
563	Kinetic parameter estimation using a closed-form expression via integration by parts. <i>Physics in Medicine and Biology</i> , 2012, 57, 5809-5821.	1.6	10
564	In Vivo Measurement of the Affinity and Density of Metabotropic Glutamate Receptor Subtype 1 in Rat Brain Using 18F-FITM in Small-Animal PET. <i>Journal of Nuclear Medicine</i> , 2012, 53, 1601-1607.	2.8	18
565	Convergent Effects of Acute Stress and Glucocorticoid Exposure upon MAO-A in Humans. <i>Journal of Neuroscience</i> , 2012, 32, 17120-17127.	1.7	29
566	Decreased dopamine activity predicts relapse in methamphetamine abusers. <i>Molecular Psychiatry</i> , 2012, 17, 918-925.	4.1	186
567	Cognitive Profile of Amyloid Burden and White Matter Hyperintensities in Cognitively Normal Older Adults. <i>Journal of Neuroscience</i> , 2012, 32, 16233-16242.	1.7	161
568	Clinical Validation of $\langle \sup \rangle 18 \langle /sup \rangle$ F-AZD4694, an Amyloid- $\hat{1}^2$ â€“Specific PET Radioligand. <i>Journal of Nuclear Medicine</i> , 2012, 53, 415-424.	2.8	204
569	Relative Equilibrium Plot Improves Graphical Analysis and Allows Bias Correction of Standardized Uptake Value Ratio in Quantitative $\langle \sup \rangle 11 \langle /sup \rangle$ C-PiB PET Studies. <i>Journal of Nuclear Medicine</i> , 2012, 53, 622-628.	2.8	16
570	$\langle \sup \rangle 18 \langle /sup \rangle$ F-FEAnGA for PET of $\hat{1}^2$ -Glucuronidase Activity in Neuroinflammation. <i>Journal of Nuclear Medicine</i> , 2012, 53, 451-458.	2.8	26
571	Recent Software Developments and Applications in Functional Imaging. <i>Current Pharmaceutical Biotechnology</i> , 2012, 13, 2166-2181.	0.9	1
572	Parametric [^{11}C]flumazenil images. <i>Nuclear Medicine Communications</i> , 2012, 33, 422-430.	0.5	9
573	Increased Adenosine A1 Receptor Levels in Hemianopia Patients After Cerebral Injury. <i>Clinical Nuclear Medicine</i> , 2012, 37, 1146-1151.	0.7	4
574	Gaussian Process Models of Dynamic PET for Functional Volume Definition in Radiation Oncology. <i>IEEE Transactions on Medical Imaging</i> , 2012, 31, 1542-1556.	5.4	11
576	Discrepancies in the P-glycoprotein-Mediated Transport of 18F-MPPF: A Pharmacokinetic Study in Mice and Non-human Primates. <i>Pharmaceutical Research</i> , 2012, 29, 2468-2476.	1.7	27
577	Difficulties in dopamine transporter radioligand PET analysis: the example of LBT-999 using [^{18}F] and [^{11}C] labelling. <i>Nuclear Medicine and Biology</i> , 2012, 39, 227-233.	0.3	12

#	ARTICLE	IF	CITATIONS
578	Initial evaluation in healthy humans of [18F]DPA-714, a potential PET biomarker for neuroinflammation. <i>Nuclear Medicine and Biology</i> , 2012, 39, 570-578.	0.3	115
579	Synthesis and preclinical evaluation of [11C]D617, a metabolite of (R)-[11C]verapamil. <i>Nuclear Medicine and Biology</i> , 2012, 39, 530-539.	0.3	16
580	The relationship between naloxone-induced cortisol and mu opioid receptor availability in mesolimbic structures is disrupted in alcohol dependent subjects. <i>Alcohol</i> , 2012, 46, 511-517.	0.8	11
581	Downregulation of Brain Phosphodiesterase Type IV Measured with 11C-(R)-Rolipram Positron Emission Tomography in Major Depressive Disorder. <i>Biological Psychiatry</i> , 2012, 72, 548-554.	0.7	60
582	Pre- and Postsynaptic Serotonergic Differences in Males with Extreme Levels of Impulsive Aggression Without Callous Unemotional Traits: A Positron Emission Tomography Study Using 11C-DASB and 11C-MDL100907. <i>Biological Psychiatry</i> , 2012, 72, 1004-1011.	0.7	41
583	A study of non-invasive Patlak quantification for whole-body dynamic FDG-PET studies of mice. <i>Biomedical Signal Processing and Control</i> , 2012, 7, 438-446.	3.5	8
584	Multi-Scale hierarchical generation of PET parametric maps: Application and testing on a [11C]DPN study. <i>NeuroImage</i> , 2012, 59, 2485-2493.	2.1	13
585	Assessment of serotonin release capacity in the human brain using dexfenfluramine challenge and [18F]altanserin positron emission tomography. <i>NeuroImage</i> , 2012, 59, 3922-3932.	2.1	30
586	A short-scan method for k3 estimation with moderately reversible PET ligands: Application of irreversible model to early-phase PET data. <i>NeuroImage</i> , 2012, 59, 3149-3158.	2.1	5
587	Comparative evaluation of Logan and relative-equilibrium graphical methods for parametric imaging of dynamic [18F]FDDNP PET determinations. <i>NeuroImage</i> , 2012, 60, 241-251.	2.1	5
588	PET imaging of cholinergic deficits in rats using [18F]fluoroethoxybenzovesamicol ([18F]FEOBV). <i>NeuroImage</i> , 2012, 62, 555-561.	2.1	33
589	Combining image-derived and venous input functions enables quantification of serotonin-1A receptors with [carbonyl-11C]WAY-100635 independent of arterial sampling. <i>NeuroImage</i> , 2012, 62, 199-206.	2.1	19
590	Combined imaging biomarkers for therapy evaluation in glioblastoma multiforme: correlating sodium MRI and F-18 FLT PET on a voxel-wise basis. <i>Magnetic Resonance Imaging</i> , 2012, 30, 1268-1278.	1.0	32
591	Quantification of Neuroreceptors and Neurotransporters. <i>NeuroMethods</i> , 2012, , 149-161.	0.2	1
592	Measuring endogenous changes in serotonergic neurotransmission in humans: a [11C]CUMI-101 PET challenge study. <i>Molecular Psychiatry</i> , 2012, 17, 1254-1260.	4.1	63
593	Functional Neuroimaging in Exercise and Sport Sciences. , 2012, , .		17
594	[11C]phenytoin revisited: synthesis by [11C]CO carbonylation and first evaluation as a P-gp tracer in rats. <i>EJNMMI Research</i> , 2012, 2, 36.	1.1	28
595	Kinetic analysis and test-retest variability of the radioligand [11C](R)-PK11195 binding to TSPO in the human brain - a PET study in control subjects. <i>EJNMMI Research</i> , 2012, 2, 15.	1.1	86

#	ARTICLE	IF	CITATIONS
596	Blockade of the brain histamine H3 receptor by JNJ-39220675: preclinical PET studies with [11C]GSK189254 in anesthetized baboon. <i>Psychopharmacology</i> , 2012, 223, 447-455.	1.5	16
597	Nonuniform Cardiac Denervation Observed by 11C-meta-Hydroxyephedrine PET in 6-OHDA-Treated Monkeys. <i>PLoS ONE</i> , 2012, 7, e35371.	1.1	22
598	Combining [11C]-Anx5 PET Imaging with Serum Biomarkers for Improved Detection in Live Mice of Modest Cell Death in Human Solid Tumor Xenografts. <i>PLoS ONE</i> , 2012, 7, e42151.	1.1	11
599	Dynamic PET and Optical Imaging and Compartment Modeling using a Dual-labeled Cyclic RGD Peptide Probe. <i>Theranostics</i> , 2012, 2, 746-756.	4.6	34
600	Improved kinetic analysis of dynamic PET data with optimized HYPR-RLR. <i>Medical Physics</i> , 2012, 39, 3319-3331.	1.6	39
601	Compensation for cranial spill-in into the cerebellum improves quantitation of striatal dopamine D _{2/3} receptors in rats with prolonged [¹⁸ F]â€”DMFP infusions. <i>Synapse</i> , 2012, 66, 705-713.	0.6	9
602	Analysis of (R)- and (S)-[11C]rolipram Kinetics in Canine Myocardium for the Evaluation of Phosphodiesterase-4 with PET. <i>Molecular Imaging and Biology</i> , 2012, 14, 225-236.	1.3	9
603	Importance of Quantification for the Analysis of PET Data in Oncology: Review of Current Methods and Trends for the Future. <i>Molecular Imaging and Biology</i> , 2012, 14, 131-146.	1.3	86
604	Imaging for metabotropic glutamate receptor subtype 1 in rat and monkey brains using PET with [18F]FITM. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 632-641.	3.3	27
605	Model-independent plot of dynamic PET data facilitates data interpretation and model selection. <i>Journal of Theoretical Biology</i> , 2012, 295, 1-8.	0.8	1
606	The relationship between naloxone-induced cortisol and delta opioid receptor availability in mesolimbic structures is disrupted in alcohol-dependent subjects. <i>Addiction Biology</i> , 2013, 18, 181-192.	1.4	13
607	Introduction to the analysis of PET data in oncology. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2013, 40, 419-436.	0.8	5
608	Modeling of PET data in CNS drug discovery and development. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2013, 40, 267-279.	0.8	37
609	In vivo TSPO imaging in patients with multiple sclerosis: a brain PET study with [18F]FEDAA1106. <i>EJNMMI Research</i> , 2013, 3, 30.	1.1	66
610	The relationship between antipsychotic D2 occupancy and change in frontal metabolism and working memory. <i>Psychopharmacology</i> , 2013, 227, 221-229.	1.5	49
611	The neuroinflammation marker translocator protein is not elevated in individuals with mild-to-moderate depression: A [11C]PBR28 PET study. <i>Brain, Behavior, and Immunity</i> , 2013, 33, 131-138.	2.0	180
612	Low background and high contrast PET imaging of amyloid-Î² with [11C]AZD2995 and [11C]AZD2184 in Alzheimer's disease patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 580-593.	3.3	16
613	Suitability of [18F]Altanserin and PET to Determine 5-HT2A Receptor Availability in the Rat Brain: In Vivo and In Vitro Validation of Invasive and Non-Invasive Kinetic Models. <i>Molecular Imaging and Biology</i> , 2013, 15, 456-467.	1.3	9

#	ARTICLE	IF	CITATIONS
614	GABAA Receptor Imaging With Positron Emission Tomography in the Human Newborn: A Unique Binding Pattern. <i>Pediatric Neurology</i> , 2013, 48, 459-462.	1.0	15
615	[¹¹ C]quinidine and [¹¹ C]laniquidar PET imaging in a chronic rodent epilepsy model: Impact of epilepsy and drug-responsiveness. <i>Nuclear Medicine and Biology</i> , 2013, 40, 764-775.	0.3	22
616	An Overview of PET Neuroimaging. <i>Seminars in Nuclear Medicine</i> , 2013, 43, 449-461.	2.5	55
620	Imaging the Role of GABA in Movement Disorders. <i>Current Neurology and Neuroscience Reports</i> , 2013, 13, 385.	2.0	20
621	Noninvasive k ₃ estimation method for slow dissociation PET ligands: application to [¹¹ C]Pittsburgh compound B. <i>EJNMMI Research</i> , 2013, 3, 76.	1.1	0
622	Model selection in measures of vascular parameters using dynamic contrast-enhanced MRI: experimental and clinical applications. <i>NMR in Biomedicine</i> , 2013, 26, 1028-1041.	1.6	86
623	Quantification of the Specific Translocator Protein Signal of ¹⁸ F-PBR111 in Healthy Humans: A Genetic Polymorphism Effect on In Vivo Binding. <i>Journal of Nuclear Medicine</i> , 2013, 54, 1915-1923.	2.8	105
624	Microglial activation in Alzheimer's disease: an (R)-[¹¹ C]PK11195 positron emission tomography study. <i>Neurobiology of Aging</i> , 2013, 34, 128-136.	1.5	145
625	Assessment of cerebral P-glycoprotein expression and function with PET by combined [¹¹ C]inhibitor and [¹¹ C]substrate scans in rats. <i>Nuclear Medicine and Biology</i> , 2013, 40, 755-763.	0.3	15
626	Characterizing infarction and selective neuronal loss following temporary focal cerebral ischemia in the rat: A multi-modality imaging study. <i>Neurobiology of Disease</i> , 2013, 51, 120-132.	2.1	38
627	CRH receptor antagonism reverses the effect of social subordination upon central GABAA receptor binding in estradiol-treated ovariectomized female rhesus monkeys. <i>Neuroscience</i> , 2013, 250, 300-308.	1.1	26
628	Analysis of [¹¹ C]methyl-candesartan kinetics in the rat kidney for the assessment of angiotensin II type 1 receptor density in vivo with PET. <i>Nuclear Medicine and Biology</i> , 2013, 40, 252-261.	0.3	12
629	Graphic plot analysis for estimating binding potential of translocator protein (TSPO) in positron emission tomography studies with [¹⁸ F]FEDAA1106. <i>NeuroImage</i> , 2013, 69, 78-86.	2.1	5
630	A positron emission tomography study in healthy volunteers to estimate mGluR5 receptor occupancy of AZD2066 – Estimating occupancy in the absence of a reference region. <i>NeuroImage</i> , 2013, 82, 160-169.	2.1	40
631	Pre-clinical characterization of [¹¹ C]R05013853 as a novel radiotracer for imaging of the glycine transporter type 1 by positron emission tomography. <i>NeuroImage</i> , 2013, 75, 291-300.	2.1	16
632	SAKE: A new quantification tool for positron emission tomography studies. <i>Computer Methods and Programs in Biomedicine</i> , 2013, 111, 199-213.	2.6	14
633	Advances in PET Imaging of P-Glycoprotein Function at the Blood-Brain Barrier. <i>ACS Chemical Neuroscience</i> , 2013, 4, 225-237.	1.7	64
634	¹⁸ F-FPEB, a PET Radiopharmaceutical for Quantifying Metabotropic Glutamate 5 Receptors: A First-in-Human Study of Radiochemical Safety, Biokinetics, and Radiation Dosimetry. <i>Journal of Nuclear Medicine</i> , 2013, 54, 388-396.	2.8	95

#	ARTICLE	IF	CITATIONS
635	Predominance of D2 Receptors in Mediating Dopamine's Effects in Brain Metabolism: Effects of Alcoholism. <i>Journal of Neuroscience</i> , 2013, 33, 4527-4535.	1.7	36
636	CD33 Alzheimer's disease locus: altered monocyte function and amyloid biology. <i>Nature Neuroscience</i> , 2013, 16, 848-850.	7.1	485
637	The relation of developmental changes in brain serotonin transporter (5HTT) and 5HT1A receptor binding to emotional behavior in female rhesus monkeys: Effects of social status and 5HTT genotype. <i>Neuroscience</i> , 2013, 228, 83-100.	1.1	22
638	Kinetic analysis of [¹¹ C]befloxatone in the human brain, a selective radioligand to image monoamine oxidase A. <i>EJNMMI Research</i> , 2013, 3, 78.	1.1	17
639	In vivo characterization of the early states of the amyloid-beta network. <i>Brain</i> , 2013, 136, 2239-2252.	3.7	104
640	Glycine Transporter Type 1 Occupancy by Bitopertin: a Positron Emission Tomography Study in Healthy Volunteers. <i>Neuropsychopharmacology</i> , 2013, 38, 504-512.	2.8	47
641	Subanesthetic Doses of Ketamine Transiently Decrease Serotonin Transporter Activity: A PET Study in Conscious Monkeys. <i>Neuropsychopharmacology</i> , 2013, 38, 2666-2674.	2.8	58
642	Reference Region Approaches in PET: a Comparative Study on Multiple Radioligands. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2013, 33, 888-897.	2.4	80
643	Voxelwise Quantification of [¹¹ C]-Rolipram PET Data: A Comparison Between Model-Based and Data-Driven Methods. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2013, 33, 1032-1040.	2.4	12
644	First Experience of ¹⁸ F-Alfatide in Lung Cancer Patients Using a New Lyophilized Kit for Rapid Radiofluorination. <i>Journal of Nuclear Medicine</i> , 2013, 54, 691-698.	2.8	167
645	Effects of Anesthesia and Species on the Uptake or Binding of Radioligands In Vivo in the Göttingen Minipig. <i>BioMed Research International</i> , 2013, 2013, 1-9.	0.9	20
646	Voxel-Based Imaging of Translocator Protein 18Kda (TSPO) in High-Resolution PET. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2013, 33, 348-350.	2.4	10
647	PET Imaging of High-Affinity ¹⁸ F-AZAN, a Radioligand with Optimal Brain Kinetics. <i>Journal of Nuclear Medicine</i> , 2013, 54, 1308-1314.	2.8	46
648	Reference Region Automatic Extraction in Dynamic [¹¹ C]PIB. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2013, 33, 1725-1731.	2.4	20
649	Initial Human PET Studies of Metabotropic Glutamate Receptor Type 1 Ligand ¹¹ C-ITMM. <i>Journal of Nuclear Medicine</i> , 2013, 54, 1302-1307.	2.8	34
650	Propofol Decreases In Vivo Binding of ¹¹ C-PBR28 to Translocator Protein (18 kDa) in the Human Brain. <i>Journal of Nuclear Medicine</i> , 2013, 54, 64-69.	2.8	30
651	Synthesis and Evaluation of ¹⁸ F-FE-PEO in Rodents: An ¹⁸ F-Labeled Full Agonist for Opioid Receptor Imaging. <i>Journal of Nuclear Medicine</i> , 2013, 54, 299-305.	2.8	19
652	Assessment of Cellular Proliferation in Tumors by PET Using ¹⁸ F-ISO-1. <i>Journal of Nuclear Medicine</i> , 2013, 54, 350-357.	2.8	76

#	ARTICLE	IF	CITATIONS
653	PET probes for imaging brain acetylcholinesterase. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2013, 56, 172-179.	0.5	24
654	Population derived principle component analysis based model for the [¹⁸ F]PBR111 arterial input function in rats. , 2013, , .		0
655	A whole body mouse sized \times SPECT image quality phantom. , 2013, , .		0
656	In Vivo Imaging of Brain Aromatase in Female Baboons: [¹¹ C]Vorzole Kinetics and Effect of the Menstrual Cycle. <i>Molecular Imaging</i> , 2013, 12, 7290.2013.00068.	0.7	18
657	Molecular Imaging PET and SPECT Approaches for Improving Productivity of Antipsychotic Drug Discovery and Development. <i>Current Medicinal Chemistry</i> , 2013, 20, 378-388.	1.2	6
658	Development of [¹¹ C]erlotinib Positron Emission Tomography for <i>In Vivo</i> Evaluation of EGF Receptor Mutational Status. <i>Clinical Cancer Research</i> , 2013, 19, 183-193.	3.2	117
659	Population-Based Input Function Modeling for [¹⁸ F]FMPEP-d2, an Inverse Agonist Radioligand for Cannabinoid CB1 Receptors: Validation in Clinical Studies. <i>PLoS ONE</i> , 2013, 8, e60231.	1.1	31
660	Quantitative Analysis of PiB-PET with FreeSurfer ROIs. <i>PLoS ONE</i> , 2013, 8, e73377.	1.1	192
661	PET Reveals Inflammation around Calcified <i>Taenia solium</i> Granulomas with Perilesional Edema. <i>PLoS ONE</i> , 2013, 8, e74052.	1.1	41
662	Direct Estimation of Kinetic Parametric Images for Dynamic PET. <i>Theranostics</i> , 2013, 3, 802-815.	4.6	103
664	How to Study Smoking and Drinking with PET. , 0, , .		2
665	Human Brain Imaging of Adenosine Receptors. , 2014, , 161-186.		0
666	BMI Modulates Calorie-Dependent Dopamine Changes in Accumbens from Glucose Intake. <i>PLoS ONE</i> , 2014, 9, e101585.	1.1	37
667	Quantitative preclinical PET imaging: opportunities and challenges. <i>Frontiers in Physics</i> , 2014, 2, .	1.0	55
668	Brain Imaging of Sigma Receptors. , 2014, , 99-112.		0
669	Functional brain imaging and its application to uncover mechanisms driving food intake in humans. <i>Journal of Biomedical Graphics and Computing</i> , 2014, 4, .	0.2	2
670	Physiological Modelling of Positron Emission Tomography Images. , 2014, , 417-448.		1
671	Test-retest variability of adenosine A2A binding in the human brain with ¹¹ C-TMSX and PET. <i>EJNMMI Research</i> , 2014, 4, 76.	1.1	13

#	ARTICLE	IF	CITATIONS
672	PET Imaging of Ischemia-Induced Impairment of Mitochondrial Complex I Function in Monkey Brain. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2014, 34, 708-714.	2.4	34
673	Noninvasive Quantification of Metabotropic Glutamate Receptor Type 1 with [¹¹ C]ITDM: a Small-Animal PET Study. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2014, 34, 606-612.	2.4	17
674	A Graphical Method to Compare the <i>in vivo</i> Binding Potential of PET Radioligands in the Absence of a Reference Region: Application to [¹¹ C]PBR28 and [¹⁸ F]PBR111 for TSPO Imaging. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2014, 34, 1162-1168.	2.4	38
675	Kinetic Modeling of the Monoamine Oxidase B Radioligand [¹¹ C]SL25.1188 in Human Brain with High-Resolution Positron Emission Tomography. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2014, 34, 883-889.	2.4	83
676	Radiosynthesis and Validation of ¹⁸ F-FP-CMT, a Phenyltropane with Superior Properties for Imaging the Dopamine Transporter in Living Brain. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2014, 34, 1148-1156.	2.4	16
678	First D1-like receptor PET imaging of the rat and primate kidney: implications for human disease monitoring. <i>American Journal of Physiology - Renal Physiology</i> , 2014, 307, F116-F121.	1.3	4
679	Comparison of methods for evaluating radiolabelled Annexin A5 uptake in pre-clinical PET oncological studies. <i>Nuclear Medicine and Biology</i> , 2014, 41, 793-800.	0.3	5
680	The Use of 18F-BCPP-EF as a PET Probe for Complex I Activity in the Brain. <i>Methods in Enzymology</i> , 2014, 547, 417-431.	0.4	9
681	Modulation of Brain Functioning by Deep Brain Stimulation: Contributions from PET Functional Imaging. , 2014, , 1011-1033.		0
682	Decreased dopamine brain reactivity in marijuana abusers is associated with negative emotionality and addiction severity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, E3149-56.	3.3	180
683	Recent advances in parametric neuroreceptor mapping with dynamic PET: basic concepts and graphical analyses. <i>Neuroscience Bulletin</i> , 2014, 30, 733-754.	1.5	9
684	Evaluation of a direct 4D reconstruction method using generalised linear least squares for estimating nonlinear micro-parametric maps. <i>Annals of Nuclear Medicine</i> , 2014, 28, 860-873.	1.2	4
685	Development of novel PET probe [¹¹ C](<i>R,R</i>)HAPT and its stereoisomer [¹¹ C](<i>S,S</i>)HAPT for vesicular acetylcholine transporter imaging: A PET study in conscious monkey. <i>Synapse</i> , 2014, 68, n/a-n/a.	0.6	9
686	Dose-dependent, saturable occupancy of the metabotropic glutamate subtype 5 receptor by fenobam as measured with [¹¹ C]ABP688 PET imaging. <i>Synapse</i> , 2014, 68, 565-573.	0.6	21
687	Parametric Methods for Quantification of 18F-FAZA Kinetics in Non-Small Cell Lung Cancer Patients. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1772-1777.	2.8	12
688	Oestradiol Alters Central 5-HT _{1A} Receptor Binding Potential Differences Related to Psychosocial Stress but not Differences Related to 5-HTTLPR Genotype in Female Rhesus Monkeys. <i>Journal of Neuroendocrinology</i> , 2014, 26, 80-88.	1.2	14
689	Dynamic contrast enhanced MRI parameters and tumor cellularity in a rat model of cerebral glioma at 7 T. <i>Magnetic Resonance in Medicine</i> , 2014, 71, 2206-2214.	1.9	63
690	Development of 18F-labeled radiotracers for neuroreceptor imaging with positron emission tomography. <i>Neuroscience Bulletin</i> , 2014, 30, 777-811.	1.5	46

#	ARTICLE	IF	CITATIONS
691	Effects of repeated treatment with the dopamine D2/D3 receptor partial agonist aripiprazole on striatal D2/D3 receptor availability in monkeys. <i>Psychopharmacology</i> , 2014, 231, 613-619.	1.5	5
692	Evaluation of ¹⁸ F-BCPP-EF for mitochondrial complex 1 imaging in the brain of conscious monkeys using PET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 755-763.	3.3	35
693	Imaging Nicotine- and Amphetamine-Induced Dopamine Release in Rhesus Monkeys with [¹¹ C]PHNO vs [¹¹ C]raclopride PET. <i>Neuropsychopharmacology</i> , 2014, 39, 866-874.	2.8	43
694	In Vivo Assessment of Brain White Matter Inflammation in Multiple Sclerosis with ¹⁸ F-PBR111 PET. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1112-1118.	2.8	82
695	¹⁸ F-ASEM, a Radiolabeled Antagonist for Imaging the $\alpha 7$ -Nicotinic Acetylcholine Receptor with PET. <i>Journal of Nuclear Medicine</i> , 2014, 55, 672-677.	2.8	65
696	Stimulant-induced dopamine increases are markedly blunted in active cocaine abusers. <i>Molecular Psychiatry</i> , 2014, 19, 1037-1043.	4.1	116
697	Evaluation of ¹⁸ F-UCB-H as a Novel PET Tracer for Synaptic Vesicle Protein 2A in the Brain. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1336-1341.	2.8	65
698	Synthesis and evaluation of the novel 2-[¹⁸ F]fluoro-3-propoxy-triazole-pyridine-substituted losartan for imaging AT1 receptors. <i>Bioorganic and Medicinal Chemistry</i> , 2014, 22, 3931-3937.	1.4	15
699	Synthesis and Evaluation of Translocator 18 kDa Protein (TSPO) Positron Emission Tomography (PET) Radioligands with Low Binding Sensitivity to Human Single Nucleotide Polymorphism rs6971. <i>ACS Chemical Neuroscience</i> , 2014, 5, 963-971.	1.7	91
700	Deriving physiological information from PET images: from SUV to compartmental modelling. <i>Clinical and Translational Imaging</i> , 2014, 2, 239-251.	1.1	38
701	Imaging of $\alpha 7$ nicotinic acetylcholine receptors in brain and cerebral vasculature of juvenile pigs with [¹⁸ F]NS14490. <i>EJNMMI Research</i> , 2014, 4, 43.	1.1	17
702	Discovery and Development of ¹¹ C-Lu AE92686 as a Radioligand for PET Imaging of Phosphodiesterase10A in the Brain. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1513-1518.	2.8	35
703	Quality and Precision of Parametric Images Created From PET Sinogram Data by Direct Reconstruction: Proof of Concept. <i>IEEE Transactions on Medical Imaging</i> , 2014, 33, 695-707.	5.4	4
704	¹¹ C-Cetrozole: An Improved C- ¹¹ C-Methylated PET Probe for Aromatase Imaging in the Brain. <i>Journal of Nuclear Medicine</i> , 2014, 55, 852-857.	2.8	31
705	Characterization of [¹¹ C]Cimbi-36 as an agonist PET radioligand for the 5-HT2A and 5-HT2C receptors in the nonhuman primate brain. <i>NeuroImage</i> , 2014, 84, 342-353.	2.1	60
706	Effects of serotonin-2A receptor binding and gender on personality traits and suicidal behavior in borderline personality disorder. <i>Psychiatry Research - Neuroimaging</i> , 2014, 222, 140-148.	0.9	66
707	Cortical surface-based analysis reduces bias and variance in kinetic modeling of brain PET data. <i>NeuroImage</i> , 2014, 92, 225-236.	2.1	179
708	Kinetic modeling in pre-clinical positron emission tomography. <i>Zeitschrift Fur Medizinische Physik</i> , 2014, 24, 274-285.	0.6	16

#	ARTICLE	IF	CITATIONS
709	[18F]Altanserin and small animal PET: Impact of multidrug efflux transporters on ligand brain uptake and subsequent quantification of 5-HT _{2A} receptor densities in the rat brain. Nuclear Medicine and Biology, 2014, 41, 1-9.	0.3	13
710	¹⁸ F-MCL-524, an ¹⁸ F-Labeled Dopamine D ₂ and D ₃ Receptor Agonist Sensitive to Dopamine: A Preliminary PET Study. Journal of Nuclear Medicine, 2014, 55, 1164-1170.	2.8	20
711	Kinetic Analysis of [¹¹ C]Vorzole Binding in the Human Brain with Positron Emission Tomography. Molecular Imaging, 2014, 13, 7290.2014.00004.	0.7	8
712	Impact of acquisition time-window on clinical whole-body PET parametric imaging. , 2014, , .		16
713	PET imaging studies show enhanced expression of mGluR5 and inflammatory response during progressive degeneration in ALS mouse model expressing SOD1-G93A gene. Journal of Neuroinflammation, 2015, 12, 217.	3.1	26
714	Exploring the effects of coexisting amyloid in subcortical vascular cognitive impairment. BMC Neurology, 2015, 15, 197.	0.8	9
715	Further evaluation of [¹¹ C]MP-10 as a radiotracer for phosphodiesterase 10A: PET imaging study in rhesus monkeys and brain tissue metabolite analysis. Synapse, 2015, 69, 86-95.	0.6	18
716	In vivo quantification of the [¹¹ C]DASB binding in the normal canine brain using positron emission tomography. BMC Veterinary Research, 2015, 11, 308.	0.7	4
717	Generalized whole-body Patlak parametric imaging for enhanced quantification in clinical PET. Physics in Medicine and Biology, 2015, 60, 8643-8673.	1.6	78
718	Peritumoral tissue compression is predictive of exudate flux in a rat model of cerebral tumor: an MRI study in an embedded tumor. NMR in Biomedicine, 2015, 28, 1557-1569.	1.6	21
719	Balanced modulation of striatal activation from D ₂ /D ₃ receptors in caudate and ventral striatum: Disruption in cannabis abusers. Human Brain Mapping, 2015, 36, 3154-3166.	1.9	19
720	Quantitative Graphical Analysis of Simultaneous Dynamic PET/MRI For Assessment of Prostate Cancer. Clinical Nuclear Medicine, 2015, 40, e236-e240.	0.7	10
721	Positron Emission Tomography (PET): Quantification and Kinetic Modeling. , 2015, , .		1
722	Quantitative Amyloid Imaging Using Image-Derived Arterial Input Function. PLoS ONE, 2015, 10, e0122920.	1.1	30
723	Improved Visualization and Specific Binding for Metabotropic Glutamate Receptor Subtype 1 (mGluR1) Using [¹¹ C]ITMM with Ultra-High Specific Activity in Small-Animal PET. PLoS ONE, 2015, 10, e0130006.	1.1	7
724	Novel Histone Deacetylase Class IIa Selective Substrate Radiotracers for PET Imaging of Epigenetic Regulation in the Brain. PLoS ONE, 2015, 10, e0133512.	1.1	23
725	Comparison of DCE-CT models for quantitative evaluation of <i>K^{trans}</i> in larynx tumors. Physics in Medicine and Biology, 2015, 60, 3759-3773.	1.6	8
726	COBRA: A prospective multimodal imaging study of dopamine, brain structure and function, and cognition. Brain Research, 2015, 1612, 83-103.	1.1	67

#	ARTICLE	IF	CITATIONS
727	Acute Vagal Nerve Stimulation Lowers α_2 Adrenoceptor Availability: Possible Mechanism of Therapeutic Action. <i>Brain Stimulation</i> , 2015, 8, 702-707.	0.7	34
728	Radiosynthesis and initial characterization of a PDE10A specific PET tracer [¹⁸ F]AMG 580 in non-human primates. <i>Nuclear Medicine and Biology</i> , 2015, 42, 654-663.	0.3	11
729	In Vivo Ketamine-Induced Changes in [¹¹ C]ABP688 Binding to Metabotropic Glutamate Receptor Subtype 5. <i>Biological Psychiatry</i> , 2015, 77, 266-275.	0.7	82
730	Comparison of standardized uptake values with volume of distribution for quantitation of [¹¹ C]PBR28 brain uptake. <i>Nuclear Medicine and Biology</i> , 2015, 42, 305-308.	0.3	18
731	Evidence that Formulations of the Selective MAO-B Inhibitor, Selegiline, which Bypass First-Pass Metabolism, also Inhibit MAO-A in the Human Brain. <i>Neuropsychopharmacology</i> , 2015, 40, 650-657.	2.8	63
732	Decreased in vivo α_2 adrenoceptor binding in the Flinders Sensitive Line rat model of depression. <i>Neuropharmacology</i> , 2015, 91, 97-102.	2.0	22
733	[¹⁸ F]DPA-714 PET imaging of translocator protein TSPO (18 kDa) in the normal and excitotoxically-lesioned nonhuman primate brain. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 478-494.	3.3	45
734	Mapping α_2 Adrenoceptors of the Human Brain with [¹¹ C]-Yohimbine. <i>Journal of Nuclear Medicine</i> , 2015, 56, 392-398.	2.8	31
735	Recovery of dopamine transporters with methamphetamine detoxification is not linked to changes in dopamine release. <i>NeuroImage</i> , 2015, 121, 20-28.	2.1	61
736	The Effect of Body Posture on Brain Glymphatic Transport. <i>Journal of Neuroscience</i> , 2015, 35, 11034-11044.	1.7	283
737	Preclinical evaluation of a promising C-11 labeled PET tracer for imaging phosphodiesterase 10A in the brain of living subject. <i>NeuroImage</i> , 2015, 121, 253-262.	2.1	16
738	Effect of the myeloperoxidase inhibitor AZD3241 on microglia: a PET study in Parkinson's disease. <i>Brain</i> , 2015, 138, 2687-2700.	3.7	168
739	Evaluation of [¹¹ C]methyl-losartan and [¹¹ C]methyl-EXP3174 for PET imaging of renal AT1 receptor in rats. <i>Nuclear Medicine and Biology</i> , 2015, 42, 850-857.	0.3	7
740	Lower Monoamine Oxidase-A Total Distribution Volume in Impulsive and Violent Male Offenders with Antisocial Personality Disorder and High Psychopathic Traits: An [¹¹ C] Harmine Positron Emission Tomography Study. <i>Neuropsychopharmacology</i> , 2015, 40, 2596-2603.	2.8	60
742	Quantification of [¹¹ C]yohimbine Binding to α_2 Adrenoceptors in Rat Brain <i>in vivo</i> . <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2015, 35, 501-511.	2.4	13
743	Pharmacokinetic Modeling of Dynamic PET. , 2015, , 209-215.		0
744	Quantification of [¹⁸ F]DPA-714 Binding in the Human Brain: Initial Studies in Healthy Controls and Alzheimer's Disease Patients. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2015, 35, 766-772.	2.4	99
745	Evaluation of [¹¹ C]CB184 for imaging and quantification of TSPO overexpression in a rat model of herpes encephalitis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 1106-1118.	3.3	14

#	ARTICLE	IF	CITATIONS
746	[11C]PBR28 PET Imaging is Sensitive to Neuroinflammation in the Aged Rat. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2015, 35, 1331-1338.	2.4	26
747	An exploratory efficacy study of the amyloid imaging agent [18F]flutemetamol in Japanese Subjects. <i>Annals of Nuclear Medicine</i> , 2015, 29, 391-399.	1.2	3
748	Comparative Assessment of Parametric Neuroreceptor Mapping Approaches Based on the Simplified Reference Tissue Model Using [¹¹ C]ABP688 PET. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2015, 35, 2098-2108.	2.4	8
749	Imaging the Cannabinoid CB1 Receptor in Humans with [¹¹ C] OMAR: Assessment of Kinetic Analysis Methods, Test-Retest Reproducibility, and Gender Differences. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2015, 35, 1313-1322.	2.4	79
750	Quantitative kinetic analysis of PET amyloid imaging agents [11C]BF227 and [18F]FACT in human brain. <i>Nuclear Medicine and Biology</i> , 2015, 42, 734-744.	0.3	9
751	Quantitative <i>in vivo</i> cell-surface receptor imaging in oncology: kinetic modeling and paired-agent principles from nuclear medicine and optical imaging. <i>Physics in Medicine and Biology</i> , 2015, 60, R239-R269.	1.6	83
752	First-in-human PET quantification study of cerebral $\alpha 4\beta 2$ nicotinic acetylcholine receptors using the novel specific radioligand (α^3)-[18F]Flubatine. <i>NeuroImage</i> , 2015, 118, 199-208.	2.1	49
753	Putamen midbrain functional connectivity is related to striatal dopamine transporter availability in patients with Lewy body diseases. <i>NeuroImage: Clinical</i> , 2015, 8, 554-559.	1.4	22
754	Partial volume correction in quantitative amyloid imaging. <i>NeuroImage</i> , 2015, 107, 55-64.	2.1	188
755	Neuroinflammation and brain atrophy in former NFL players: An <i>in vivo</i> multimodal imaging pilot study. <i>Neurobiology of Disease</i> , 2015, 74, 58-65.	2.1	208
756	Presynaptic Serotonergic Regulation of Emotional Processing: A Multimodal Brain Imaging Study. <i>Biological Psychiatry</i> , 2015, 78, 563-571.	0.7	19
757	Overlapping patterns of brain activation to food and cocaine cues in cocaine abusers. <i>Human Brain Mapping</i> , 2015, 36, 120-136.	1.9	102
758	Multiple Brain Markers are Linked to Age-Related Variation in Cognition. <i>Cerebral Cortex</i> , 2016, 26, 1388-1400.	1.6	146
759	Effects of Amyloid- β Deposition on Mitochondrial Complex I Activity in Brain: A PET Study in Monkeys. , 2016, , .		1
760	Spectral Analysis of Dynamic PET Studies: A Review of 20 Years of Method Developments and Applications. <i>Computational and Mathematical Methods in Medicine</i> , 2016, 2016, 1-15.	0.7	28
761	Direct EM reconstruction of parametric images from list-mode brain PET using a novel model based on logan graphical analysis. , 2016, , .		3
762	Joint direct dynamic analysis in dual-tracer PET imaging. , 2016, , .		0
763	Quantitative Amyloid Imaging in Autosomal Dominant Alzheimer's Disease: Results from the DIAN Study Group. <i>PLoS ONE</i> , 2016, 11, e0152082.	1.1	45

#	ARTICLE	IF	CITATIONS
764	Positron emission tomography. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, 135, 229-240.	1.0	4
765	The PET Radioligand ¹⁸ F-FIMX Images and Quantifies Metabotropic Glutamate Receptor 1 in Proportion to the Regional Density of Its Gene Transcript in Human Brain. Journal of Nuclear Medicine, 2016, 57, 242-247.	2.8	32
766	Dopamine transporter availability in clinically normal aging is associated with individual differences in white matter integrity. Human Brain Mapping, 2016, 37, 621-631.	1.9	24
767	Cross-Sectional and Longitudinal Cognitive Correlates of FDDNP PET and CSF Amyloid- β^2 and Tau in Parkinson's Disease. Journal of Alzheimer's Disease, 2016, 55, 1261-1272.	1.2	27
768	Dopamine D ₁ signaling organizes network dynamics underlying working memory. Science Advances, 2016, 2, e1501672.	4.7	59
769	Cerebrospinal Fluid A β^{42} /40 Corresponds Better than A β^{42} to Amyloid PET in Alzheimer's Disease. Journal of Alzheimer's Disease, 2016, 55, 813-822.	1.2	191
770	Comparison of [¹¹ C]TZ1964B and [¹⁸ F]MNI659 for PET imaging brain PDE10A in nonhuman primates. Pharmacology Research and Perspectives, 2016, 4, e00253.	1.1	8
771	A Novel PET Imaging Probe for the Detection and Monitoring of Translocator Protein 18 kDa Expression in Pathological Disorders. Scientific Reports, 2016, 6, 20422.	1.6	44
772	[¹¹ C]UCB-A, a novel PET tracer for synaptic vesicle protein 2A. Nuclear Medicine and Biology, 2016, 43, 325-332.	0.3	48
773	Pharmacokinetic Analysis of ¹¹ C-PBR28 in the Rat Model of Herpes Encephalitis: Comparison with [¹¹ C]-PK11195. Journal of Nuclear Medicine, 2016, 57, 785-791.	2.8	21
774	In vivo markers of inflammatory response in recent-onset schizophrenia: a combined study using [¹¹ C]DPA-713 PET and analysis of CSF and plasma. Translational Psychiatry, 2016, 6, e777-e777.	2.4	134
775	PET Imaging Study of S1PR1 Expression in a Rat Model of Multiple Sclerosis. Molecular Imaging and Biology, 2016, 18, 724-732.	1.3	35
776	Positron Emission Tomography (PET) Use in Pharmacology. , 2016, , 49-70.		0
777	NIA-AA staging of preclinical Alzheimer disease: discordance and concordance of CSF and imaging biomarkers. Neurobiology of Aging, 2016, 44, 1-8.	1.5	80
778	Novel Approach to Repeated Arterial Blood Sampling in Small Animal PET: Application in a Test-Retest Study with the Adenosine A1 Receptor Ligand [¹¹ C]MPDX. Molecular Imaging and Biology, 2016, 18, 715-723.	1.3	7
779	Accelerated decline in white matter integrity in clinically normal individuals at risk for Alzheimer's disease. Neurobiology of Aging, 2016, 42, 177-188.	1.5	57
780	Decreased hippocampal metabolism in high amyloid mild cognitive impairment. Alzheimer's and Dementia, 2016, 12, 1288-1296.	0.4	23
781	Pilot PET Study to Assess the Functional Interplay Between ABCB1 and ABCG2 at the Human Blood-Brain Barrier. Clinical Pharmacology and Therapeutics, 2016, 100, 131-141.	2.3	50

#	ARTICLE	IF	CITATIONS
782	Tau positron emission tomographic imaging in aging and early ^A Alzheimer disease. <i>Annals of Neurology</i> , 2016, 79, 110-119.	2.8	778
783	Association between striatal dopamine D2/D3 receptors and brain activation during visual attention: effects of sleep deprivation. <i>Translational Psychiatry</i> , 2016, 6, e828-e828.	2.4	15
784	Evidence of Brain Inflammation in Patients with Human T-Lymphotropic Virus Type 1-Associated Myelopathy (HAM): A Pilot, Multimodal Imaging Study Using ¹¹C-PBR28 PET, MR T1-Weighted, and Diffusion-Weighted Imaging. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1905-1912.	2.8	18
785	In Vivo Tau, Amyloid, and Gray Matter Profiles in the Aging Brain. <i>Journal of Neuroscience</i> , 2016, 36, 7364-7374.	1.7	153
786	Noninvasive bi-graphical analysis for the quantification of slowly reversible radioligand binding. <i>Physics in Medicine and Biology</i> , 2016, 61, 6770-6790.	1.6	4
787	Regularized linear resolution of a one-compartment model to improve the reproducibility of perfusion parameters in CEUS., 2016, .		0
788	Parametric Binding Images of the TSPO Ligand ¹⁸F-DPA-714. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1543-1547.	2.8	23
789	Decreased renal AT1 receptor binding in rats after subtotal nephrectomy: PET study with [18F]FPyKYNE-losartan. <i>EJNMMI Research</i> , 2016, 6, 55.	1.1	4
790	In vivo evidence of a functional association between immune cells in blood and brain in healthy human subjects. <i>Brain, Behavior, and Immunity</i> , 2016, 54, 149-157.	2.0	48
791	[11 C]NS9531, [11 C]NS9762 and [11 C]NS6417, specific SERT tracers: pre-clinical evaluation in pigs and optimization of synthesis conditions using [11 C]methyl triflate. <i>Nuclear Medicine and Biology</i> , 2016, 43, 42-51.	0.3	4
792	Image-derived arterial input function for quantitative fluorescence imaging of receptor-drug binding <i>in vivo</i>. <i>Journal of Biophotonics</i> , 2016, 9, 282-295.	1.1	7
793	Tracer Kinetic Analysis of (<i>S</i>)-¹⁸F-THK5117 as a PET Tracer for Assessing Tau Pathology. <i>Journal of Nuclear Medicine</i> , 2016, 57, 574-581.	2.8	51
794	Sigma-1 Agonist Binding in the Aging Rat Brain: a MicroPET Study with [11C]SA4503. <i>Molecular Imaging and Biology</i> , 2016, 18, 588-597.	1.3	11
795	Reduced sleep duration mediates decreases in striatal D2/D3 receptor availability in cocaine abusers. <i>Translational Psychiatry</i> , 2016, 6, e752-e752.	2.4	32
796	Maternal dementia age at onset in relation to amyloid burden in non-demented elderly offspring. <i>Neurobiology of Aging</i> , 2016, 40, 61-67.	1.5	11
797	Kinetics modeling and occupancy studies of a novel C-11 PET tracer for VACHT in nonhuman primates. <i>Nuclear Medicine and Biology</i> , 2016, 43, 131-139.	0.3	13
798	[11C]TASP457, a novel PET ligand for histamine H3 receptors in human brain. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1653-1663.	3.3	13
799	Association of ventral striatum monoamine oxidase-A binding and functional connectivity in antisocial personality disorder with high impulsivity: A positron emission tomography and functional magnetic resonance imaging study. <i>European Neuropsychopharmacology</i> , 2016, 26, 777-786.	0.3	26

#	ARTICLE	IF	CITATIONS
800	Functional segmentation of dynamic PET studies: Open source implementation and validation of a leader-follower-based algorithm. <i>Computers in Biology and Medicine</i> , 2016, 69, 181-188.	3.9	1
801	Elevated Monoamine Oxidase-A Distribution Volume in Borderline Personality Disorder Is Associated With Severity Across Mood Symptoms, Suicidality, and Cognition. <i>Biological Psychiatry</i> , 2016, 79, 117-126.	0.7	35
802	Quantitative longitudinal imaging of activated microglia as a marker of inflammation in the pilocarpine rat model of epilepsy using [¹¹ C]-(<i>R</i>)-PK11195 PET and MRI. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2017, 37, 1251-1263.	2.4	24
803	Microglial activation in Parkinson's disease using [18F]-FEPPA. <i>Journal of Neuroinflammation</i> , 2017, 14, 8.	3.1	88
804	Simple and rapid quantification of serotonin transporter binding using [11C]DASB bolus plus constant infusion. <i>NeuroImage</i> , 2017, 149, 23-32.	2.1	19
805	A Variational Bayesian inference method for parametric imaging of PET data. <i>NeuroImage</i> , 2017, 150, 136-149.	2.1	23
806	Association of In Vivo [¹⁸ F]AV-1451 Tau PET Imaging Results With Cortical Atrophy and Symptoms in Typical and Atypical Alzheimer Disease. <i>JAMA Neurology</i> , 2017, 74, 427.	4.5	236
807	Acute Temporal Changes of MRI-Tracked Tumor Vascular Parameters after Combined Anti-angiogenic and Radiation Treatments in a Rat Glioma Model: Identifying Signatures of Synergism. <i>Radiation Research</i> , 2017, 187, 79-88.	0.7	15
808	State of the art in vivo imaging techniques for laboratory animals. <i>Laboratory Animals</i> , 2017, 51, 465-478.	0.5	56
809	Effect of P-glycoprotein inhibition at the blood-brain barrier on brain distribution of (<i>R</i>)-[¹¹ C]verapamil in elderly vs. young subjects. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 1991-1999.	1.1	28
810	New Repeat Polymorphism in the <i>AKT1</i> Gene Predicts Striatal Dopamine D2/D3 Receptor Availability and Stimulant-Induced Dopamine Release in the Healthy Human Brain. <i>Journal of Neuroscience</i> , 2017, 37, 4982-4991.	1.7	15
811	Radiosynthesis and in Vivo Evaluation of [11C]A1070722, a High Affinity GSK-3 PET Tracer in Primate Brain. <i>ACS Chemical Neuroscience</i> , 2017, 8, 1697-1703.	1.7	16
812	Fully parametric imaging with reversible tracer 18F-FLT within a reasonable time. <i>Radiological Physics and Technology</i> , 2017, 10, 41-48.	1.0	3
813	Reduction of PK11195 uptake observed in multiple sclerosis lesions after natalizumab initiation. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 15, 27-33.	0.9	25
814	Microglial positron emission tomography (PET) imaging in epilepsy: Applications, opportunities and pitfalls. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2017, 44, 42-47.	0.9	28
815	Association of Protein Distribution and Gene Expression Revealed by PET and Post-Mortem Quantification in the Serotonergic System of the Human Brain. <i>Cerebral Cortex</i> , 2017, 27, 117-130.	1.6	30
816	Imaging of Glial Cell Activation and White Matter Integrity in Brains of Active and Recently Retired National Football League Players. <i>JAMA Neurology</i> , 2017, 74, 67.	4.5	134
817	Reaching out for Sensitive Evaluation of the Mu Opioid Receptor in Vivo: Positron Emission Tomography Imaging of the Agonist [¹¹ C]AH7921. <i>ACS Chemical Neuroscience</i> , 2017, 8, 1847-1852.	1.7	11

#	ARTICLE	IF	CITATIONS
818	Parametric Method Performance for Dynamic ^3H -Deoxy- ^3H -18F-Fluorothymidine PET/CT in Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Carcinoma Patients Before and During Therapy. <i>Journal of Nuclear Medicine</i> , 2017, 58, 920-925.	2.8	4
819	Effects of social reorganization on dopamine D2/D3 receptor availability and cocaine self-administration in male cynomolgus monkeys. <i>Psychopharmacology</i> , 2017, 234, 2673-2682.	1.5	11
820	Test-retest reproducibility of quantitative binding measures of [^{11}C]Ro15-4513, a PET ligand for GABA A receptors containing $\alpha 5$ subunits. <i>NeuroImage</i> , 2017, 152, 270-282.	2.1	17
821	Memory self-awareness in the preclinical and prodromal stages of Alzheimer's disease. <i>Neuropsychologia</i> , 2017, 99, 343-349.	0.7	67
822	In vivo tau PET imaging in dementia: Pathophysiology, radiotracer quantification, and a systematic review of clinical findings. <i>Ageing Research Reviews</i> , 2017, 36, 50-63.	5.0	107
823	Phases of Hyperconnectivity and Hypoconnectivity in the Default Mode and Salience Networks Track with Amyloid and Tau in Clinically Normal Individuals. <i>Journal of Neuroscience</i> , 2017, 37, 4323-4331.	1.7	237
824	In vivo evaluation of [^{18}F]FECIMBI-36, an agonist 5-HT 2A/2C receptor PET radioligand in nonhuman primate. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 21-23.	1.0	11
825	A Study of Dynamic PET Frame-Binning on the Reference Logan Binding Potential. <i>IEEE Transactions on Radiation and Plasma Medical Sciences</i> , 2017, 1, 128-135.	2.7	3
826	Pathological correlations of [^{18}F]AV-451 imaging in non-Alzheimer tauopathies. <i>Annals of Neurology</i> , 2017, 81, 117-128.	2.8	174
827	A physiology-based parametric imaging method for FDG-PET data. <i>Inverse Problems</i> , 2017, 33, 125010.	1.0	12
828	Reproducibility and relative stability in magnetic resonance imaging indices of tumor vascular physiology over a period of 24 h in a rat 9L gliosarcoma model. <i>Magnetic Resonance Imaging</i> , 2017, 44, 131-139.	1.0	7
829	Brain amyloid PET interpretation approaches: from visual assessment in the clinic to quantitative pharmacokinetic modeling. <i>Clinical and Translational Imaging</i> , 2017, 5, 561-573.	1.1	4
830	Radioligand binding analysis of $\beta 2$ adrenoceptors with [^{11}C]yohimbine in brain in vivo: Extended Inhibition Plot correction for plasma protein binding. <i>Scientific Reports</i> , 2017, 7, 15979.	1.6	14
831	Quantification of positron emission tomography brain imaging using 18 F-fallypride: a simulation. <i>Physica Medica</i> , 2017, 41, S7.	0.4	0
832	Quantitative positron emission tomography in brain research. <i>Brain Research</i> , 2017, 1670, 220-234.	1.1	38
833	Associations between cerebral amyloid and changes in cognitive function and falls risk in subcortical ischemic vascular cognitive impairment. <i>BMC Geriatrics</i> , 2017, 17, 133.	1.1	6
834	Partial volume correction of brain PET studies using iterative deconvolution in combination with HYPR denoising. <i>EJNMMI Research</i> , 2017, 7, 36.	1.1	21
835	Imaging $\beta 2$ Nicotinic Acetylcholine Receptors (nAChRs) in Baboons with [^{18}F]XTRA, a Radioligand with Improved Specific Binding in Extra-Thalamic Regions. <i>Molecular Imaging and Biology</i> , 2017, 19, 280-288.	1.3	11

#	ARTICLE	IF	CITATIONS
836	Compartmental Modeling in PET Kinetics. , 2017, , 323-352.		1
837	Estimation of the binding potential BPND without a reference region or blood samples for brain PET studies. <i>NeuroImage</i> , 2017, 146, 121-131.	2.1	10
838	Assessment of P-Glycoprotein Transport Activity at the Human Bloodâ€“Retina Barrier with (<i>R</i>) ¹¹ C-Verapamil PET. <i>Journal of Nuclear Medicine</i> , 2017, 58, 678-681.	2.8	23
839	Modeling Strategies for Quantification of In Vivo ¹⁸ F-AV-1451 Binding in Patients with Tau Pathology. <i>Journal of Nuclear Medicine</i> , 2017, 58, 623-631.	2.8	53
840	Characterization of [¹¹ C]Lu AE92686 as a PET radioligand for phosphodiesterase 10A in the nonhuman primate brain. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 308-320.	3.3	7
841	Acute effect of intravenously applied alcohol in the human striatal and extrastriatal D2 /D3 dopamine system. <i>Addiction Biology</i> , 2017, 22, 1449-1458.	1.4	7
842	Strategies to Inhibit ABCB1- and ABCG2-Mediated Efflux Transport of Erlotinib at the Bloodâ€“Brain Barrier: A PET Study on Nonhuman Primates. <i>Journal of Nuclear Medicine</i> , 2017, 58, 117-122.	2.8	43
843	Pharmacokinetic Evaluation of the Tau PET Radiotracer ¹⁸ F-T807 (¹⁸ F-AV-1451) in Human Subjects. <i>Journal of Nuclear Medicine</i> , 2017, 58, 484-491.	2.8	73
844	cAMP signaling in brain is decreased in unmedicated depressed patients and increased by treatment with a selective serotonin reuptake inhibitor. <i>Molecular Psychiatry</i> , 2017, 22, 754-759.	4.1	81
845	Parametric Methods for Dynamic ¹¹ C-Phenytoin PET Studies. <i>Journal of Nuclear Medicine</i> , 2017, 58, 479-483.	2.8	2
846	Federated optimisation of kinetic analysis problems. <i>Medical Image Analysis</i> , 2017, 35, 116-132.	7.0	0
847	Comparison of two PET radioligands, [¹¹ C]FPEB and [¹¹ C]SP203, for quantification of metabotropic glutamate receptor 5 in human brain. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2017, 37, 2458-2470.	2.4	21
848	Parametric PET Image Reconstruction via Regional Spatial Bases and Pharmacokinetic Time Activity Model. <i>Entropy</i> , 2017, 19, 629.	1.1	2
849	Kinetic Modelling of Infection Tracers [¹⁸ F]FDG, [⁶⁸ Ga]Ga-Citrate, [¹¹ C]Methionine, and [¹¹ C]Donepezil in a Porcine Osteomyelitis Model. <i>Contrast Media and Molecular Imaging</i> , 2017, 2017, 1-18.	0.4	11
850	A human PET study of [¹¹ C]HMS011, a potential radioligand for AMPA receptors. <i>EJNMMI Research</i> , 2017, 7, 63.	1.1	17
851	Revisiting the Logan plot to account for non-negligible blood volume in brain tissue. <i>EJNMMI Research</i> , 2017, 7, 66.	1.1	8
852	Simplified Quantification and Acquisition Protocol for ¹²³ I-MIBG Dynamic SPECT. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1574-1580.	2.8	5
853	[¹¹ C]Harmine Binding to Brain Monoamine Oxidase A: Test-Retest Properties and Noninvasive Quantification. <i>Molecular Imaging and Biology</i> , 2018, 20, 667-681.	1.3	13

#	ARTICLE	IF	CITATIONS
854	Reference tissue models in the assessment of ¹¹ C- α -DTBZ binding to the VMAT2 in rat striatum: A test-retest reproducibility study. <i>Synapse</i> , 2018, 72, e22029.	0.6	5
855	¹⁸ F-XTRA PET for Enhanced Imaging of the Extrathalamic α 2 Nicotinic Acetylcholine Receptor. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1603-1608.	2.8	15
856	The metabotropic glutamate receptor 5 radioligand [¹¹ C]AZD9272 identifies unique binding sites in primate brain. <i>Neuropharmacology</i> , 2018, 135, 455-463.	2.0	13
857	Nicotinic Acetylcholine Receptor Signaling in Neuroprotection. , 2018, , .		10
858	DARK Classics in Chemical Neuroscience: Cocaine. <i>ACS Chemical Neuroscience</i> , 2018, 9, 2358-2372.	1.7	38
859	Structural tract alterations predict downstream tau accumulation in amyloid-positive older individuals. <i>Nature Neuroscience</i> , 2018, 21, 424-431.	7.1	198
860	Influence of breast cancer resistance protein and P-glycoprotein on tissue distribution and excretion of Ko143 assessed with PET imaging in mice. <i>European Journal of Pharmaceutical Sciences</i> , 2018, 115, 212-222.	1.9	4
861	α 2 pathology downregulates brain mGluR5 density in a mouse model of Alzheimer. <i>Neuropharmacology</i> , 2018, 133, 512-517.	2.0	25
862	Association Between Amyloid and Tau Accumulation in Young Adults With Autosomal Dominant Alzheimer Disease. <i>JAMA Neurology</i> , 2018, 75, 548.	4.5	137
863	Lower Limbic Metabotropic Glutamate Receptor 5 Availability in Alcohol Dependence. <i>Journal of Nuclear Medicine</i> , 2018, 59, 682-690.	2.8	27
864	Kinetic modeling of [¹⁸ F]VAT, a novel radioligand for positron emission tomography imaging vesicular acetylcholine transporter in non-human primate brain. <i>Journal of Neurochemistry</i> , 2018, 144, 791-804.	2.1	21
865	Minocycline reduces chronic microglial activation after brain trauma but increases neurodegeneration. <i>Brain</i> , 2018, 141, 459-471.	3.7	143
866	Characterization of 3 Novel Tau Radiopharmaceuticals, ¹¹ C-RO-963, ¹¹ C-RO-643, and ¹⁸ F-RO-948, in Healthy Controls and in Alzheimer Subjects. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1869-1876.	2.8	81
867	Toward a noninvasive estimate of interstitial fluid pressure by dynamic contrast-enhanced MRI in a rat model of cerebral tumor. <i>Magnetic Resonance in Medicine</i> , 2018, 80, 2040-2052.	1.9	21
868	Advances in PET/MR instrumentation and image reconstruction. <i>British Journal of Radiology</i> , 2018, 91, 20160363.	1.0	47
869	¹¹ C-DPA-713 has much greater specific binding to translocator protein 18kDa (TSPO) in human brain than ¹¹ C-(R)-PK11195. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2018, 38, 393-403.	2.4	51
870	Parametric Imaging of [¹¹ C]Flumazenil Binding in the Rat Brain. <i>Molecular Imaging and Biology</i> , 2018, 20, 114-123.	1.3	5
871	Modification of population based arterial input function to incorporate individual variation. <i>Magnetic Resonance Imaging</i> , 2018, 45, 66-71.	1.0	8

#	ARTICLE	IF	CITATIONS
872	Preclinical Evaluation of ¹⁸ F-RO6958948, ¹¹ C-RO6931643, and ¹¹ C-RO6924963 as Novel PET Radiotracers for Imaging Tau Aggregates in Alzheimer Disease. <i>Journal of Nuclear Medicine</i> , 2018, 59, 675-681.	2.8	71
873	The distribution of the alpha7 nicotinic acetylcholine receptor in healthy aging: An in vivo positron emission tomography study with [18F]ASEM. <i>NeuroImage</i> , 2018, 165, 118-124.	2.1	27
874	Pseudoreference Regions for Glial Imaging with ¹¹ C-PBR28: Investigation in 2 Clinical Cohorts. <i>Journal of Nuclear Medicine</i> , 2018, 59, 107-114.	2.8	32
875	Evaluation of ¹¹ C-Me-NB1 as a Potential PET Radioligand for Measuring GluN2B-Containing NMDA Receptors, Drug Occupancy, and Receptor Cross Talk. <i>Journal of Nuclear Medicine</i> , 2018, 59, 698-703.	2.8	46
876	A first-in-man PET study of [18F]PSS232, a fluorinated ABP688 derivative for imaging metabotropic glutamate receptor subtype 5. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1041-1051.	3.3	16
877	Mitochondrial Complex I Deficit in the Olfactory Systems of Age-related Neurodegenerative Monkey Models: A PET Study using 18F-BCPP-EF. , 2018, 08, .		1
878	Reproducible quantification of cardiac sympathetic innervation using graphical modeling of carbon-11-meta-hydroxyephedrine kinetics with dynamic PET-CT imaging. <i>EJNMMI Research</i> , 2018, 8, 63.	1.1	9
880	Association between aromatase in human brains and personality traits. <i>Scientific Reports</i> , 2018, 8, 16841.	1.6	21
882	In vivo evaluation of [11C]TMI, a COX-2 selective PET tracer, in baboons. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2018, 28, 3592-3595.	1.0	23
883	Comparison of two different methods of image analysis for the assessment of microglial activation in patients with multiple sclerosis using (R)-[N-methyl-carbon-11]PK11195. <i>PLoS ONE</i> , 2018, 13, e0201289.	1.1	8
884	APPIAN: Automated Pipeline for PET Image Analysis. <i>Frontiers in Neuroinformatics</i> , 2018, 12, 64.	1.3	12
885	Advances in PET Methodology. <i>International Review of Neurobiology</i> , 2018, 141, 3-30.	0.9	7
886	Dedifferentiation of caudate functional connectivity and striatal dopamine transporter density predict memory change in normal aging. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 10160-10165.	3.3	49
887	Disease-related patterns of in vivo pathology in Corticobasal syndrome. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 2413-2425.	3.3	26
888	Tracer Kinetics in Radionanomedicine. <i>Biological and Medical Physics Series</i> , 2018, , 293-310.	0.3	0
889	Likelihood estimation of drug occupancy for brain PET studies. <i>NeuroImage</i> , 2018, 178, 255-265.	2.1	14
890	Neurocognitive Profiles of Older Adults with Working-Memory Dysfunction. <i>Cerebral Cortex</i> , 2018, 28, 2525-2539.	1.6	25
891	In Vivo Brain Imaging, Biodistribution, and Radiation Dosimetry Estimation of [11C]Celecoxib, a COX-2 PET Ligand, in Nonhuman Primates. <i>Molecules</i> , 2018, 23, 1929.	1.7	20

#	ARTICLE	IF	CITATIONS
892	Hybrid Imaging: Instrumentation and Data Processing. <i>Frontiers in Physics</i> , 2018, 6, .	1.0	30
893	Assessment of Translocator Protein Density, as Marker of Neuroinflammation, in Major Depressive Disorder: A Pilot, Multicenter, Comparative, Controlled, Brain PET Study (INFLADEP Study). <i>Frontiers in Psychiatry</i> , 2018, 9, 326.	1.3	14
894	In vivo quantification of neurofibrillary tangles with [¹⁸ F]MK-6240. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 74.	3.0	120
895	Noninvasive Relative Quantification of [¹¹ C]ABP688 PET Imaging in Mice Versus an Input Function Measured Over an Arteriovenous Shunt. <i>Frontiers in Neurology</i> , 2018, 9, 516.	1.1	26
897	Variations of quantitative perfusion measurement on dynamic contrast enhanced CT for colorectal cancer: implication of standardized image protocol. <i>Physics in Medicine and Biology</i> , 2018, 63, 165009.	1.6	6
898	Evaluation of ¹⁸ F-RO-948 PET for Quantitative Assessment of Tau Accumulation in the Human Brain. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1877-1884.	2.8	64
899	Imaging Brain Metabolism in the Newborn. <i>Journal of Child Neurology</i> , 2018, 33, 851-860.	0.7	19
900	3-Substituted 1,5-Diaryl-1 <i>H</i> -1,2,4-triazoles as Prospective PET Radioligands for Imaging Brain COX-1 in Monkey. Part 2: Selection and Evaluation of [¹¹ C]PS13 for Quantitative Imaging. <i>ACS Chemical Neuroscience</i> , 2018, 9, 2620-2627.	1.7	24
901	Regional times to equilibria and their impact on semi-quantification of [¹⁸ F]AV-1451 uptake. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2019, 39, 2223-2232.	2.4	5
902	Functional Data Analysis of Dynamic PET Data. <i>Journal of the American Statistical Association</i> , 2019, 114, 595-609.	1.8	5
903	Characterization of [¹¹ C]PXT012253 as a PET Radioligand for mGlu4 Allosteric Modulators in Nonhuman Primates. <i>Molecular Imaging and Biology</i> , 2019, 21, 500-508.	1.3	8
904	Development and In Vivo Preclinical Imaging of Fluorine-18-Labeled Synaptic Vesicle Protein 2A (SV2A) PET Tracers. <i>Molecular Imaging and Biology</i> , 2019, 21, 509-518.	1.3	49
905	Regulation of human brown adipose tissue by adenosine and A2A receptors “ studies with [¹⁵ O]H ₂ O and [¹¹ C]TMSX PET/CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 743-750.	3.3	37
906	Change in the Binding of [¹¹ C]BU99008 to Imidazoline I2 Receptor Using Brain PET in Zucker Rats. <i>Molecular Imaging and Biology</i> , 2019, 21, 105-112.	1.3	3
907	Building a database for brain 18 kDa translocator protein imaged using [¹¹ C]PBR28 in healthy subjects. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2019, 39, 1138-1147.	2.4	16
908	Age dependency of mGluR5 availability in 5xFAD mice measured by PET. <i>Neurobiology of Aging</i> , 2019, 84, 208-216.	1.5	27
909	Essentials of Quantitative Imaging with PET. , 2019, , 219-233.		3
910	In vivo imaging of D2 receptors and corticosteroids predict behavioural responses to captivity stress in a wild bird. <i>Scientific Reports</i> , 2019, 9, 10407.	1.6	3

#	ARTICLE	IF	CITATIONS
911	Evaluation of pharmacokinetic modeling strategies for in-vivo quantification of tau with the radiotracer [18F]MK6240 in human subjects. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 2099-2111.	3.3	26
912	Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Brain Tumors. , 2019, , 405-428.		0
913	Disease activity in rheumatoid arthritis is inversely related to cerebral TSPO binding assessed by [11C]PBR28 positron emission tomography. <i>Journal of Neuroimmunology</i> , 2019, 334, 577000.	1.1	15
914	In Vivo Availability of Cannabinoid 1 Receptor Levels in Patients With First-Episode Psychosis. <i>JAMA Psychiatry</i> , 2019, 76, 1074.	6.0	50
915	Assessment of glucagon receptor occupancy by Positron Emission Tomography in non-human primates. <i>Scientific Reports</i> , 2019, 9, 14960.	1.6	11
916	Pulmonary PET imaging confirms preferential lung target occupancy of an inhaled bronchodilator. <i>EJNMMI Research</i> , 2019, 9, 9.	1.1	9
917	Inhibition of ABCB1 and ABCG2 at the Mouse Bloodâ€“Brain Barrier with Marketed Drugs To Improve Brain Delivery of the Model ABCB1/ABCG2 Substrate [¹¹ C]erlotinib. <i>Molecular Pharmaceutics</i> , 2019, 16, 1282-1293.	2.3	20
918	Time-dependent assessment of stimulus-evoked regional dopamine release. <i>Nature Communications</i> , 2019, 10, 336.	5.8	31
919	Human Positron Emission Tomography Neuroimaging. <i>Annual Review of Biomedical Engineering</i> , 2019, 21, 551-581.	5.7	48
920	PET quantification of [18F]MPPF in the canine brain using blood input and reference tissue modelling. <i>PLoS ONE</i> , 2019, 14, e0218237.	1.1	2
921	Kinetic Modeling of Radiotracers. , 2019, , 501-514.		2
922	Joint pattern analysis applied to PET DAT and VMAT2 imaging reveals new insights into Parkinson's disease induced presynaptic alterations. <i>NeuroImage: Clinical</i> , 2019, 23, 101856.	1.4	21
923	Imaging histamine H3 receptors with [18 F]FMH3: Testâ€“retest and occupancy studies in the nonâ€“human primate. <i>Synapse</i> , 2019, 73, e22096.	0.6	1
924	Molecular imaging HDACs class IIa expression-activity and pharmacologic inhibition in intracerebral glioma models in rats using PET/CT/(MRI) with [18F]TFAHA. <i>Scientific Reports</i> , 2019, 9, 3595.	1.6	23
925	Expectation effects on brain dopamine responses to methylphenidate in cocaine use disorder. <i>Translational Psychiatry</i> , 2019, 9, 93.	2.4	17
926	Imaging metabotropic glutamate receptor system: Application of positron emission tomography technology in drug development. <i>Medicinal Research Reviews</i> , 2019, 39, 1892-1922.	5.0	12
927	Optimal Time of Single Static PET Scan to Determine Tumor Hypoxia with 18F-FMISO in Glioblastoma. , 2019, , .		0
928	Dynamic PET Image Reconstruction Using Nonnegative Matrix Factorization Incorporated With Deep Image Prior. , 2019, , .		31

#	ARTICLE	IF	CITATIONS
929	Optimal time frame required to accurately estimate K _{trans} , v _p and veusing graphical method: Simulation Study. , 2019, , .		2
930	Kinetic analysis of [18F] altanserin bolus injection in the canine brain using PET imaging. BMC Veterinary Research, 2019, 15, 415.	0.7	0
931	Is There a Role for GPCR Agonist Radiotracers in PET Neuroimaging?. Frontiers in Molecular Neuroscience, 2019, 12, 255.	1.4	29
932	Brain glial activation in fibromyalgia â€œ A multi-site positron emission tomography investigation. Brain, Behavior, and Immunity, 2019, 75, 72-83.	2.0	186
933	Quantitative susceptibility mapping identifies inflammation in a subset of chronic multiple sclerosis lesions. Brain, 2019, 142, 133-145.	3.7	136
934	Tau Accumulation in Clinically Normal Older Adults Is Associated with Hippocampal Hyperactivity. Journal of Neuroscience, 2019, 39, 548-556.	1.7	75
935	Direct Estimation of Voxel-Wise Neurotransmitter Response Maps From Dynamic PET Data. IEEE Transactions on Medical Imaging, 2019, 38, 1371-1383.	5.4	18
936	Dopamine D _{2/3} Binding Potential Modulates Neural Signatures of Working Memory in a Load-Dependent Fashion. Journal of Neuroscience, 2019, 39, 537-547.	1.7	37
937	Single Inflammatory Trigger Leads to Neuroinflammation in LRRK2 Rodent Model without Degeneration of Dopaminergic Neurons. Journal of Parkinson's Disease, 2019, 9, 121-139.	1.5	17
938	<i>C957T</i> -mediated Variation in Ligand Affinity Affects the Association between ¹¹ C-raclopride Binding Potential and Cognition. Journal of Cognitive Neuroscience, 2019, 31, 314-325.	1.1	13
939	Hunting for the highâ€œaffinity state of Gâ€œproteinâ€œcoupled receptors with agonist tracers: Theoretical and practical considerations for positron emission tomography imaging. Medicinal Research Reviews, 2019, 39, 1014-1052.	5.0	22
940	Quantification of [18F]UCB-H Binding in the Rat Brain: From Kinetic Modelling to Standardised Uptake Value. Molecular Imaging and Biology, 2019, 21, 888-897.	1.3	10
941	Parcellation of the Human Cerebral Cortex Based on Molecular Targets in the Serotonin System Quantified by Positron Emission Tomography In vivo. Cerebral Cortex, 2019, 29, 372-382.	1.6	12
942	Longitudinal evaluation of tumor microenvironment in rat focal brainstem glioma using diffusion and perfusion MRI. Journal of Magnetic Resonance Imaging, 2019, 49, 1322-1332.	1.9	2
943	Quantitative Analysis of ¹⁸ F-PF-06684511, a Novel PET Radioligand for Selective β^2 -Secretase 1 Imaging, in Nonhuman Primate Brain. Journal of Nuclear Medicine, 2019, 60, 992-997.	2.8	6
944	A Proof-of-Concept Study to Inhibit ABCG2- and ABCB1-Mediated Efflux Transport at the Human Bloodâ€œBrain Barrier. Journal of Nuclear Medicine, 2019, 60, 486-491.	2.8	25
945	¹⁸ F-JNJ-64413739, a Novel PET Ligand for the P2X7 Ion Channel: Radiation Dosimetry, Kinetic Modeling, Test-Retest Variability, and Occupancy of the P2X7 Antagonist JNJ-54175446. Journal of Nuclear Medicine, 2019, 60, 683-690.	2.8	63
946	Quantitative PET Imaging in Drug Development: Estimation of Target Occupancy. Bulletin of Mathematical Biology, 2019, 81, 3508-3541.	0.9	21

#	ARTICLE	IF	CITATIONS
947	The role of phosphodiesterase 4 in excessive daytime sleepiness in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2020, 77, 163-169.	1.1	11
948	Quantitative parametric maps of O-(2-[¹⁸ F]fluoroethyl)-L-tyrosine kinetics in diffuse glioma. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2020, 40, 895-903.	2.4	8
949	Parametric Imaging With PET and SPECT. <i>IEEE Transactions on Radiation and Plasma Medical Sciences</i> , 2020, 4, 1-23.	2.7	43
950	Positron emission tomography studies of organophosphate chemical threats and oxime countermeasures. <i>Neurobiology of Disease</i> , 2020, 133, 104455.	2.1	9
951	First in-human PET study and kinetic evaluation of [¹⁸ F]AS2471907 for imaging 11 β -hydroxysteroid dehydrogenase type 1. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2020, 40, 695-704.	2.4	10
952	Parametric methods for [¹⁸ F]flortaucipir PET. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2020, 40, 365-373.	2.4	22
953	¹⁸ F-FIBT may expand PET for β -amyloid imaging in neurodegenerative diseases. <i>Molecular Psychiatry</i> , 2020, 25, 2608-2619.	4.1	13
954	High long-term test-retest reliability for extrastriatal [¹¹ C]-raclopride binding in healthy older adults. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2020, 40, 1859-1868.	2.4	15
955	High Availability of the α 7-Nicotinic Acetylcholine Receptor in Brains of Individuals with Mild Cognitive Impairment: A Pilot Study Using ¹⁸ F-ASEM PET. <i>Journal of Nuclear Medicine</i> , 2020, 61, 423-426.	2.8	22
956	The pro-psychotic metabotropic glutamate receptor compounds fenobam and AZD9272 share binding sites with monoamine oxidase-B inhibitors in humans. <i>Neuropharmacology</i> , 2020, 162, 107809.	2.0	10
957	Validation and noninvasive kinetic modeling of [¹¹ C]UCB-J PET imaging in mice. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2020, 40, 1351-1362.	2.4	32
958	Image-based biomedical data modeling and parametric imaging. , 2020, , 461-521.		0
959	Repurposing radiotracers for myelin imaging: a study comparing ¹⁸ F-florbetaben, ¹⁸ F-florbetapir, ¹⁸ F-flutemetamol, ¹¹ C-MeDAS, and ¹¹ C-PiB. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 490-501.	3.3	34
960	Molecular imaging in biology and pharmacology. , 2020, , 523-560.		0
961	Elevated Type 1 Metabotropic Glutamate Receptor Availability in a Mouse Model of Huntington's Disease: a Longitudinal PET Study. <i>Molecular Neurobiology</i> , 2020, 57, 2038-2047.	1.9	8
962	Modeling of [¹⁸ F]FEOBV Pharmacokinetics in Rat Brain. <i>Molecular Imaging and Biology</i> , 2020, 22, 931-939.	1.3	2
963	Automatic delineation algorithm of reference region for amyloid imaging based on kinetics. <i>Annals of Nuclear Medicine</i> , 2020, 34, 102-107.	1.2	2
964	Evaluation of the total distribution volume of ¹⁸ F-FBPA in normal tissues of healthy volunteers by non-compartmental kinetic modeling. <i>Annals of Nuclear Medicine</i> , 2020, 34, 155-162.	1.2	13

#	ARTICLE	IF	CITATIONS
965	In vitro and In vivo Assessment of Suitable Reference Region and Kinetic Modelling for the mGluR1 Radioligand [¹¹ C]ITDM in Mice. <i>Molecular Imaging and Biology</i> , 2020, 22, 854-863.	1.3	15
966	Evaluation of the potassium channel tracer [¹⁸ F]3F4AP in rhesus macaques. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2021, 41, 1721-1733.	2.4	27
967	Complete inhibition of ABCB1 and ABCG2 at the blood-brain barrier by co-infusion of erlotinib and tariquidar to improve brain delivery of the model ABCB1/ABCG2 substrate [¹¹ C]erlotinib. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2021, 41, 1634-1646.	2.4	17
968	Spatial heterogeneity of radiolabeled choline positron emission tomography in tumors of patients with non-small cell lung cancer: first-in-patient evaluation of [¹⁸ F]fluoromethyl-(1,2- ² H ₄)-choline. <i>Theranostics</i> , 2020, 10, 8677-8690.	4.6	9
969	Inhibition of Colony-Stimulating Factor 1 Receptor by PLX3397 Prevents Amyloid Beta Pathology and Rescues Dopaminergic Signaling in Aging 5xFAD Mice. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5553.	1.8	30
970	Methods for Quantifying Neurotransmitter Dynamics in the Living Brain With PET Imaging. <i>Frontiers in Physiology</i> , 2020, 11, 792.	1.3	18
971	Quantification of aromatase binding in the female human brain using [¹¹ C]cetrozole positron emission tomography. <i>Journal of Neuroscience Research</i> , 2020, 98, 2208-2218.	1.3	5
972	4,4,16-Trifluoropalmitate: Design, Synthesis, Tritiation, Radiofluorination and Preclinical PET Imaging Studies on Myocardial Fatty Acid Oxidation. <i>ChemMedChem</i> , 2020, 15, 2317-2331.	1.6	0
973	The Latin American Spanish version of the Face-Name Associative Memory Exam is sensitive to cognitive and pathological changes in preclinical autosomal dominant Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 104.	3.0	7
974	Mathematical modelling of nuclear medicine data. , 2020, , .		3
975	Kinetic Modeling of 18F-(2S,4R)4-Fluoroglutamine in Mouse Models of Breast Cancer to Estimate Glutamine Pool Size as an Indicator of Tumor Glutamine Metabolism. <i>Journal of Nuclear Medicine</i> , 2020, 62, jnumed.120.250977.	2.8	15
976	Noninvasive Measurement of [¹¹ C]PiB Distribution Volume Using Integrated PET/MRI. <i>Diagnostics</i> , 2020, 10, 993.	1.3	3
977	Penalized Parametric PET Image Estimation Using Local Linear Fitting. <i>IEEE Transactions on Radiation and Plasma Medical Sciences</i> , 2020, 4, 750-758.	2.7	1
978	First-in-human evaluation of [¹¹ C]PS13, a novel PET radioligand, to quantify cyclooxygenase-1 in the brain. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 3143-3151.	3.3	27
979	Activation of NMDA receptor ion channels by deep brain stimulation in the pig visualised with [¹⁸ F]GE-179 PET. <i>Brain Stimulation</i> , 2020, 13, 1071-1078.	0.7	11
980	PET ligands [¹⁸ F]LSN3316612 and [¹¹ C]LSN3316612 quantify <i>α</i> -linked- ² -N-acetyl-glucosamine hydrolase in the brain. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	21
981	Preclinical PET Studies of [¹¹ C]UCB-J Binding in Minipig Brain. <i>Molecular Imaging and Biology</i> , 2020, 22, 1290-1300.	1.3	8
982	PET technology for drug development in psychiatry. <i>Neuropsychopharmacology Reports</i> , 2020, 40, 114-121.	1.1	19

#	ARTICLE	IF	CITATIONS
983	The presubiculum links incipient amyloid and tau pathology to memory function in older persons. <i>Neurology</i> , 2020, 94, e1916-e1928.	1.5	13
984	Recovery of Decreased Metabotropic Glutamate Receptor 5 Availability in Abstinent Alcohol-Dependent Patients. <i>Journal of Nuclear Medicine</i> , 2020, 61, 256-262.	2.8	24
985	Noninvasive Estimation of Macro-Parameters by Deep Learning. <i>IEEE Transactions on Radiation and Plasma Medical Sciences</i> , 2020, 4, 684-695.	2.7	8
986	PET imaging of beta-secretase 1 in the human brain: radiation dosimetry, quantification, and test-retest examination of [18F]PF-06684511. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2429-2439.	3.3	4
987	Associative memory and in vivo brain pathology in asymptomatic presenilin-1 E280A carriers. <i>Neurology</i> , 2020, 95, e1312-e1321.	1.5	7
988	Image-Derived Input Functions for Quantification of A1 Adenosine Receptors Availability in Mice Brains Using PET and [18F]CPFPX. <i>Frontiers in Physiology</i> , 2019, 10, 1617.	1.3	1
989	[18F]Fluciclatide PET as a biomarker of response to combination therapy of pazopanib and paclitaxel in platinum-resistant/refractory ovarian cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 1239-1251.	3.3	12
990	A strategy to account for noise in the X-variable to reduce underestimation in Logan graphical analysis for quantifying receptor density in positron emission tomography. <i>BMC Medical Imaging</i> , 2020, 20, 15.	1.4	3
991	Visualization of AMPA receptors in living human brain with positron emission tomography. <i>Nature Medicine</i> , 2020, 26, 281-288.	15.2	50
992	Mitochondrial Complex 1, Sigma 1, and Synaptic Vesicle α 2A in Early Drug-Naive Parkinson's Disease. <i>Movement Disorders</i> , 2020, 35, 1416-1427.	2.2	48
993	Reliable quantification of 18F-GE-180 PET neuroinflammation studies using an individually scaled population-based input function or late tissue-to-blood ratio. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2887-2900.	3.3	10
994	Quantitative amyloid PET in Alzheimer's disease: the AMYPAD prognostic and natural history study. <i>Alzheimer's and Dementia</i> , 2020, 16, 750-758.	0.4	29
995	Clinical validation of the novel HDAC6 radiotracer [18F]EKZ-001 in the human brain. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 596-611.	3.3	16
996	NMDA receptor ion channel activation detected in vivo with [¹⁸ F]GE-179 PET after electrical stimulation of rat hippocampus. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2021, 41, 1301-1312.	2.4	12
997	Multimodality imaging beyond CLEM: Showcases of combined in-vivo preclinical imaging and ex-vivo microscopy to detect murine mural vascular lesions. <i>Methods in Cell Biology</i> , 2021, 162, 389-415.	0.5	5
998	Analysis of Four-Dimensional Data for Total Body PET Imaging. <i>PET Clinics</i> , 2021, 16, 55-64.	1.5	8
999	Distinct Uptake Kinetics of Alzheimer Disease Amyloid- β 40 and 42 at the Blood-Brain Barrier Endothelium. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2021, 376, 482-490.	1.3	13
1000	Comparison of blind deconvolution- and Patlak analysis-based methods for determining vascular permeability. <i>Microvascular Research</i> , 2021, 133, 104102.	1.1	2

#	ARTICLE	IF	CITATIONS
1001	Parametric Mapping for TSPO PET Imaging with Spectral Analysis Impulsive Response Function. <i>Molecular Imaging and Biology</i> , 2021, 23, 560-571.	1.3	4
1002	New PET radiopharmaceuticals for imaging CNS diseases. , 2021, , .		0
1003	Role of dopamine and gray matter density in aging effects and individual differences of functional connectomes. <i>Brain Structure and Function</i> , 2021, 226, 743-758.	1.2	9
1004	Pharmacokinetic Modeling. , 2021, , 1625-1631.		1
1005	Optimized Methodology for Reference Region and Image-Derived Input Function Kinetic Modeling in Preclinical PET. <i>IEEE Transactions on Radiation and Plasma Medical Sciences</i> , 2022, 6, 454-462.	2.7	2
1006	Preliminary Investigation of a Novel ¹⁸ F Radiopharmaceutical for Imaging CB2 Receptors in a SOD Mouse Model. <i>Australian Journal of Chemistry</i> , 2021, 74, 443.	0.5	4
1007	Synthesis of [¹⁸ F]PS13 and Evaluation as a PET Radioligand for Cyclooxygenase-1 in Monkey. <i>ACS Chemical Neuroscience</i> , 2021, 12, 517-530.	1.7	12
1008	A first-in-human study of ¹¹ C-MTP38, a novel PET ligand for phosphodiesterase 7. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2846-2855.	3.3	6
1009	Pharmacokinetic neuroimaging to study the dose-related brain kinetics and target engagement of buprenorphine in vivo. <i>Neuropsychopharmacology</i> , 2021, 46, 1220-1228.	2.8	10
1010	First-in-human neuroimaging of soluble epoxide hydrolase using [¹⁸ F]FNDP PET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3122-3128.	3.3	6
1011	Associations between plasma neurofilament light, in vivo brain pathology, and cognition in non-demented individuals with autosomal-dominant Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, 813-821.	0.4	8
1012	Cross-validation study between the HRRT and the PET component of the SIGNA PET/MRI system with focus on neuroimaging. <i>EJNMMI Physics</i> , 2021, 8, 20.	1.3	8
1013	Radiochemical Synthesis and Evaluation in Non-Human Primates of 3- ¹¹ C-methoxy-4-aminopyridine: A Novel PET Tracer for Imaging Potassium Channels in the CNS. <i>ACS Chemical Neuroscience</i> , 2021, 12, 756-765.	1.7	8
1014	Association of Memory Impairment With Concomitant Tau Pathology in Patients With Cerebral Amyloid Angiopathy. <i>Neurology</i> , 2021, 96, e1975-e1986.	1.5	16
1015	Quantification of Hypoxia in Human Glioblastoma using PET with ¹⁸ F-FMISO. <i>Nuclear Medicine and Molecular Imaging</i> , 2021, 55, 107-115.	0.6	2
1016	Synthesis and preclinical evaluation of [¹¹ C]MTP38 as a novel PET ligand for phosphodiesterase 7 in the brain. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3101-3112.	3.3	6
1017	Distinct and Common Large-Scale Networks of the Hippocampal Long Axis in Older Age: Links to Episodic Memory and Dopamine D2 Receptor Availability. <i>Cerebral Cortex</i> , 2021, 31, 3435-3450.	1.6	7
1018	Improving contrast between gray and white matter of Logan graphical analysis's parametric images in positron emission tomography through least-squares cubic regression and principal component analysis. <i>Biomedical Physics and Engineering Express</i> , 2021, 7, 035003.	0.6	2

#	ARTICLE	IF	CITATIONS
1019	In Vivo Receptor Visualization and Evaluation of Receptor Occupancy with Positron Emission Tomography. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 5226-5251.	2.9	9
1020	Population-based input function for TSPO quantification and kinetic modeling with [11C]-DPA-713. <i>EJNMMI Physics</i> , 2021, 8, 39.	1.3	6
1021	Region- and voxel-based quantification in human brain of [18F]LSN3316612, a radioligand for O-GlcNAcase. <i>EJNMMI Research</i> , 2021, 11, 35.	1.1	2
1022	Imaging acute effects of bevacizumab on tumor vascular kinetics in a preclinical orthotopic model of U251 glioma. <i>NMR in Biomedicine</i> , 2021, 34, e4516.	1.6	7
1023	The pharmacokinetics of [18F]UCB-H revisited in the healthy non-human primate brain. <i>EJNMMI Research</i> , 2021, 11, 36.	1.1	5
1024	Brain imaging of cannabinoid type I (CB ₁) receptors in women with cannabis use disorder and male and female healthy controls. <i>Addiction Biology</i> , 2021, 26, e13061.	1.4	27
1025	Dynamic alterations in the central glutamatergic status following food and glucose intake: <i>in vivo</i> multimodal assessments in humans and animal models. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2021, 41, 2928-2943.	2.4	4
1026	Inference in functional mixed regression models with applications to Positron Emission Tomography imaging data. <i>Statistics in Medicine</i> , 2021, 40, 4640-4659.	0.8	0
1028	ABCB1 and ABCG2 Together Limit the Distribution of ABCB1/ABCG2 Substrates to the Human Retina and the ABCG2 Single Nucleotide Polymorphism Q141K (c.421C>A) May Lead to Increased Drug Exposure. <i>Frontiers in Pharmacology</i> , 2021, 12, 698966.	1.6	6
1032	In Vitro and In Vivo Evaluation of GSK-3 Radioligands in Alzheimer's Disease: Preliminary Evidence of Sex Differences. <i>ACS Pharmacology and Translational Science</i> , 2021, 4, 1287-1294.	2.5	7

1033

#	ARTICLE	IF	CITATIONS
1043	Glucagon Like Peptide-1 receptor imaging in individuals with Type 2 Diabetes. Journal of Nuclear Medicine, 2021, , jnumed.121.262506.	2.8	2
1044	In vivo and neuropathology data support locus coeruleus integrity as indicator of Alzheimer's disease pathology and cognitive decline. Science Translational Medicine, 2021, 13, eabj2511.	5.8	107
1045	Test-retest reproducibility of cerebral adenosine A2A receptor quantification using [11C]preladenant. Annals of Nuclear Medicine, 2022, 36, 15-23.	1.2	0
1046	In vivo imaging of synaptic density with [11C]UCB-J PET in two mouse models of neurodegenerative disease. NeuroImage, 2021, 239, 118302.	2.1	19
1047	Concepts for design and analysis of receptor radiopharmaceuticals: The Receptor-Binding Radiotracers series of meetings provided the foundation. Nuclear Medicine and Biology, 2021, 92, 5-23.	0.3	2
1048	Quantification of Radiotracer Uptake Into Tissue. , 2021, , 1613-1624.		0
1049	Tracer Kinetic Modeling: Basics and Concepts. , 2021, , 531-549.		1
1051	Quantitative Approaches to Amyloid Imaging. Methods in Molecular Biology, 2011, 680, 201-225.	0.4	4
1052	Exact Parameter Determination for Parkinson's Disease Diagnosis with PET Using an Algebraic Approach. Lecture Notes in Computer Science, 2007, , 110-124.	1.0	4
1053	Compartmental Modeling in Emission Tomography. , 2012, , 1065-1081.		3
1054	Ligand Tracer Kinetics: Theory and Application. , 2004, , 75-93.		4
1055	Serotonin Synthesis Studied with Positron Emission Tomography (PET). , 2014, , 687-709.		1
1056	PET Imaging of Sigma1 Receptors. , 2014, , 741-763.		1
1057	Modelling Metabolite and Tracer Kinetics. , 2003, , 121-169.		7
1058	Investigation of the Dopamine System with Positron Emission Tomography: General Issues in Modelling. , 1991, , 65-83.		6
1060	Dopamine Reuptake Sites: The Issues. , 1991, , 111-119.		1
1061	PET/CT for Neuroinflammation. , 2020, , 217-228.		1
1062	Sigma-1 and dopamine D2/D3 receptor occupancy of pridopidine in healthy volunteers and patients with Huntington disease: a [18F] fluspidine and [18F] fallypride PET study. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1103-1115.	3.3	28

#	ARTICLE	IF	CITATIONS
1063	Limitations of Binding Potential as a Measure of Receptor Function: A Two-Point Correction for the Effects of Mass. , 1998, , 407-413.		2
1064	PET Measurement of Endogenous Neurotransmitter Activity Using High and Low Affinity Radiotracers 1 1Transcripts of the BRAINPET97 discussion of this chapter can be found in Section VIII.. , 1998, , 441-448.		8
1065	Quantification of Extracellular Dopamine Release in Schizophrenia and Cocaine Use by Means of TREMBLE 1 1Transcripts of the BRAINPET97 discussion of this chapter can be found in Section VIII.. , 1998, , 463-468.		7
1066	Amphetamine-Induced Dopamine Release. , 2001, , 205-209.		12
1067	Amphetamine-Induced Dopamine Release Greater in Ventral Than in Dorsal Striatum. , 2001, , 211-218.		1
1068	Serotonin Release and Reuptake Studied by PET Neuroimaging Using Fenfluramine, [15O]Water, [15O]Oxygen, [18F]Fluorodeoxyglucose, [11C]NS2381., , 2001, , 237-247.		3
1069	Scatchard Analysis with Bolus/Infusion Administration of [11C]Raclopride. , 2002, , 63-69.		3
1070	Tracer Kinetic Modeling via Basis Pursuit. , 2002, , 115-121.		4
1071	Animal PET for Brain Research from Receptor Binding to Second Messenger System. , 2002, , 201-II.		1
1072	[11 C]Erlotinib PET cannot detect acquired erlotinib resistance in NSCLC tumor xenografts in mice. Nuclear Medicine and Biology, 2017, 52, 7-15.	0.3	6
1074	14 Amyloid Imaging and (What is "Normal"?) Aging. , 2009, , 191-244.		2
1075	Strategies to Improve Neuroreceptor Parameter Estimation by Linear Regression Analysis. Journal of Cerebral Blood Flow and Metabolism, 2002, , 1271-1281.	2.4	84
1076	Positron Emission Tomography Compartmental Models: A Basis Pursuit Strategy for Kinetic Modeling. Journal of Cerebral Blood Flow and Metabolism, 2002, , 1425-1439.	2.4	79
1077	On the Undecidability Among Kinetic Models: From Model Selection to Model Averaging. Journal of Cerebral Blood Flow and Metabolism, 2003, , 490-498.	2.4	40
1078	MR-PET Image Coregistration for Quantitation of Striatal Dopamine D2 Receptors. Journal of Computer Assisted Tomography, 1996, 20, 423-428.	0.5	29
1083	CT-guided PET parametric image reconstruction using deep neural network without prior training data. , 2019, , .		11
1084	PET Imaging of Serotonin Type 2A Receptors in Late-Life Neuropsychiatric Disorders. American Journal of Psychiatry, 1999, 156, 1871-1878.	4.0	144
1085	Prediction of Reinforcing Responses to Psychostimulants in Humans by Brain Dopamine D ₂ Receptor Levels. American Journal of Psychiatry, 1999, 156, 1440-1443.	4.0	323

#	ARTICLE	IF	CITATIONS
1086	Assessment of brain delivery of a model ABCB1/ABCG2 substrate in patients with non-contrast-enhancing brain tumors with positron emission tomography. <i>EJNMMI Research</i> , 2019, 9, 110.	1.1	2
1087	PET imaging of soluble epoxide hydrolase in non-human primate brain with [18F]FNDP. <i>EJNMMI Research</i> , 2020, 10, 67.	1.1	10
1088	Kinfitr – An open-source tool for reproducible PET modelling: validation and evaluation of test-retest reliability. <i>EJNMMI Research</i> , 2020, 10, 77.	1.1	14
1089	Sapap3 deletion causes dynamic synaptic density abnormalities: a longitudinal [11C]UCB-J PET study in a model of obsessive-compulsive disorder-like behaviour. <i>EJNMMI Research</i> , 2020, 10, 140.	1.1	12
1090	Intravenous and oral copper kinetics, biodistribution and dosimetry in healthy humans studied by [64Cu]copper PET/CT. <i>EJNMMI Radiopharmacy and Chemistry</i> , 2020, 5, 15.	1.8	21
1091	Binding of Pramipexole to Extrastriatal Dopamine D2/D3 Receptors in the Human Brain: A Positron Emission Tomography Study Using 11C-FLB 457. <i>PLoS ONE</i> , 2011, 6, e17723.	1.1	25
1092	Long-Term Stimulant Treatment Affects Brain Dopamine Transporter Level in Patients with Attention Deficit Hyperactive Disorder. <i>PLoS ONE</i> , 2013, 8, e63023.	1.1	99
1093	Meningiomas: A Comparative Study of 68Ga-DOTATOC, 68Ga-DOTANOC and 68Ga-DOTATATE for Molecular Imaging in Mice. <i>PLoS ONE</i> , 2014, 9, e111624.	1.1	31
1094	Image Derived Input Function for [18F]-FEPPA: Application to Quantify Translocator Protein (18 kDa) in the Human Brain. <i>PLoS ONE</i> , 2014, 9, e115768.	1.1	11
1095	In Vivo Evaluation of Blood Based and Reference Tissue Based PET Quantifications of [11C]DASB in the Canine Brain. <i>PLoS ONE</i> , 2016, 11, e0148943.	1.1	3
1096	Feasibility study of TSPO quantification with [18F]FEPPA using population-based input function. <i>PLoS ONE</i> , 2017, 12, e0177785.	1.1	20
1097	Quantitative in vivo mapping of myocardial mitochondrial membrane potential. <i>PLoS ONE</i> , 2018, 13, e0190968.	1.1	30
1098	Impaired memory is more closely associated with brain beta-amyloid than leukoaraiosis in hypertensive patients with cognitive symptoms. <i>PLoS ONE</i> , 2018, 13, e0191345.	1.1	11
1099	Considerations in the Development of Reversibly Binding PET Radioligands for Brain Imaging. <i>Current Medicinal Chemistry</i> , 2016, 23, 1818-1869.	1.2	149
1100	Unidirectional Influx and Net Accumulation of PIB. <i>Open Neuroimaging Journal</i> , 2008, 2, 114-125.	0.2	53
1101	Low Retention of [S-methyl-11C]MeS-IMPY to β 2-amyloid Plaques in Patients with Alzheimers Disease. <i>Current Radiopharmaceuticals</i> , 2009, 2, 129-136.	0.3	5
1102	Attenuation of dopamine-modulated prefrontal value signals underlies probabilistic reward learning deficits in old age. <i>ELife</i> , 2017, 6, .	2.8	37
1103	[18F]2-Fluoro-2-deoxy-sorbitol PET Imaging for Quantitative Monitoring of Enhanced Blood-Brain Barrier Permeability Induced by Focused Ultrasound. <i>Pharmaceutics</i> , 2021, 13, 1752.	2.0	17

#	ARTICLE	IF	CITATIONS
1104	Comparison of Invasive and Non-invasive Estimation of [11C]PBR28 Binding in Non-human Primates. <i>Molecular Imaging and Biology</i> , 2022, 24, 404-415.	1.3	0
1105	Microglial activation states drive glucose uptake and FDG-PET alterations in neurodegenerative diseases. <i>Science Translational Medicine</i> , 2021, 13, eabe5640.	5.8	108
1106	Longitudinal preclinical evaluation of the novel radioligand [11C]CHDI-626 for PET imaging of mutant huntingtin aggregates in Huntington's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 1166-1175.	3.3	8
1107	Basic CNS Drug Transport and Binding Kinetics In Vivo. , 2000, , .		2
1108	Comparison of Kinetic Modeling Methods for the In Vivo Quantification of 5-HT1A Receptors Using WAY 100635. , 2001, , 249-255.		1
1109	Patterns of Distribution of [18F]6-Fluoro-l-m-Tyrosine in PET Images of Patients with Movement Disorders. , 2002, , 291-301.		0
1110	Comparison between Bolus and Infusion [11C]Raclopride Delivery for the Quantification of Dopamine Release. , 2002, , 71-75.		0
1111	Quantification of μ -Opioid Receptor Binding with [11C]Carfentanil. , 2002, , 27-32.		0
1112	Wavelet Methods for the Mathematical and Statistical Modeling of PET Images. , 2002, , 101-106.		0
1113	BIOLOGICAL INTERPRETATION OF QUANTITATIVE PET BRAIN DATA. , 2002, , .		0
1114	Measurements of Biochemical Reactions In Vivo. , 2003, , 3-29.		0
1115	Mixture modeling for PET neuroreceptor studies. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2005, 25, S636-S636.	2.4	0
1116	Techniques for Parametric Imaging. , 2008, , 137-IX.		6
1117	Molecular Imaging in Biology and Pharmacology. , 2008, , 457-XLV.		0
1118	Diagnostic PET in Image Guided Neurosurgery. , 2009, , 307-323.		0
1119	Quantitative Analysis of Amyloid Beta Deposition in the Brain of Alzheimer's Disease Patients Using PET and [11C]BF-227 and [18F]FACT. <i>IFMBE Proceedings</i> , 2010, , 1648-1651.	0.2	0
1120	Tracer Kinetic Modeling: Basics and Concepts. , 2010, , 333-351.		3
1121	GABAA Receptor Imaging by Positron Emission Tomography with [11C]flumazenil. <i>Radioisotopes</i> , 2010, 59, 49-58.	0.1	0

#	ARTICLE	IF	CITATIONS
1122	Kinetic Modelling. , 2011, , 387-403.		1
1123	Imaging in Neurology Research III: Focus on Neurotransmitter Imaging. , 2011, , 515-541.		1
1124	Statistical Modeling for Data of Positron Emission Tomography in Depression. , 2011, , 247-256.		0
1125	PET: Theoretical Background and Practical Aspects. , 2012, , 319-331.		0
1126	An Introduction to Kinetic Modeling and Quantification and its Role in Drug Development. , 2012, , 417-453.		1
1128	Tumor Development. , 2014, , 151-209.		0
1129	Imaging Platforms and Drug Development: An Introduction. AAPS Advances in the Pharmaceutical Sciences Series, 2014, , 1-43.	0.2	0
1131	PET Quantification in Neuropsychiatry. , 2014, , 15-44.		0
1132	Imaging Histamine Receptors Using PET and SPECT. , 2014, , 331-376.		0
1133	Tracer Kinetic Modelling. , 2014, , 59-73.		5
1134	Kinetic Models for PET/SPECT Imaging. , 2014, , 1-14.		0
1137	Studies of the Brain Cannabinoid System Using Positron and Single-Photon Emission Tomography. , 1999, , 163-176.		0
1138	Kinetic Models for PET/SPECT Imaging. , 2015, , 1471-1481.		0
1141	Kinetic Modeling. , 2017, , 559-580.		0
1142	Dynamic PET imaging. Imaging in Medical Diagnosis and Therapy, 2017, , 321-335.	0.0	0
1143	Semiautomatic Determination of Arterial Input Function in DCE-MRI of the Abdomen. Journal of Biomedical Engineering and Medical Imaging, 2017, 4, 96-104.	0.1	3
1144	In Vivo Imaging of Nicotinic Acetylcholine Receptors in the Central Nervous System. , 2018, , 17-44.		0
1145	Molecular Contrast Agents. , 2018, , 131-184.		0

#	ARTICLE	IF	CITATIONS
1147	Sex differences in methylphenidate-induced dopamine increases in ventral striatum. <i>Molecular Psychiatry</i> , 2022, 27, 939-946.	4.1	11
1151	Compartmental Modeling in Emission Tomography. , 2020, , 1-20.		0
1152	Quantitative Analysis of Amyloid β Deposition in Patients with Alzheimer's Disease Using Positron Emission Tomography. , 0, , 220-230.		1
1153	A novel PET tracer ^{18}F -deoxy-thiamine: synthesis, metabolic kinetics, and evaluation on cerebral thiamine metabolism status. <i>EJNMMI Research</i> , 2020, 10, 126.	1.1	1
1154	Clinical and Preclinical Bariatric Surgery Approaches to Studying Obesity. <i>NeuroMethods</i> , 2021, , 187-201.	0.2	0
1158	Comparison of (+)-(11)C-McN5652 and (11)C-DASB as serotonin transporter radioligands under various experimental conditions. <i>Journal of Nuclear Medicine</i> , 2002, 43, 678-92.	2.8	81
1160	Role of Kinetic Modeling in Biomedical Imaging. <i>Journal of Medical Sciences (Taiwan)</i> , 2008, 28, 57-63.	0.1	3
1161	Limitations of SRTM, Logan graphical method, and equilibrium analysis for measuring transient dopamine release with [(11)C]raclopride PET. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 3, 247-60.	1.0	14
1162	How to design PET experiments to study neurochemistry: application to alcoholism. <i>Yale Journal of Biology and Medicine</i> , 2014, 87, 33-54.	0.2	8
1163	Positron Emission Tomography (PET) and Graphical Kinetic Data Analysis of the Dopamine Neurotransmitter System: An Exercise for an Undergraduate Laboratory Course. <i>Journal of Undergraduate Neuroscience Education: JUNE: A Publication of FUN, Faculty for Undergraduate Neuroscience</i> , 2014, 12, A114-22.	0.6	0
1164	Modeling and imaging cardiac sympathetic neurodegeneration in Parkinson's disease. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 4, 125-59.	1.0	15
1165	Kinetic modeling in PET imaging of hypoxia. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 4, 490-506.	1.0	17
1167	Variability in Quantitative DCE-MRI: Sources and Solutions. <i>Journal of Nature and Science</i> , 2018, 4, .	1.1	18
1168	Evaluation of quantitative modeling methods in whole-body, dynamic [C]-erlotinib PET. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 11, 143-153.	1.0	3
1169	Co-registration of Imaging Modalities (MRI, CT and PET) to Perform Frameless Stereotaxic Robotic Injections in the Common Marmoset. <i>Neuroscience</i> , 2022, 480, 143-154.	1.1	5
1170	Thalamic dopamine D2-receptor availability in schizophrenia: a study on antipsychotic-naïve patients with first-episode psychosis and a meta-analysis. <i>Molecular Psychiatry</i> , 2022, 27, 1233-1240.	4.1	13
1171	Compartmental Modeling in Emission Tomography. , 2021, , 1431-1450.		0
1172	Imaging Histamine H3 Receptors with Positron Emission Tomography. <i>Current Topics in Behavioral Neurosciences</i> , 2021, , .	0.8	0

#	ARTICLE	IF	CITATIONS
1173	Synthesis and Characterization of 5-(2-Fluoro-4- ¹¹ C-methoxyphenyl)-2,2-dimethyl-3,4-dihydro-2H-pyrano[2,3-b]pyridine-7-carboxamide as a PET Imaging Ligand for Metabotropic Glutamate Receptor 2. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 2593-2609.	2.9	2
1174	Spatial and temporal dynamics of HDACs class IIa following mild traumatic brain injury in adult rats. <i>Molecular Psychiatry</i> , 2022, 27, 1683-1693.	4.1	3
1175	Effects on weight loss and glycemic control with SAR441255, a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist. <i>Cell Metabolism</i> , 2022, 34, 59-74.e10.	7.2	92
1176	Brain 5-HT _{2A} receptor binding and its neural network related to behavioral inhibition system. <i>Brain Imaging and Behavior</i> , 2022, 16, 1337-1348.	1.1	4
1178	First-in-human in vivo imaging and quantification of monoacylglycerol lipase in the brain: a PET study with 18F-T-401. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 3150-3161.	3.3	3
1179	Validation and test-retest repeatability performance of parametric methods for [11C]UCB-J PET. <i>EJNMMI Research</i> , 2022, 12, 3.	1.1	3
1180	A Baboon Brain Atlas for Magnetic Resonance Imaging and Positron Emission Tomography Image Analysis. <i>Frontiers in Neuroanatomy</i> , 2021, 15, 778769.	0.9	3
1181	Critical Review of the simple theoretical models in Dynamic Imaging: Up-Slope Method and Graphical Analysis. <i>Current Radiopharmaceuticals</i> , 2022, 15, .	0.3	0
1182	An iterative image-based inter-frame motion compensation method for dynamic brain PET imaging. <i>Physics in Medicine and Biology</i> , 2022, 67, 035012.	1.6	4
1183	Development of a ligand for in vivo imaging of mutant huntingtin in Huntington's disease. <i>Science Translational Medicine</i> , 2022, 14, eabm3682.	5.8	18
1184	Reduced Acquisition Time [18F]GE-180 PET Scanning Protocol Replaces Gold-Standard Dynamic Acquisition in a Mouse Ischemic Stroke Model. <i>Frontiers in Medicine</i> , 2022, 9, 830020.	1.2	5
1185	Parametric imaging used in nuclear medicine. , 2022, , .		0
1186	Principal Component Analysis versus Subject's Residual Profile Analysis for Neuroinflammation Investigation in Parkinson Patients: A PET Brain Imaging Study. <i>Journal of Imaging</i> , 2022, 8, 56.	1.7	3
1188	Principles of Tracer Kinetic Analysis in Oncology, Part I: Principles and Overview of Methodology. <i>Journal of Nuclear Medicine</i> , 2022, 63, 342-352.	2.8	13
1189	An in vivo Pig Model for Testing Novel Positron Emission Tomography Radioligands Targeting Cerebral Protein Aggregates. <i>Frontiers in Neuroscience</i> , 2022, 16, 847074.	1.4	3
1190	Kinetic modeling and non-invasive approach for translocator protein quantification with 11C-DPA-713. <i>Nuclear Medicine and Biology</i> , 2022, 108-109, 76-84.	0.3	4
1191	Application of correlated component analysis to dynamic PET time-activity curves denoising. , 2021, 2021, 3680-3683.		0
1194	Associations Between Brainstem Volume and Alzheimer's Disease Pathology in Middle-Aged Individuals of the Framingham Heart Study. <i>Journal of Alzheimer's Disease</i> , 2022, 86, 1603-1609.	1.2	0

#	ARTICLE	IF	CITATIONS
1195	Positron Emission Tomography and Single-Photon Emission Computed Tomography Methods and Applications in Substance Abuse Research. , 0, , 29-46.		1
1205	Rest/stress myocardial perfusion imaging by positron emission tomography with 18F-Flurpiridaz: A feasibility study in mice. Journal of Nuclear Cardiology, 2023, 30, 62-73.	1.4	4
1206	Beyond monoamines: I. Novel targets and radiotracers for Positron emission tomography imaging in psychiatric disorders. Journal of Neurochemistry, 2023, 164, 364-400.	2.1	7
1208	Image Quantification for TSPO PET with a Novel Image-Derived Input Function Method. Diagnostics, 2022, 12, 1161.	1.3	7
1209	Validation, kinetic modeling, and test-retest reproducibility of [¹⁸ F]SynVesT-1 for PET imaging of synaptic vesicle glycoprotein 2A in mice. Journal of Cerebral Blood Flow and Metabolism, 2022, 42, 1867-1878.	2.4	8
1211	Cortical D1 and D2 dopamine receptor availability modulate methylphenidate-induced changes in brain activity and functional connectivity. Communications Biology, 2022, 5, .	2.0	4
1212	Dopamine and reward-related vigor in younger and older adults. Neurobiology of Aging, 2022, 118, 34-43.	1.5	4
1213	Unsupervised PET logan parametric image estimation using conditional deep image prior. Medical Image Analysis, 2022, 80, 102519.	7.0	6
1214	Evaluation of [18F]F-TZ3108 for PET Imaging of Metabolic-Associated Fatty Liver Disease. Molecular Imaging and Biology, 0, , .	1.3	0
1215	Kinetic Models for PET/SPECT Imaging. , 2022, , 1753-1763.		0
1216	¹⁸ F-Fluciclovine PET Imaging of Glutaminase Inhibition in Breast Cancer Models. Journal of Nuclear Medicine, 2023, 64, 131-136.	2.8	4
1217	Innate immune cells and myelin profile in multiple sclerosis: a multi-tracer PET/MR study. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 4551-4566.	3.3	3
1218	Relationship Between Replay-Associated Ripples and Hippocampal ¹⁴ C-Methyl-D-Aspartate Receptors: Preliminary Evidence From a PET-MEG Study in Schizophrenia. Schizophrenia Bulletin Open, 2022, 3, .	0.9	1
1219	TG-Net: Combining transformer and GAN for nasopharyngeal carcinoma tumor segmentation based on total-body uEXPLORER PET/CT scanner. Computers in Biology and Medicine, 2022, 148, 105869.	3.9	8
1220	Modeling Blood-Brain Barrier Permeability to Solutes and Drugs In Vivo. Pharmaceutics, 2022, 14, 1696.	2.0	3
1221	Hetero-aryl bromide precursor fluorine-18 radiosynthesis and preclinical evaluation of a novel positron emission tomography (PET) tracer [18F]GSK1482160. Bioorganic and Medicinal Chemistry, 2022, 73, 116996.	1.4	7
1222	Four decades of mapping and quantifying neuroreceptors at work in vivo by positron emission tomography. Frontiers in Neuroscience, 0, 16, .	1.4	2
1223	First-in-human use of 11C-CPPC with positron emission tomography for imaging the macrophage colony-stimulating factor 1 receptor. EJNMMI Research, 2022, 12, .	1.1	13

#	ARTICLE	IF	CITATIONS
1224	PET imaging studies to investigate functional expression of mGluR2 using [¹¹ C]mG2P001. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2023, 43, 296-308.	2.4	1
1225	Monte-Carlo Modelling of a WristPET Scanner for Non-Invasive Measurement of the Arterial Input Function. , 2021, , .		0
1226	[¹⁸ F]NOS PET Brain Imaging Suggests Elevated Neuroinflammation in Idiopathic Parkinson's Disease. <i>Cells</i> , 2022, 11, 3081.	1.8	2
1227	18 kDa translocator protein positron emission tomography facilitates early and robust tumor detection in the immunocompetent SB28 glioblastoma mouse model. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	4
1228	Direct dynamic tomographic reconstruction without explicit blood input function. <i>Biomedical Signal Processing and Control</i> , 2023, 80, 104313.	3.5	0
1229	Advances in molecular neuroimaging methodology. , 2023, , 53-66.		0
1230	Radiochemical Synthesis and Evaluation of 3-[¹¹ C]Methyl-4-aminopyridine in Rodents and Nonhuman Primates for Imaging Potassium Channels in the CNS. <i>ACS Chemical Neuroscience</i> , 2022, 13, 3342-3351.	1.7	2
1231	Aberrant L-Fucose Accumulation and Increased Core Fucosylation Are Metabolic Liabilities in Mesenchymal Glioblastoma. <i>Cancer Research</i> , 2023, 83, 195-218.	0.4	5
1232	Kinetic evaluation and assessment of longitudinal changes in reference region and extracerebral [¹⁸ F]MK-6240 PET uptake. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2023, 43, 581-594.	2.4	5
1233	PET Imaging of P2X7 Receptor (P2X7R) for Neuroinflammation with Improved Radiosynthesis of Tracer [¹⁸ F]4A in Mice and Non-human Primates. <i>ACS Chemical Neuroscience</i> , 2022, 13, 3464-3476.	1.7	8
1234	[¹⁸ F] MFBC PET imaging: biodistribution, pharmacokinetics, and comparison with [¹²³ I] MIBG in neural crest tumour patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2023, 50, 1134-1145.	3.3	3
1236	Plasma p-tau217 predicts in vivo brain pathology and cognition in autosomal dominant Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2023, 19, 2585-2594.	0.4	11
1237	Transient equilibrium determination of dopamine D2/D3 receptor densities and affinities in brain. <i>Frontiers in Nuclear Medicine</i> , 0, 2, .	0.7	1
1238	First Total-Body Kinetic Modeling and Parametric Imaging of Dynamic [⁶⁸ Ga]FAPI-04 PET in Pancreatic and Gastric Cancer. <i>Journal of Nuclear Medicine</i> , 2023, 64, 960-967.	2.8	11
1239	Non-invasive kinetic modelling approaches for quantitative analysis of brain PET studies. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2023, 50, 1636-1650.	3.3	8
1240	Machine learning-based approach reveals essential features for simplified TSPO PET quantification in ischemic stroke patients. <i>Zeitschrift Fur Medizinische Physik</i> , 2023, , .	0.6	1
1241	Molecular Imaging of Pulmonary Inflammation in Users of Electronic and Combustible Cigarettes: A Pilot Study. <i>Journal of Nuclear Medicine</i> , 2023, 64, 797-802.	2.8	8
1242	Small-animal PET study for noninvasive quantification of transmembrane AMPA receptor regulatory protein β -8 (TARP β -8) in the brain. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 0, , 0271678X2311520.	2.4	0

#	ARTICLE	IF	CITATIONS
1243	Time-varying SUVR reflects the dynamics of dopamine increases during methylphenidate challenges in humans. <i>Communications Biology</i> , 2023, 6, .	2.0	3
1244	Neuroinflammation and amyloid deposition in the progression of mixed Alzheimer and vascular dementia. <i>NeuroImage: Clinical</i> , 2023, 38, 103373.	1.4	0
1245	Design of a generic method for single dual-tracer PET imaging acquisition in clinical routine. <i>Physics in Medicine and Biology</i> , 2023, 68, 085016.	1.6	0
1246	Microglial activation persists beyond clinical recovery following sport concussion in collegiate athletes. <i>Frontiers in Neurology</i> , 0, 14, .	1.1	3
1247	[18F]F-DED PET imaging of reactive astrogliosis in neurodegenerative diseases: preclinical proof of concept and first-in-human data. <i>Journal of Neuroinflammation</i> , 2023, 20, .	3.1	8
1248	Pharmacokinetics and Modeling. , 2023, , 291-302.		0
1251	Monitoring β -Cell Survival After Intrahepatic Islet Transplantation Using Dynamic Exendin PET Imaging: A Proof-of-Concept Study in Individuals With Type 1 Diabetes. <i>Diabetes</i> , 2023, 72, 898-907.	0.3	2
1264	Quantitation of dynamic total-body PET imaging: recent developments and future perspectives. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2023, 50, 3538-3557.	3.3	2
1269	PET Quantification and Kinetic Analysis. , 2023, , 183-194.		0
1280	Kinetic Modeling Methods in Preclinical Positron Emission Tomography Imaging. <i>Methods in Molecular Biology</i> , 2024, , 441-455.	0.4	0
1284	The Role of Individuals for Innovation: The Nuclear Medicine Biotope. , 2024, , 187-195.		0